(12) STANDARD PATENT (11) Application No. AU 2018349387 B2
(19) AUSTRALIAN PATENT OFFICE

(54) Title
Thioredoxin 1 epitope and monoclonal antibody specifically binding thereto

(51) International Patent Classification(s)
C07K 16/40 (2006.01) ***G01N 33/574*** (2006.01)
C07K 7/06 (2006.01)

(21) Application No: **2018349387** (22) Date of Filing: **2018.10.12**

(87) WIPO No: **WO19/074333**

(30) Priority Data

(31) Number	(32) Date	(33) Country
10-2017-0132536	**2017.10.12**	**KR**

(43) Publication Date: **2019.04.18**
(44) Accepted Journal Date: **2022.05.19**

(71) Applicant(s)
E&S Healthcare Co., Ltd.

(72) Inventor(s)
SUH, Kyong Hoon;KIM, Dae Joong;KIM, Young;KIM, Mi Kyung;JUNG, Jong Hwan;LEE, Ki Se

(74) Agent / Attorney
Pizzeys Patent and Trade Mark Attorneys Pty Ltd, GPO Box 1374, Brisbane, QLD, 4001, AU

(56) Related Art
WO 2018/052153 A1

(12) 특허협력조약에 의하여 공개된 국제출원

정정판

(19) 세계지식재산권기구
국제사무국

(43) 국제공개일
2019 년 4 월 18 일 (18.04.2019)

(10) 국제공개번호
WO 2019/074333 A9

(51) 국제특허분류:
C07K 7/06 (2006.01) *G01N 33/574* (2006.01)
C07K 16/40 (2006.01)

(21) 국제출원번호: PCT/KR2018/012069

(22) 국제출원일: 2018 년 10 월 12 일 (12.10.2018)

(25) 출원언어: 한국어

(26) 공개언어: 한국어

(30) 우선권정보:
10-2017-0132536 2017 년 10 월 12 일 (12.10.2017) KR

(71) 출원인: **주식회사 이앤에스헬스케어 (E&S HEALTH-CARE CO., LTD.)** [KR/KR]; 34015 대전시 유성구 테크노1로 11-3, 3층 N309호 (관평동, 배재대학교대덕산학협력관), Daejeon (KR).

(72) 발명자: **서경훈 (SUH, Kyong Hoon)**; 35209 대전시 서구 둔산중로 138, 908호 (둔산동), Daejeon (KR). **김대중 (KIM, Dae Joong)**; 05269 서울시 강동구 고덕로 62길 29, 102동 1708호 (명일삼환아파트), Seoul (KR). **김용 (KIM, Young)**; 28340 충청북도 청주시 청원구 주성로96번길 8, 302동 1010호 (한울아파트), Chungcheong-buk-do (KR). **김미경 (KIM, Mi Kyung)**; 34583 대전시 동구 계족로368번길 11, 211동 802호 (성남동, 효촌마을아파트), Daejeon (KR). **정종환 (JUNG, Jong Hwan)**; 34582 대전시 동구 성남로 15, 109동 306호 (성남동, 스마트뷰아파트), Daejeon (KR). **이기세 (LEE, Ki Se)**; 30100 세종

(54) **Title:** THIOREDOXIN 1 EPITOPE AND MONOCLONAL ANTIBODY SPECIFICALLY BINDING THERETO

(54) **발명의 명칭:** 티오레독신 1 에피토프 및 이에 특이적으로 결합하는 단일클론항체

[도21a]



(57) **Abstract:** The present invention relates to an epitope of a thioredoxin-1 (Trx1) antigen and a use thereof and, more specifically, provides the epitope and an antibody or antigen-binding fragment that binds thereto. An epitope region of a human Trx1 antigen identified in the present invention can be usefully utilized for developing an improved antibody for improving the binding affinity of an anti-Trx1 antibody. In addition, the improved antibody of the present invention is superior to existing anti-Trx1 antibodies in terms of the binding affinity to thioredoxin 1 and has very high levels of sensitivity and specificity, thereby being useful for improving the performance of a breast cancer diagnostic kit. Furthermore, detection of thioredoxin 1 using an antibody that specifically binds to thioredoxin 1 of the present invention is far superior in sensitivity and specificity to detection of the existing breast cancer diagnostic

WO 2019/074333 A9

[다음 쪽 계속]

시 달빛로 109, 402동 2103호 (아름동, 범지기마을 4단지), Sejong (KR).

(74) 대리인: 특허법인 이룸리온 (ERUUM & LEEON INTELLECTUAL PROPERTY LAW FIRM); 06575 서울시 서초구 사평대로 108, 3층 (반포동), Seoul (KR).

(81) 지정국 (별도의 표시가 없는 한, 가능한 모든 종류의 국내 권리의 보호를 위하여): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) 지정국 (별도의 표시가 없는 한, 가능한 모든 종류의 역내 권리의 보호를 위하여): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), 유라시아 (AM, AZ, BY, KG, KZ, RU, TJ, TM), 유럽 (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

공개:

— 국제조사보고서와 함께 (조약 제21조(3))
— 명세서의 서열목록 부분과 함께 (규칙 5.2(a))
— 규칙 91.3(b) 규정에 의한 명백한 잘못의 정정 허가에 관한 정보와 함께 (규칙 48.2(i))

(88) 국제조사보고서 공개일:
2019 년 7 월 4 일 (04.07.2019)

(48) 본 정정판 공개일:
2019 년 9 월 12 일 (12.09.2019)

(15) 정정사항에 관한 정보:
2019 년 9 월 12 일 (12.09.2019) 자 공지 참조

biomarker CA15-3, and thus the accuracy and reliability of diagnosis of breast cancer can be remarkably improved.

(57) 요약서: 본 발명은 티오레독신 1(Trx1) 항원의 에피토프 및 이의 용도에 관한 것으로, 보다 상세하게는 상기 에피토프 및 이에 결합하는 항체 또는 항원 결합 단편을 제공한다. 본 발명에서 확인된 인간 Trx1 항원의 에피토프 부위는 항-Trx1 항체의 결합 친화도를 향상시키기 위한 개량 항체 개발에 유용하게 활용될 수 있다. 또한, 본 발명의 개량된 항체는 기존의 항-Trx1 항체 보다 티오레독신 1 에 대한 결합 친화도가 우수하고, 민감도와 특이도가 매우 높아 유방암 진단키트의 성능을 개선하는데 유용하다. 나아가, 기존의 다른 유방암 진단 바이오마커인 CA15-3 을 검출하는 것 보다 본 발명의 티오레독신 1 에 특이적으로 결합하는 항체를 사용하여 티오레독신 1 을 검출하는 것이 민감도와 특이도가 월등히 우수하여 유방암 진단의 정확성 및 신뢰성을 현저히 높일 수 있다.

2018349387 04 Apr 2022

[DESCRIPTION]

[Invention Title]

THIOREDOXIN-1 EPITOPE AND MONOCLONAL ANTIBODY SPECIFICALLY BINDING THERETO

[Government Support]

This work was supported by the Promotion of Innovative Businesses for Regulation-Free Special Zones funded by the Ministry of SMEs and Startups (MSS, Korea).

[Technical Field]

The present invention relates to an epitope of a thioredoxin-1 (Trx1) antigen and a monoclonal antibody specifically binding thereto, and more particularly, to the epitope, a monoclonal antibody binding thereto, an antigen-binding fragment thereof, a nucleic acid molecule encoding a heavy chain and/or light chain of the antibody or antigen-binding fragment thereof, a recombinant vector containing the nucleic acid molecule, a host cell containing the recombinant vector, a method of preparing the antibody or antigen-binding fragment thereof, a kit for diagnosing breast cancer, and a method of providing information necessary for breast cancer diagnosis.

[Background Art]

Thioredoxin (Trx) is a small redox protein of about 12 kDa, which is present in the reduced state by a thioredoxin reductase through NADPH-dependent reduction, and includes thioredoxin-1 (Trx1) and thioredoxin-2 (Trx2) in mammals. Thioredoxin acts as a growth factor, removes hydrogen peroxide which is toxic in cells, promotes binding of critical factors relating to the role of a ribonucleotide reductase and transcription in bacteria to DNA, and affects the activity of a transcription factor such as nuclear transcription factor kB (NF-kB) in eukaryotic cells. Therefore, thioredoxin affects cell death and tumors and thus plays a pivotal role in regulation of cancer cell growth, and cleaves a disulfide bond of another oxidized protein to assist the maintenance of activity in a reduced state. Thioredoxin-1 and 2 reductases remove nitrogen oxide of cysteines in mammalian cells to affect cell death, and have potential

2018349387 10 Apr 2020

significance in various diseases including an inflammatory disease, a heart attack, and cancer. In addition, immunohistochemical analysis using an anti-thioredoxin antibody shows the expression of thioredoxin in human cancer tissues including the liver, colon, pancreas and cervix, and such expression indicates the possibility of involving thioredoxin in tumorigenesis.

Under these circumstances, the inventors had studied a marker for breast cancer diagnosis which can diagnose breast cancer or predict a prognosis thereof early, thioredoxin-1 was lowly expressed in normal breast tissue, but very highly expressed in breast cancer tissue, demonstrating that thioredoxin-1 is useful as a marker for breast cancer diagnosis (Korean Patent No. 10-1058230).

To develop *in vitro* diagnostics (IVD) based on an enzyme-linked immunosorbent assay (ELISA) to have high accuracy and high precision, a pair of antibodies having different sites with different affinities to the same antigen protein are required. Moreover, it is necessary to have a system producing antibodies having a certain affinity every time with low costs. In the present invention, to detect thioredoxin-1 (Trx1) present in human serum, two types of high-performance recombinant monoclonal antibodies were developed, the antibodies very specifically bind to thioredoxin-1 and thus can be useful for screening breast cancer patients. In addition, by identifying a site of a human Trx1 antigen to which the two types of antibodies bind, the present invention was completed.

[Disclosure]

[Technical Problem]

The present invention has been suggested to solve the above-mentioned problems, and is directed to providing a monoclonal antibody or an antigen-binding fragment thereof, which is able to diagnose breast cancer with high sensitivity and specificity.

The present invention is also directed to providing a nucleic acid molecule encoding a

heavy chain and/or a light chain of the monoclonal antibody or antigen-binding fragment thereof.

The present invention is also directed to providing a recombinant vector containing the nucleic acid molecule.

The present invention is also directed to providing a host cell containing the recombinant vector.

The present invention is also directed to providing an epitope of a human Trx1 antigen to which the monoclonal antibody or a binding fragment thereof binds, a nucleic acid molecule encoding the same, a recombinant vector containing the nucleic acid molecule and a host cell containing the recombinant vector.

The present invention is also directed to providing a method of preparing a monoclonal antibody specifically binding to Trx1 or an antigen-binding fragment thereof, which includes culturing the host cell.

The present invention is also directed to providing a kit for diagnosing breast cancer, including the above-described monoclonal antibody or antigen-binding fragment thereof.

The present invention is also directed to providing a method of providing information necessary for breast cancer diagnosis using the above-described monoclonal antibody or antigen-binding fragment thereof.

[Technical Solution]

To solve the above-described problems, the present invention provides a monoclonal antibody specifically binding to Trx1 or an antigen-binding fragment thereof, which includes a light chain variable region including light chain CDR1 consisting of an amino acid sequence of SEQ ID NO: 1, light chain CDR2 consisting of an amino acid sequence of SEQ ID NO: 2

and light chain CDR3 consisting of an amino acid sequence of SEQ ID NO: 3, and a heavy chain variable region including heavy chain CDR1 consisting of an amino acid sequence of SEQ ID NO: 4, heavy chain CDR2 consisting of an amino acid sequence of SEQ ID NO: 5 and heavy chain CDR3 consisting of an amino acid sequence of SEQ ID NO: 6.

According to an exemplary embodiment of the present invention, the antibody may include a light chain variable region consisting of an amino acid sequence of SEQ ID NO: 13 and a heavy chain variable region consisting of an amino acid sequence of SEQ ID NO: 14.

According to another exemplary embodiment of the present invention, the antibody may include a light chain consisting of an amino acid sequence of SEQ ID NO: 17 and a heavy chain consisting of an amino acid sequence of SEQ ID NO: 18.

The present invention also provides a monoclonal antibody specifically binding to Trx1 or an antigen-binding fragment thereof, which includes a light chain variable region including light chain CDR1 consisting of an amino acid sequence of SEQ ID NO: 7, light chain CDR2 consisting of an amino acid sequence of SEQ ID NO: 8 and light chain CDR3 consisting of an amino acid sequence of SEQ ID NO: 9, and a heavy chain variable region including heavy chain CDR1 consisting of an amino acid sequence of SEQ ID NO: 10, heavy chain CDR2 consisting of an amino acid sequence of SEQ ID NO: 11 and heavy chain CDR3 consisting of an amino acid sequence of SEQ ID NO: 12.

According to one exemplary embodiment of the present invention, the antibody may include a light chain variable region consisting of an amino acid sequence of SEQ ID NO: 15 and a heavy chain variable region consisting of an amino acid sequence of SEQ ID NO: 16.

According to another exemplary embodiment of the present invention, the antibody may include a light chain consisting of an amino acid sequence of SEQ ID NO: 19 and a heavy

2018349387 10 Apr 2020

chain consisting of an amino acid sequence of SEQ ID NO: 20.

According to still another exemplary embodiment of the present invention, the antibody may include a light chain consisting of an amino acid sequence of SEQ ID NO: 25 and a heavy chain consisting of an amino acid sequence of SEQ ID NO: 26.

According to yet another exemplary embodiment of the present invention, the antibody may include an IgG1 heavy chain and a kappa (κ) light chain.

According to yet another exemplary embodiment of the present invention, the antigen-binding fragment may be Fab, F(ab'), F(ab')$_2$, Fv or a single chain antibody molecule.

According to yet another exemplary embodiment of the present invention, the antibody may be a chimeric antibody, a humanized antibody or a human antibody.

The present invention also provides a nucleic acid molecule encoding a heavy chain and/or light chain of the above-described antibody or antigen-binding fragment thereof.

According to one exemplary embodiment of the present invention, the nucleic acid molecule encoding the light chain may consist of a nucleotide sequence of SEQ ID NO: 21, a nucleotide sequence of SEQ ID NO: 23 or a nucleotide sequence of SEQ ID NO: 27.

According to one exemplary embodiment of the present invention, the nucleic acid molecule encoding the heavy chain may consist of a nucleotide sequence of SEQ ID NO: 22, a nucleotide sequence of SEQ ID NO: 24 or a nucleotide sequence of SEQ ID NO: 28.

The present invention also provides a recombinant vector containing the nucleic acid molecule encoding the heavy chain, the nucleic acid encoding the light chain or both of the nucleic acid molecules encoding the heavy chain and the light chain, and a host cell containing the same.

10 Apr 2020 2018349387

The present invention also provides an epitope of a human Trx1 antigen consisting of any one amino acid sequence selected from the group consisting of SEQ ID NOs: 32 to 34 and 172 to 176, and a nucleic acid molecule encoding the same.

According to one exemplary embodiment of the present invention, the nucleic acid molecule may consist of any one nucleotide sequence selected from the group consisting of SEQ ID NOs: 35 to 37 and 177 to 181.

The present invention also provides a recombinant vector containing the nucleic acid molecule and a host cell containing the same.

The present invention also provides a method of preparing a monoclonal antibody specifically binding to Trx1 or an antigen-binding fragment thereof, which includes culturing a host cell containing a recombinant vector including a nucleic acid molecule encoding a heavy chain of the above-described antibody, a nucleic acid encoding a light chain thereof, or both of the nucleic acid molecules encoding the heavy chain and the light chain thereof.

The present invention also provides a kit for diagnosing breast cancer, which includes the above-described antibody or antigen-binding fragment thereof.

According to one exemplary embodiment of the present invention, the kit may be an enzyme-linked immunosorbent assay (ELISA) kit.

According to another exemplary embodiment of the present invention, the ELISA may be any one selected from the group consisting of direct ELISA, indirect ELISA, direct sandwich ELISA and indirect sandwich ELISA.

The present invention also provides a method of providing information necessary for breast cancer diagnosis, which includes: (a) bringing the above-described monoclonal antibody or antigen-binding fragment thereof into contact with a biological sample isolated from a

subject suspected of having breast cancer; (b) measuring an expression level of the Trx1 protein binding to the monoclonal antibody or antigen-binding fragment thereof in the biological sample through the formation of an antigen-antibody complex; and (c) comparing the expression level of the Trx1 protein, measured in Step (b) with that of a control and, if the protein expression level is higher than that of the control, determining the subject to be a breast cancer patient.

Further, the present invention provides a method of providing information necessary for breast cancer diagnosis, which includes: (a) coating a solid support with a monoclonal antibody or an antigen-binding fragment thereof, including light chains CDR1 to CDR3 and heavy chains CDR1 to CDR3 of antibody B266 or B266-1, a monoclonal antibody or an antigen-binding fragment thereof including a light chain variable region and a heavy chain variable region of antibody B266 or B266-1, or antibody B266 or B266-1 or an antigen-binding fragment thereof; (b) applying a biological sample isolated from a subject suspected of having breast cancer to the coated solid support; (c) removing an unbound sample; (d) applying a monoclonal antibody or an antigen-binding fragment thereof, including light chains CDR1 to CDR3 and heavy chains CDR1 to CDR3 of antibody B264, a monoclonal antibody or an antigen-binding fragment thereof, including a light chain variable region and a heavy chain variable region of antibody B264, or antibody B264 or an antigen-binding fragment thereof to the solid support; (e) removing an unbound monoclonal antibody or antigen-binding fragment thereof; (f) measuring an expression level of Trx1 protein; and (g) comparing the expression level of the Trx1 protein, measured in Step (f), with that of a control, and, if the protein expression level is higher than that of the control, determining the subject to be a breast cancer patient.

According to one exemplary embodiment of the present invention, the expression level

of the Trx1 protein may be measured by any one method selected from the group consisting of Western blotting, ELISA, sandwich ELISA, a radioimmunoassay, radioimmunodiffusion, Ouchterlony immunodiffusion, an immunoprecipitation assay, a complement fixation assay, an immunochromatographic assay, FACS and a protein chip assay.

According to another exemplary embodiment of the present invention, the isolated biological sample may be any one or more selected from the group consisting of whole blood, serum, plasma, breast tissue and breast cells.

Unless defined otherwise, all technical and scientific terms used in the specification have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Generally, the nomenclature used herein is well known and commonly used in the art.

The definitions of key terms used herein are as follows.

The term “antigen” refers to a molecule which can be bound by an antibody, and can be used in an animal to produce an antibody capable of binding to an epitope of the antigen or a part of the molecule. The antigen may have one or more epitopes.

The term “antibody” or “Ab” is an immunoglobulin molecule which can recognize a specific target or antigen, for example, a carbohydrate, a polynucleotide, a lipid or a polypeptide through one or more antigen recognition sites, located in a variable region of the immunoglobulin molecule, and bind thereto. The term “antibody” used herein may refer to any type of antibody, which encompasses, but is not limited to, a monoclonal antibody; a polyclonal antibody; an “antigen-binding fragment” of an antibody possessing an ability of specifically binding to a specific antigen (e.g., Trx1), for example, Fab, Fab’, $F(ab')_2$, Fd, Fv, Fc, etc.; an isolated complementarity-determining region (CDR); a bispecific antibody; a

2018349387 10 Apr 2020

hetero-conjugated antibody, or a mutant thereof; an antibody, or a fusion protein having an antigen-binding fragment (e.g., a domain antibody); a single-chain variable fragment (ScFv) and a single domain antibody [e.g., shark and camelid antibodies]; a maxibody, a minibody, an intrabody, a diabody, a triabody, a tetrabody, v-NAR and bis-scFv; a humanized antibody; a chimeric antibody; and all other modified configurations of an immunoglobulin molecule including an antigen recognition site with required specificity (including glycosylated variants of an antibody, amino acid sequence variants of an antibody and a covalently modified antibody). The antibody may be derived from a mouse, a rat, a human, or any other origin (including a chimeric or humanized antibody).

An antibody or polypeptide which “specifically binds” to a specific target or antigen (e.g., Trx1 protein) is a term generally understood in the related art, and a method of determining such specific binding has also been widely known in the related art. A specific molecule is considered to have “specific binding” when reacting or linked to a special cell or material more frequently, more rapidly, more consistently and/or with higher affinity than that with another type of cells or material. A specific antibody “specifically binds” to a specific target or antigen with higher affinity, higher binding activity, more rapidly and/or more consistently than when binding to another material.

The term “binding affinity” or “K_D” used herein refers to an equilibrium dissociation constant of a particular antigen-antibody interaction. K_D is a ratio of a dissociation rate (also referred to as “release rate” or “k_d”) to a binding rate or an “operation rate” or “k_a (association rate constant)”. Therefore, K_D is k_d/k_a, which is expressed as molar concentration (M). It concludes that the lower K_D, the higher binding affinity. Therefore, a K_D of 1 μM indicates a lower binding affinity, compared with a K_D of 1 nM. The K_D value of the antibody may be determined using a method widely established in the art. One method of determining the K_D

of an antibody typically utilizes surface plasmon resonance using a biosensor system, for example, a Biacore® system.

The term “vector” includes a nucleic acid molecule capable of delivering a linked different nucleic acid. One type of vector is a “plasmid,” and refers to a circular double-stranded DNA loop into which an additional DNA fragment can be ligated. A different type of vector is a viral vector, and here, an additional DNA fragment may be attached to a viral genome. Some vectors can be self-replicated in host cells into which they are introduced (e.g., a bacterial vector having a bacterial origin of replication and an episomal mammalian vector). Other vectors (e.g., a non-episomal mammalian vector) may be integrated into the genome of host cells when introduced into the host cells, and thus replicated in accordance with the host genome. In addition, some vectors may direct the expression of operatively linked genes. The vectors are referred to as “recombinant expression vectors” (or simply as “expression vectors”) in the specification. Generally, the expression vector useful in the recombinant DNA technique is often present in the form of a plasmid. The “plasmid” and “vector” used herein are the types of vectors most generally used, and thus can be interchangeably used. However, the present invention is to include different types of expression vectors having the same function, for example, viral vectors (e.g., a replication-deficient retrovirus, an adenovirus, and an adeno-related virus).

The term “host cells” is used to express cells which are transformed, or transformed by a nucleic acid sequence to express a selected gene of interest. The term encompasses the descendants of mother cells whether or not the descendants are identical to the original parent in the morphological or genetic aspect, as long as the selected gene is present.

[Advantageous Effects]

A monoclonal antibody of the present invention has excellent binding affinity to

thioredoxin-1, thereby very specifically binding to thioredoxin-1, and has very high sensitivity and specificity, thereby being effectively used in screening a breast cancer patient. Further, detection of thioredoxin-1 using the monoclonal antibody specifically binding to thioredoxin-1 of the present invention, rather than detection using a conventional breast cancer diagnostic biomarker CA15-3, exhibits exceptionally high sensitivity and specificity, and thus the accuracy and reliability of breast cancer diagnosis can be significantly increased. An epitope region of a human Trx1 antigen to which an antibody binds according to the present invention can be effectively used in the development of an improved antibody to enhance the binding affinity of an anti-Trx1 antibody.

[Description of Drawings]

FIG. 1 shows the cleavage map of a recombinant vector expressing the thioredoxin-1 antigen and an isotyping result of an antibody obtained in Example 1.

FIG. 2 shows the amino acid sequences of a light chain (a) and a heavy chain (b) of a 9G7(AB1) antibody obtained in Example 1.

FIG. 3 shows the amino acid sequences of a light chain (a) and a heavy chain (b) of a 2B4(AB2) antibody obtained in Example 1.

FIG. 4 shows a set of cleavage maps of a recombinant vector expressing a light chain (a) and a heavy chain (b) of a B264 antibody with high affinity.

FIG. 5 shows a set of cleavage maps of a recombinant vector expressing a light chain (a) and a heavy chain (b) of a B266 antibody with high affinity.

FIG. 6 shows results of identifying the reduced (+) and non-reduced (-) states of antibodies using SDS-PAGE, where (a) is the result for the antibody B264, and (b) is the result for the antibody B266.

FIG. 7 shows results of identifying the reduced (+) and non-reduced (-) states of an antibody B266-1 using SDS-PAGE, in which the antibody B266-1 is prepared by modifying an Fc part of the antibody B266 to human IgG1.

FIGS. 8A to 8D show results of IMTG gap alignment for a light chain and a heavy chain of antibody B266-1 and a light chain and a heavy chain of antibody B264 in order.

FIG. 9 shows results of analyzing the affinity of the antibodies B266-1 and B264, where (A) shows a reaction value according to an antibody concentration and a graph thereof, and (B) shows the result of analyzing the affinity of antibodies using a Prism program.

FIG. 10 is a graph showing sensitivity and specificity through ROC analysis of ELISA results using the antibodies B266-1 and B264.

FIG. 11 shows the comparison of amino acid sequence homology between human Trx1 and *Chrysochloris asiatica* Trx1.

FIG. 12 shows the result of electrophoresis to confirm whether cloning succeeded through a CaTrx1-cloning plasmid and treatment with restriction enzymes (Sfi I and Xho I), where Lane 1 indicates a CaTrx1-cloning plasmid, and Lane 2 indicates a restriction enzyme-treated plasmid.

FIG. 13 shows the result of analyzing the extent of the expression of CaTrx1 protein secreted from a cell line by transfecting an animal cell with a CaTrx1 plasmid.

FIG. 14 shows results of analyzing the affinity of the antibodies B266-1 and B264 for hTrx1 and CaTrx1.

FIGS. 15A shows the comparison of amino acid sequences between CaTrx1 and hTrx1.

FIG. 15B shows the positioning of mutations according to the comparison of amino

acid sequences between CaTrx1 and hTrx1.

FIG. 15C is a schematic diagram of fusion PCR for manufacturing a hTrx1 mutant gene, which results from DNA fragment amplification and overlapping PCR, which are sequentially performed.

FIG. 15D shows the result of the amplification of DNA fragments for positioning of mutations.

FIG. 15E shows the result of manufacturing cassettes through overlapping PCR using the manufactured DNA fragments.

FIG. 15F shows the expression of 8 types of hTrx1 mutant genes by transforming 293F with plasmids cloning each hTrx1 mutant gene.

FIG. 16 shows proteins secreted in a culture solution after the genes obtained through transformation in FIG. 15 are transduced into HEK293 human cells and cultured, which are detected by SDS-PAGE. Since the size of Trx1 is approximately 12 kDa, a protein with the corresponding size is detected, confirming that the 8 types of transformed genes are expressed and secreted as proteins in a culture solution.

FIG. 17 shows a result of analyzing the extent of expression of 8 types of hTrx1 mutant proteins detected in FIG. 16 after purification.

FIGS. 18A to 18C show results of analyzing the binding strength of an anti-Trx1 antibody with respect to the 8 types of hTrx1 mutant proteins of the present invention.

FIG. 19 is a schematic diagram illustrating the general principle of epitope detection using an overlapping peptide scan used in Example 17.

FIG. 20 is an image of mini-arrays cultured with one of the antibody samples described

2018349387 10 Apr 2020

in Example 17.

FIGS. 21A to 21D are a heatmap diagram showing the extent of reaction of controls reacting with antibody samples and all probe peptides, in which the y axis represents the peptide sequences of a library, and the x axis represents the concentrations of the applied antibody samples. MMC2 values are represented by a color code range including white (0 or low intensity), yellow (medium intensity) and red (high intensity).

FIGS. 22A to 22F are images of confirming the position of an epitope in the three-dimensional structure of a hTrx1 protein.

[Modes of the Invention]

Hereinafter, the present invention will be described in further detail.

As described above, the inventors confirmed through previous research that thioredoxin-1 is expressed in normal breast tissue at a low level, but expressed in breast cancer tissue at a very high level. Therefore, it is proved that thioredoxin-1 is useful as a marker for breast cancer diagnosis.

Therefore, through further research, the inventors developed a monoclonal antibody which very specifically binds to thioredoxin-1 and is useful in screening a breast cancer patient. The monoclonal antibody of the present invention very specifically binds to thioredoxin-1 due to excellent binding affinity to thioredoxin-1 and has very high sensitivity and specificity, such that it can be effectively used in screening a breast cancer patient. Further, the detection of thioredoxin-1 using the monoclonal antibody of the present invention, which specifically binds to thioredoxin-1, rather than the detection of CA15-3, which is another, conventionally used biomarker for breast cancer diagnosis, exhibits excellent sensitivity and specificity, such that the accuracy and reliability of the diagnosis of breast cancer can be significantly increased. In addition, an epitope region of a human Trx1 antigen to which the antibody binds may be

2018349387 10 Apr 2020

effectively used in the development of an improved antibody to enhance the binding affinity of an anti-Trx1 antibody.

The present invention provides a monoclonal antibody binding to thioredoxin-1 (Trx1) or an antigen-binding fragment thereof.

The monoclonal antibody of the present invention may be prepared using a variety of methods known in the art such as hybridoma, recombination and phage display technologies, and a combination method thereof. For example, the monoclonal antibody may be prepared using a hybridoma technique, which is known in the art. The term “monoclonal antibody” used herein is not limited to an antibody produced using a hybridoma technique. The term “monoclonal antibody” refers to an antibody derived from a single clone of any eukaryote, prokaryote, or a phage clone, but does not refer to a method of producing the same.

A method of producing and screening a specific antibody using a hybridoma technique is common and well known in the art. As a non-limited example, a mouse can be immunized with a target antigen or cells expressing the same. When the immune reaction is detected, for example, an antibody specific to the antigen is detected from a mouse serum, a mouse spleen is collected to isolate spleen cells. Subsequently, the spleen cells are fused with any suitable myeloma cells, for example, P3U1, P3X63-Ag8, P3X63-Ag8-U1, P3NS1-Ag4, SP2/0-Ag14, or P3X63-Ag8-653 by a known method. A hybridoma is selected, and cloned by limiting dilution. Afterward, the hybridoma clone is evaluated for its ability to be a cell secreting an antibody capable of binding to an antigen by a method known in the art. Generally, ascites containing a high level of antibodies may be prepared by injecting positive hybridoma clones into the abdominal cavity of a mouse. In an exemplary embodiment of the present invention, a Trx1 antigen is prepared by transfecting *E. coli* with a recombinant vector having the cleavage map of (a) in FIG. 1. Afterward, the spleen of a rat immunized with the antigen is separated, and cells fused with myeloma cells (sp2/0) to produce an antibody reacting with Trx1 are

2018349387 10 Apr 2020

identified by ELISA.

The exemplary monoclonal antibody of the present invention or antigen-binding fragment thereof may include (a) or (b) as follows, which may be referred to as B264 or B266-1, respectively:

(a) a light chain variable region including a light chain CDR1 consisting of the amino acid sequence of SEQ ID NO: 1, a light chain CDR2 consisting of the amino acid sequence of SEQ ID NO: 2 and a light chain CDR3 consisting of the amino acid sequence of SEQ ID NO: 3, and a heavy chain variable region including a heavy chain CDR1 consisting of the amino acid sequence of SEQ ID NO: 4, a heavy chain CDR2 consisting of the amino acid sequence of SEQ ID NO: 5 and a heavy chain CDR3 consisting of the amino acid sequence of SEQ ID NO: 6; or

(b) a light chain variable region including a light chain CDR1 consisting of the amino acid sequence of SEQ ID NO: 7, a light chain CDR2 consisting of the amino acid sequence of SEQ ID NO: 8 and a light chain CDR3 consisting of the amino acid sequence of SEQ ID NO: 9, and a heavy chain variable region including a heavy chain CDR1 consisting of the amino acid sequence of SEQ ID NO: 10, a heavy chain CDR2 consisting of the amino acid sequence of SEQ ID NO: 11 and a heavy chain CDR3 consisting of the amino acid sequence of SEQ ID NO: 12.

The term “complementarity-determining region (CDR)” used herein refers to the amino acid sequence of a hypervariable region of the heavy chain or light chain in an immunoglobulin. Each of heavy chains (CDRH1, CDRH2 and CDRH3) and light chains (CDRL1, CDRL2 and CDRL3) has three CDRs, and these CDRs provide key contact residues when an antibody binds to an antigen or epitope.

The exemplary monoclonal antibody of the present invention or antigen-binding fragment thereof may include (c) or (d) as follows, and may be referred to as B264 or B266-1,

10 Apr 2020 2018349387

respectively:

(c) a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 13 and a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 14; or

(d) a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 15 and a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 16.

The exemplary monoclonal antibody of the present invention or antigen-binding fragment thereof may include (e) or (f) as follows, which may be referred to as B264 or B266, respectively:

(e) a light chain consisting of the amino acid sequence of SEQ ID NO: 17 and a heavy chain consisting of the amino acid sequence of SEQ ID NO: 18; or

(f) a light chain consisting of the amino acid sequence of SEQ ID NO: 19 and a heavy chain consisting of the amino acid sequence of SEQ ID NO: 20.

The exemplary monoclonal antibody of the present invention is referred to as B264, B265, B266, B267, B268 or B269, and most preferably B264 or B266-1. B266-1 is a monoclonal antibody in which the Fc part of B266 is modified to human IgG1.

The structural unit of a naturally-occurring antibody generally includes a tetramer. The tetramer is generally composed of two pairs of identical polypeptide chains, and each pair has one full-length light chain (generally having a molecular weight of about 15 kDa) and one full-length heavy chain (generally having a molecular weight of about 50 to 70 kDa). The amino end of each of the light chain and heavy chain generally includes a variable region with about 100 to 110 or more amino acids, involved in antigen recognition. The carboxyl end of each chain defines a constant region generally involved in the function of an effector. A human light chain is generally classified into κ and λ light chains. A heavy chain is generally classified into μ, δ, γ, α and ε heavy chains, which define isotypes of an antibody, such as IgM,

2018349387 10 Apr 2020

IgD, IgG, IgA and IgE, respectively. IgG has, but is not limited to, some subclasses including IgG1, IgG2, IgG3 and IgG4. IgM has, but is not limited to, subclasses including IgM1 and IgM2. Similarly, IgA is, but is not limited to, classified into subclasses including IgA1 and IgA2. In the full-length light and heavy chains, generally, variable and constant regions are connected by a "J" region with about 12 or more amino acids, and the heavy chain also includes a "D" region with about 10 or more amino acids. A variable region of each light chain/heavy chain pair generally forms an antigen-binding site. According to an exemplary embodiment of the present invention, in the monoclonal antibody of the present invention, the heavy chain may be an IgG1, IgG2a, IgG2b, IgG3, IgA or IgM isotype, and the light chain may be a κ chain or a λ chain, and preferably, a κ light chain and an IgG1 heavy chain.

In the monoclonal antibody of the present invention or antigen-binding fragment thereof, the "antigen-binding fragment thereof" means a fragment having an antigen-binding function, and includes Fab, F(ab'), $F(ab')_2$, Fv or a single-chain antibody molecule. Among the antibody-binding fragments, Fab is a structure having light and heavy chain variable regions and a light chain constant region and the first constant region (CH1) of a heavy chain, and includes one antigen-binding site. F(ab') is different from Fab in that it has a hinge region including one or more cysteine residues at the C-terminus of the heavy chain CH1 domain. $F(ab')_2$ is formed by a disulfide bond between cysteine residues in a hinge region of Fab'. Fv is the smallest antibody fragment only having a heavy chain variable region and a light chain variable region. Such an antibody fragment may be obtained using a protease, preferably gene recombination technology. For example, Fab may be obtained by, for example, digestion of the total antibody with papain, and a $F(ab')_2$ fragment may be obtained by digestion of the total antibody with pepsin.

The exemplary antibody of the present invention may be a chimeric antibody, a humanized antibody or a complete human antibody.

The chimeric antibody may be prepared by combining variable light chain and heavy chain (VL and VH) domains obtained from one type of antibody-producing cells and constant light chain and heavy chain domains obtained from another type of antibody using a recombination means. Generally, the chimeric antibody uses a rodent or rabbit variable domain and a human constant domain to produce an antibody usually having a human domain. The production of such a chimeric antibody is widely known in the art, and may be achieved by a standard means. It is further considered that the human constant region of the chimeric antibody of the present invention can be selected from an IgG1, IgG2, IgG3, IgG4, IgG5, IgG6, IgG7, IgG8, IgG9, IgG10, IgG11, IgG12, IgG13, IgG14, IgG15, IgG16, IgG17, IgG18 or IgG19 constant region.

The humanized antibody is engineered to contain an immunoglobulin domain further more similar to a human, and includes a complementarity-determining region of an animal-derived antibody. This is achieved by closely examining the sequence of a hypervariable loop of the variable region in a monoclonal antibody, and adapting the sequence to the structure of the human antibody chain.

The complete human antibody is an antibody molecule which includes CDRs such that the total sequences of both of a light chain and a heavy chain are derived from a human gene.

The present invention also provides a nucleic acid molecule(s) encoding a heavy chain and/or a light chain of a monoclonal antibody of the present invention or an antigen-binding fragment thereof.

The term “nucleic acid molecule” used herein encompasses DNA (gDNA and cDNA) and RNA molecules, and in the nucleic acid molecule, a nucleotide, which is a basic unit, also includes an analogue in which a sugar or base part is modified, as well as a natural nucleotide. The sequences of nucleic acid molecules encoding the heavy chain and light chain variable regions of the present invention may be modified. The modification includes additions,

deletions, or non-conservative or conservative substitutions of nucleotides.

The nucleic acid molecule of the present invention is interpreted to also include a nucleotide sequence having substantial identity to the nucleotide sequence described above. The substantial identity refers to a nucleotide sequence exhibiting at least 80% homology, at least 90% homology in one specific example, or at least 95% homology in another specific example when the nucleotide sequence of the present invention is aligned to correspond to a different sequence as much as possible, and the aligned sequence is analyzed using an algorithm generally used in the art.

According to an exemplary embodiment of the present invention, the nucleic acid molecule encoding a light chain of the monoclonal antibody of the present invention may consist of the nucleotide sequence of SEQ ID NO: 21, and the nucleic acid molecule encoding a heavy chain of the monoclonal antibody of the present invention may consist of the nucleotide sequence of SEQ ID NO: 22.

According to another exemplary embodiment of the present invention, the nucleic acid molecule encoding a heavy chain of the monoclonal antibody of the present invention may consist of the nucleotide sequence of SEQ ID NO: 23, and the nucleic acid molecule encoding a light chain of the monoclonal antibody of the present invention may consist of the nucleotide sequence of SEQ ID NO: 24.

According to another exemplary embodiment of the present invention, a nucleic acid molecule encoding a light chain of the monoclonal antibody of the present invention may consist of a nucleotide sequence of SEQ ID NO: 27, and a nucleic acid molecule encoding a heavy chain thereof may consist of a nucleotide sequence of SEQ ID NO: 28.

The present invention also provides a recombinant vector, which includes the nucleic acid molecule encoding a heavy chain, the nucleic acid molecule encoding a light chain in the monoclonal antibody, or both of the nucleic acid molecules.

The recombinant vector system of the present invention may be constructed by various methods known in the art. The vector of the present invention may be typically constructed as a vector for cloning or a vector for expression. In addition, the vector of the present invention may be constructed using prokaryotic or eukaryotic cells as a host. For example, the vector of the present invention is an expression vector, and when prokaryotic cells are used as a host, the vector generally includes a potent promoter capable of performing transcription (e.g., a tac promoter, a lac promoter, a lacUV5 promoter, a lpp promoter, a pLλ promoter, a pRλ promoter, a rac5 promoter, an amp promoter, a recA promoter, an SP6 promoter, a trp promoter or a T7 promoter), a ribosome-binding site for the initiation of translation and transcription/translation termination sequences. When *E. coli* (e.g., HB101, BL21, DH5α, etc.) is used as a host cell, promoter and operator regions of an *E. coli* tryptophan biosynthesis pathway, and a pLλ promoter may be used as regulatory regions. When *Bacillus* is used as a host cell, the promoter of a toxic protein gene of *Bacillus thuringiensis* or any promoter capable of being expressed in Bacillus may be used as a regulatory region.

Meanwhile, the recombinant vector of the present invention may be manufactured by manipulating a plasmid used in the art (e.g., pCL, pSC101, pGV1106, pACYC177, ColE1, pKT230, pME290, pBR322, pUC8/9, pUC6, pBD9, pHC79, pIJ61, pLAFR1, pHV14, pGEX series, pET series or pUC19), a phage (e.g., λgt4·λB, λ-Charon, λΔz1 or M13) or a virus (e.g., SV40).

When the vector of the present invention is an expression vector and eukaryotic cells are used as a host, the vector generally has a promoter derived from the genome of mammalian cells (e.g., a metallothionine promoter, a β-actin promoter, a human hemoglobin promoter or a human muscle creatine promoter) or a promoter derived from a mammalian virus (e.g., an adenovirus late promoter, a vaccinia virus 7.5K promoter, SV40 promoter, a cytomegalovirus (CMV) promoter, a tk promoter of HSV, a mouse mammary tumor virus (MMTV) promoter,

an LTR promoter of HIV, a Moloney virus promoter, an Epstein-Barr virus (EBV) promoter or a Rous sarcoma virus (RSV) promoter), and a polyadenylation sequence as a transcription termination sequence.

The recombinant vector of the present invention may be fused with a different sequence to facilitate the purification of an antibody expressed from the recombinant vector. The fused sequence may be, for example, a glutathione S-transferase (Amersham Pharmacia Biotech, USA); a maltose-binding protein (NEB, USA); FLAG (IBI, USA); a tag sequence such as 6x His (hexahistidine; Qiagen, USA), Pre-S1 or c-Myc; or a leading sequence such as *ompA* or *pelB*. In addition, since a protein expressed from the vector of the present invention is an antibody, the expressed antibody may be easily purified using a protein A column without an additional sequence for purification.

Meanwhile, the recombinant vector of the present invention includes an antibiotic-resistant gene generally used in the art as a selective marker, for example, a gene resistant to ampicillin, gentamicin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neomycin or tetracycline.

The vector expressing an antibody of the present invention may be a vector system expressing both of a light chain and a heavy chain using one vector, or a vector system respectively expressing a light chain and a heavy chain using two vectors. In the latter, two vectors are introduced into host cells through co-transformation and targeted transformation. The co-transformation is a method of selecting cells expressing both a light chain and a heavy chain after vector DNAs respectively encoding the light chain and the heavy chain are introduced into host cells. Targeted transformation is a method of selecting cells transformed by a vector including a light chain (or a heavy chain), transforming the selected cells expressing the light chain by a vector including a heavy chain (or a light chain), and finally selecting cells expressing both of the light chain and the heavy chain.

The present invention also provides host cells including a recombinant vector of the present invention. The host cells are cells transformed with the recombinant vector of the present invention. Host cells capable of stably and continuously cloning and expressing the vector of the present invention may be any host cells known in the art, and include prokaryotic host cells, for example, *Bacillus* sp. strains such as *Escherichia coli*, *Bacillus subtilis* and *Bacillus thuringiensis*, *Streptomyces*, *Pseudomonas* (e.g., *Pseudomonas putida*), *Proteus mirabilis* or *Staphylococcus* (e.g., *Staphylococcus carnosus*), but the present invention is not limited thereto.

As eukaryotic host cells suitable for the vector, multicellular fungi such as *Aspergillus* sp. strains belonging to the Phylum Ascomycota and *Neurospora crassa*, and unicellular fungi including enzymes such as yeasts such as *Pichia pastoris*, *Saccharomyces cerevisiae* and *Schizosaccharomyces*, other low eukaryotic cells, high eukaryotic cells such as insect-derived cells, and cells derived from a plant or mammal may be used.

The term “transfection” used herein refers to introduction of a gene of interest into host cells using the recombinant vector of the present invention, and is used with the same meaning as “transformation.” Therefore, the “transfection” and/or “transformation” into host cells may be performed by suitable standard technology known in the art according to host cells, including methods of introducing a nucleic acid into an organism, cells, tissue or an organ. Such methods include electroporation, protoplast fusion, calcium phosphate ($CaPO_4$) precipitation, calcium chloride ($CaCl_2$) precipitation, stirring using a silicon carbide fiber, agrobacteria-mediated transformation, PEG, dextran sulfate, Lipofectamine and drying/inhibition-mediated transformation, but the present invention is not limited thereto.

The present invention also provides an epitope of a human Trx1 antigen consisting of any one amino acid sequence selected from the group consisting of SEQ ID NOs: 32 to 34 and 172 to 176.

2018349387 10 Apr 2020

The inventors confirmed that although hTrx1 and CaTrx1 have an amino acid homology of 82%, two types of antibodies against hTrx1 according to the present invention do not bind to CaTrx1 (FIGS. 11 and 15A). Accordingly, eight parts at which the amino acid sequences of hTrx1 and CaTrx1 are different were identified (FIG. 15B), and gene cassettes for expressing hTrx1 mutant proteins were manufactured to clone the genes (FIGS. 15C to 15F). The cloned genes were transformed into an N293F cell line, the expression of 8 types of hTrx1 mutant proteins was confirmed (FIG. 16), and each mutant protein was purified (FIG. 17), followed by confirming the binding strengths with antibody B266-1 (hTrx1-hIgG1) and with antibody B264 (hTrx1-mIgG1).

As shown in FIGS. 18A to 18C, it was confirmed that binding between the antibody B266-1 and a M4 mutant protein (YSNVIFGNMV) was decreased compared to hTrx1, and bindings between the antibody B264 and M1 (QIESKTAEIEGKED), M2 (QEALDAHAALSS) and M4 mutant proteins were decreased compared to hTrx1. Therefore, it was confirmed that the antibodies B266-1 and B264 are most likely to share an M4 site of the binding sites.

In addition, a microarray analysis was performed using 108 peptides manufactured by overlapping the amino acid sequence of a hTrx1 protein by one amino acid residue (FIGS. 19 and 20), and epitopes of the antibodies B266-1 and B264 were identified through heatmap evaluation, as shown in Table 25 (FIGS. 21A to 21D and 22A to 22F).

The present invention also provides a nucleic acid molecule encoding the above-described epitope of the Trx1 antigen, a recombinant vector containing the same, and a host cell containing the recombinant vector.

The nucleic acid molecule of the epitope of the Trx1 antigen according to the present invention may consist of any one amino acid sequence selected from the group consisting of SEQ ID NOs: 32 to 34 and 172 to 176.

Descriptions of the nucleic acid molecule encoding the above-described epitope, the

recombinant vector containing the same, and the host cell containing the recombinant vector are the same as those of the antibody of the present invention described above, and thus will be omitted.

The present invention also provides a method of preparing a monoclonal antibody specifically binding to thioredoxin-1 or an antigen-binding fragment thereof, which includes culturing the host cells.

The culture of host cells to prepare an antibody or antigen-binding fragment thereof may be performed in a suitable medium known in the art under culture conditions. The culture process may be easily adjusted according to a strain by one of ordinary skill in the art. Cell culture is classified by suspension culture or attachment culture depending on a growth method, and batch culture, fed-batch culture or continuous culture according to a culture method. The medium used in culture has to suitably satisfy requirements for specific strains.

The medium used in animal cell culture includes various carbon sources, nitrogen sources, and trace elements. Examples of carbon sources used herein may be carbohydrates such as glucose, sucrose, lactose, fructose, maltose, starch and cellulose, lipids such as soybean oil, sunflower oil, castor oil and coconut oil, fatty acids such as palmitic acid, stearic acid and linoleic acid, alcohols such as glycerol and ethanol, and organic acids such as acetic acid. These carbon sources may be used independently or in combination. Examples of nitrogen sources used herein include organic nitrogen sources such as peptones, yeast extracts, beef stock, malt extracts, corn steep liquor (CSL) and soybean powder, and inorganic nitrogen sources such as urea, ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate. These nitrogen sources may be used independently or in combination. The medium may include potassium dihydrogen phosphate, dipotassium hydrogen phosphate and a corresponding sodium-containing salt as a phosphorus source. In addition, the medium may contain a metal salt such as magnesium sulfate or iron

sulfate. In addition, an amino acid, a vitamin, and a suitable precursor may be included.

During culture, compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid and sulfuric acid may be added to a cell culture by a suitable method to adjust a pH of the cell culture. In addition, the generation of bubbles may be inhibited using a foaming agent such as fatty acid polyglycol ester during culture. In addition, to maintain an aerobic condition of the cell culture, oxygen or an oxygen-containing gas (e.g., air) is injected into the cell culture. The temperature of the cell culture is generally 20 to 45 °C, and preferably 25 to 40 °C.

The antibody obtained by culturing host cells may be used without purification, or may be used by purification with high purity using various conventional methods, for example, dialysis, salt precipitation, and chromatography. Among these methods, chromatography is most widely used, and the types and order of columns may be selected for ion exchange chromatography, size exclusion chromatography, or affinity chromatography according to the characteristic of an antibody or a culture method.

The present invention provides a breast cancer diagnostic kit which includes the monoclonal antibody of the present invention or antigen-binding fragment thereof, and a method of providing information necessary for breast cancer diagnosis using the same.

The term “diagnosis” used herein refers to confirmation of the presence or feature of a pathological state. For the purpose of the present invention, diagnosis is to confirm whether breast cancer occurs or not.

The thioredoxin-1 protein is a breast cancer diagnostic marker, and highly expressed in breast cancer tissue, compared with normal breast tissue.

According to an exemplary embodiment of the present invention, the breast cancer diagnostic kit may be an enzyme linked immunosorbent assay (ELISA) kit, and preferably, one or more selected from the group consisting of direct ELISA, indirect ELISA, direct sandwich

ELISA and indirect sandwich ELISA. In an exemplary embodiment of the present invention, two types of antibodies included in the sandwich ELISA kit include a monoclonal antibody B266-1 as a coating antibody, and a monoclonal antibody B264 as a detection antibody.

The breast cancer diagnostic kit of the present invention may further include a tool or reagent known in the art, which is used in immunological analysis, in addition to an antibody against Trx1.

Here, the immunological analysis may be carried out with any of the methods capable of measuring the binding of an antibody to an antigen. Such methods are known in the art include, for example, western blotting, ELISA, radioimmunoprecipitation, radial immunodiffusion, an immunofluorescence assay, immunoblotting, Ouchterlony immunodiffusion, rocket immunoelectrophoresis, immunohistochemical staining, an immunoprecipitation assay, a complement fixation assay, an immunochromatographic assay, FACS, and a protein chip assay, but the present invention is not limited thereto.

As a tool or reagent used in immunological analysis, a suitable carrier or support, a marker capable of producing a detectable signal, a solubilizer, a cleaning agent, or a stabilizer may be included. When a marker is an enzyme, suitable carriers include a substrate capable of measuring enzyme activity, a suitable buffer solution, a secondary antibody labeled with a chromogenic enzyme or a fluorescent material, a chromogenic substrate or a reaction stopping agent, but the present invention is not limited thereto.

The antibody against Trx1 included in the kit of the present invention is preferably fixed to a suitable carrier or support using various methods disclosed in a document, and examples of suitable carriers and supports include PBS, polystyrene, polyethylene, polypropylene, polyester, polyacrylonitrile, a fluorine resin, agarose, cellulose, nitrocellulose, dextran, Sephadex, Sepharose, a liposome, carboxymethyl cellulose, polyacrylamide, polystyrene, gabbro, filter paper, an ion exchange resin, a plastic film, a plastic tube, a

polyamine-methyl vinyl-ether-maleic acid copolymer, an amino acid copolymer, an ethylene-maleic acid copolymer, nylon, a metal, glass, a glass bead, and a magnetic particle. Other solid supports include a cell culture plate, an ELISA plate, a tube and a polymer film. The support may have any possible shape, for example, a spherical (bead), cylindrical (test tube or the inside of well), or a planar (sheet or test strip) shape.

The marker capable of producing a detectable signal is able to qualitatively or quantitatively measure the formation of an antigen-antibody complex, and may be, for example, an enzyme, a fluorescent material, a ligand, a luminous material, a microparticle, a redox molecule or a radioisotope. As an enzyme, β-glucuronidase, β-D-glucosidase, a urease, a peroxidase (e.g., horseradish peroxidase), alkaline phosphatase, acetylcholinesterase, glucose oxidase, a hexokinase, malate dehydrogenase, glucose-6-phosphate dehydrogenase, invertase, or a luciferase may be used. As a fluorescent material, fluorescein, isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, or fluorescein isothiocyanate may be used. As a ligand, a biotin derivative may be used, and as a luminous material, acridinium ester or a luciferin may be used. As a microparticle, colloidal gold or colored latex may be used, and as a redox molecule, ferrocene, a ruthenium complex, a viologen, a quinone, a Ti ion, a Cs ion, diimide, 1,4-benzoquinone or hydroquinone may be used. As a radioisotope, ^{3}H, ^{14}C, ^{32}P, ^{35}S, ^{36}Cl, ^{51}Cr, ^{57}Co, ^{58}Co, ^{59}Fe, ^{90}Y, ^{125}I, ^{131}I, or ^{186}Re may be used. However, other than the materials listed above, any one capable of being used in immunological analysis may be used.

As an enzyme chromogenic substrate, for example, when horseradish peroxidase (HRP) is selected as an enzyme marker, a solution containing 3-amino-9-ethylcarbazole, 5-aminosalicylic acid, 4-chloro-1-naphthol, o-phenylenediamine, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid), 3,3-diaminobenzidine, 3,3',5,5'-tetramethylbenzidine, o-dianisidine or 3,3-dimethoxybenzidine may be used as a substrate. In addition, when an alkaline phosphatase is selected as an enzyme marker, a solution containing 5-bromo-4-chloro-

3-indolyl phosphate, nitroblue tetrazolium or p-nitrophenyl phosphate may be used as a substrate. In addition, when β-D-galactosidase is selected as an enzyme marker, a solution containing o-nitrophenyl-β-D-galactoside or 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside may be used as a substrate. Other than these, various enzymes and enzyme chromogenic substances, which are known in the art, may be used.

According to an exemplary embodiment of the present invention, the method of providing information necessary for breast cancer diagnosis of the present invention may be performed with the following steps:

(a) bringing any one type of monoclonal antibody of the present invention or antigen-binding fragment thereof into contact with a biological sample isolated from a subject suspected of having breast cancer;

(b) measuring an expression level of the thioredoxin-1 protein binding to the monoclonal antibody or an antigen-binding fragment thereof in the biological sample through the formation of an antigen-antibody complex; and

(c) comparing the expression level of the thioredoxin-1 protein, measured in step (b) with that of a control and, if the protein expression level is higher than that of the control, determining the subject to be a breast cancer patient.

According to another exemplary embodiment of the present invention, a method of providing information necessary for the diagnosis of breast cancer may be performed with the following steps:

(a) coating a solid support with a monoclonal antibody or an antigen-binding fragment thereof, including light chains CDR1 to CDR3 and heavy chains CDR1 to CDR3 of antibody B266 or B266-1, a monoclonal antibody or an antigen-binding fragment thereof, including a light chain variable region and a heavy chain variable region of antibody B266 or B266-1, or antibody B266 or B266-1 or an antigen-binding fragment thereof;

10 Apr 2020 2018349387

(b) applying a biological sample isolated from a subject suspected of having breast cancer to the coated solid support;

(c) removing an unbound sample;

(d) applying a monoclonal antibody or an antigen-binding fragment thereof, including light chains CDR1 to CDR3 and heavy chains CDR1 to CDR3 of antibody B264, a monoclonal antibody or an antigen-binding fragment thereof, including a light chain variable region and a heavy chain variable region of antibody B264, or antibody B264 or an antigen-binding fragment thereof to the solid support;

(e) removing an unbound monoclonal antibody or antigen-binding fragment thereof;

(f) measuring an expression level of Trx1 protein; and

(g) comparing the expression level of the Trx1 protein, measured in Step (f), with that of a control, and, if the protein expression level is higher than that of the control, determining the subject to be a breast cancer patient.

The term “isolated biological sample” used herein includes tissue (breast tissue), cells (breast cells), whole blood, plasma, serum, blood, saliva, synovial fluid, urine, sputum, lymphatic fluid, cerebrospinal fluid, a tissue autopsy sample (brain, skin, lymph nodes, spinal cord or the like), a cell culture supernatant, or ruptured eukaryotic cells, which is different in expression level of the Trx1 protein, which is a breast cancer marker, and includes a sample derived from a primary lesion or metastatic lesion. These biological samples, which are manipulated or not manipulated, may be reacted with the monoclonal antibody of the present invention to confirm an expression level of the Trx1 protein.

The term “subject” used herein includes mammals including a cow, a pig, sheep, a chicken, a dog and a human, birds, etc., and any subject suspected of having breast cancer without limitation.

Hereinafter, the present invention will be described in detail with reference to

examples to help in understanding the present invention. However, examples according to the present invention may be modified into a variety of different forms, and it should not be construed that the scope of the present invention is limited to the following examples. The examples of the present invention are provided to more completely explain the present invention to those of ordinary skill in the art.

[Examples]

[Example 1]

Preparation of human thioredoxin-1 (Trx1) antigen

1-1. Preparation of Trx1 expression vector

A gene was synthesized based on the *E. coli* codon usage to express the gene encoding the human thioredoxin-1 protein in *E. coli*. A sequence of the synthesized human thioredoxin-1 gene is shown in Table 1 below.

[Table 1]

	Base sequence
Trx 1 gene	ATGGTCAAACAGATCGAATCAAAAACCGCATTTCAAGAAGCCCT GGACGCCGCTGGTGACAAACTGGTCGTGGTGGACTTTAGTGCTA CCTGGTGCGGCCCGTGTAAAATGATTAAACCGTTTTTCCATAGCC TGTCTGAAAAATACAGTAACGTTATCTTTCTGGAAGTGGATGTTG ATGACTGCCAGGACGTCGCGAGCGAATGCGAAGTGAAATGTATG CCGACGTTCCAGTTTTTCAAAAAAGGTCAAAAAGTCGGTGAATT TAGCGGTGCCAACAAAGAAAAACTGGAAGCCACGATTAACGAA CTGGTG (SEQ ID NO: 29)

A primer sequence used to amplify the human thioredoxin-1 gene is shown in Table 2 below.

[Table 2]

hTrx1-For	TAATGGTCAAACAGATCGAATC (SEQ ID NO: 30)
hTrx1-Rev	CACCAGTTCGTTAATCGTGGTAATGAAAGCT (SEQ ID NO: 31)

To amplify a gene for cloning in a plasmid, a polymerase chain reaction (PCR) was

performed. 10 pmol of a gene synthesized as a template, 10 pmol each of primers (hTrx1-For and hTrx1-Rev), dNTPs (each 2.5 mM), Exprime taq polymerase, and a buffer solution were mixed. This solution was reacted for 35 cycles at 95 °C for 2 minutes, at 95 °C for 30 seconds, at 55 °C for 30 seconds, and at 70 °C for 20 seconds, and further reacted at 70 °C for 2 minutes, and then the reaction was terminated. The amplified gene was purified, and then to clone an *Eco*RV site present in the multi-cloning site (MCS) of a pUC57 plasmid, the plasmid was treated with the corresponding restriction enzyme and purified. The plasmid treated with the purified gene and the restriction enzyme, a ligase and a buffer solution were mixed and reacted. To transform *E. coli* DH5α with the plasmid, a *E. coli* DH5α competent cell line was warmed at 4 °C, mixed with a plasmid-mixed solution, and reacted at 4 °C for 30 minutes. After the reaction, the cells were subjected to heat shock at 42 °C for 30 seconds, stabilized at 4 °C for 2 minutes, dispensed on a Luria-Bertani (LB) solid medium containing an antibiotic (50 ug/mL of ampicillin) for uniform absorption, and cultured at 37 °C for 16 hours or more. A plasmid having the human thioredoxin-1 gene was screened from colonies grown in the cultured medium.

1-2. Trx1 expression and purification

The screened plasmid having the human thioredoxin-1 gene was purified, and then to express the protein, an *E. coli* BL21 strain was transformed with the purified plasmid according to the method described above. To express the thioredoxin-1 protein from the transformed strain, the strain was cultured in an LB broth containing an antibiotic to OD_{600}=0.5 at 37 °C, and further cultured for 3 hours by adding isopropyl β-D-thiogalactopyranoside (IPTG) so that a concentration became 1 mM. Afterward, SDS-PAGE was performed to confirm protein expression. To purify the protein, the obtained cell line was disrupted using ultrasonication and then centrifuged (12,000 rpm, 30 min, 4 °C), thereby obtaining a supernatant. A commercially available anti-thioredoxin I antibody (LF-MA0055, Abfrontier) was added to the

10 Apr 2020 2018349387

obtained supernatant to bind to the expressed thioredoxin-1, protein A/G PLUS-agarose (sc-2003, Santa Cruz) which bound to the antibody was added to react therewith, and then centrifugation and purification were performed. Afterward, the purity and molecular weight of the resulting product were confirmed through SDS-PAGE.

[Example 2]

Production and purification of Trx1-specific monoclonal antibody

2-1. Immunization of mouse

The purified human thioredoxin-1 protein was mixed with an adjuvant and then injected into a mouse (BALB/c), and the mouse blood was collected and subjected to ELISA to confirm antibody production. After two immunizations, it was confirmed that an antibody titer (1:5,000) increases properly.

2-2. Cell fusion and preparation of hybridoma

A B lymphocyte was isolated from the spleen extracted from the immunized mouse, and fused with cultured myeloma cells (sp2/0). The fused cells were cultured in a medium (HAT medium) containing hypoxanthine, aminopterine and thymidine, and cells (hybridomas) in which only a myeloma cell and a B lymphocyte are fused were selectively cultured.

2-3. Selection of hybridoma cells producing Trx1-specific monoclonal antibody

In the obtained hybridoma cells, three types of antibodies that react with the human thioredoxin-1 protein were confirmed through ELISA. The hybridoma producing an antibody that reacts with an antigen was selected from the ELISA-positive cells using a limiting dilution method.

2-4. Production and purification of monoclonal antibody

The obtained three types of hybridomas were injected into mice, and then ascites was obtained from each mouse and purified using protein A affinity chromatography. The purified antibody was identified by SDS-PAGE.

[Example 3]

Identification of isotype of monoclonal antibody

The three antibody isotypes obtained in Example 2 were confirmed using a Rapid ELISA Mouse mAbs Isotyping Kit (Pierce, Cat. 37503).

As a result, as shown in (b) in FIG. 1, it was confirmed that the heavy chain of a monoclonal antibody 2B4 is IgG1, the heavy chain of a monoclonal antibody 8F3 is IgG12a, and the heavy chain of a monoclonal antibody 9G7 is IgG2b, and the light chains are all kappa types.

[Example 4]

Analyses of amino acid sequences of monoclonal antibodies 9G7(AB1) and 2B4(AB2)

The heavy chain and light chain amino acid sequences of the monoclonal antibodies 9G7(AB1) and 2B4(AB2) of the three types of monoclonal antibodies obtained in Example 2 were analyzed. As a sequence capable of being fused with an Fc region, which is suitable for back-translation and recombination expression, an amino acid sequence was determined. The sequence determined by IMTG gap alignment was aligned, and hypermutated and complete CDR3 parts were found using a hypermutation table. The sequences were identified using accurate mass peptide maps (FIGS. 2 and 3), and hypermutation and CDR3s were confirmed using MS/MS spectra.

[Example 5]

Comparison of affinity and determination of antibody using ELISA

A hypermutation-available position was determined in the amino acid sequence obtained through the above-described process, and therefore, genes were synthesized by altering amino acid sequences of four types (B266, B297, B268 and B269) of 9G7(AB1) and two types (B264 and B265) of 2B4(AB2). The six types of antibodies obtained above

(B264~B269) were expressed, and then affinity of each antibody to an antigen was confirmed through ELISA (the numbers after "T" in Tables 3 to 5 represent production batch numbers, respectively).

Affinities to three types of antigens, that is, naked Trx1, Fc-binding Trx1(Trx1-Fc) and His-tagged Trx1 (Trx1-His) were determined through direct ELISA, and the results are sequentially shown in Tables 3 to 5. As shown in Tables 3 to 5, B264 as IgG1(κ) and B266 as IgG2b(κ) exhibited the highest affinity to three types of antigens.

[Table 3]

Results of reactions to naked Trx1 antigens

Antibody ID	5000X(OD Value)
AB264-T150514-7	2.0575
B265-T150514-10	1.3225
AB264-T150514-8	1.1635
B265-T150514-9	0.9515
B267-T150519-5	0.8155
B269-T150519-9	0.735
B268-T150519-8	0.716
B268-T150519-7	0.670
B266-T150519-3	0.6625
B266-T150519-4	0.6615
B269-T150519-10	0.626
B267-T150519-6	0.522

[Table 4]

Results of reactions to Trx1-Fc antigens

Antibody ID	5000X(OD Value)
AB264-T150514-7	1.171
AB264-T150514-8	0.494
B265-T150514-10	0.378
B265-T150514-9	0.273
B266-T150519-3	0.198
B266-T150519-4	0.181
B267-T150519-5	0.043

B267-T150519-6	0.023
B268-T150519-8	0.015
B268-T150519-7	0.003
B269-T150519-9	0.002
B269-T150519-10	-0.001

[Table 5]

Results of reactions to Trx1-His antigens

Antibody ID	5000X(OD Value)
AB264-T150514-7	1.996
B265-T150514-10	1.465
AB264-T150514-8	1.142
B265-T150514-9	1.03
B267-T150519-5	0.857
B268-T150519-8	0.783
B269-T150519-9	0.77
B268-T150519-7	0.761
B269-T150519-10	0.717
B266-T150519-3	0.696
B266-T150519-4	0.667
B267-T150519-6	0.554

The amino acid sequences of the antibodies B264 and B266 with high affinity are shown in Table 6 below.

[Table 6]

	Amino acid sequence
B264 light chain	DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQ KPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAED LGVYYCFQGSHVPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLT SGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDS KDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRN EC (SEQ ID NO: 17)
B264 heavy chain	QVQLQQSGAELARPGASVKMSCKASGYTFTSYTMHWVKQRP GQGLEWIGYINPTSDYTNYNQKFKDKATLTADKSSSTAYMQL SSLTSEDSAVYFCASEGGFLYYFDYWGQGTTLTVSSASTTPPSV YPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGV HTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVD KKIVPRDCGCKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCV

2018349387 10 Apr 2020

	VVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSVSE LPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRPKAPQV YTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENY KNTQPIMDTDGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLH NHHTEKSLSHSPGK (SEQ ID NO: 18)
B266 light chain	QIVLTQSPAIMSASPGEKVTMTCSASSRISYMYWYQQKPGTSP KRWIYDTSKLASGVPARFSGSGSGTSYSLTISTMEAEDAATYY CHQRSSYPTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASV VCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYS MSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ ID NO: 19)
B266 heavy chain	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTFMHWVKQRPE QGLEWIGRIDPANGNTKYDPKFQGKATITADTSSNTAYLQLSS LTSEDTAVYYCALLQYSAMDYWGQGTSVTVSSAKTTPPSVYP LAPGCGDTTGSSVTLGCLVKGYFPESVTVTWNSGSLSSSVHTF PALLQSGLYTMSSSVTVPSSTWPSQTVTCSVAHPASSTTVDKK LEPSGPISTINPCPPCKECHKCPAPNLEGGPSVFIFPPNIKDVLMI SLTPKVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHRED YNSTIRVVSTLPIQHQDWMSGKEFKCKVNNKDLPSPIERTISKI KGLVRAPQVYILPPPAEQLSRKDVSLTCLVVGFNPGDISVEWTS NGHTEENYKDTAPVLDSDGSYFIYSKLNMKTSKWEKTDSFSC NVRHEGLKNYYLKKTISRSPG (SEQ ID NO: 20)

[Example 6]

Production of antibodies B264 and B266

6-1. Preparation of plasmids expressing antibodies B264 and B266

Since the amino acid sequences of the antibodies B264 and B266 are identified as shown in Table 6, genes corresponding to the light chain and heavy chain of the respectively antibodies can be chemically synthesized. The synthesized gene sequences are shown in Table 7 below. The synthesized genes were cloned in pcDNA3.0.

[Table 7]

	Gene sequence
B264 light chain	GACGTGCTGATGACACAGACACCACTCAGCCTCCCTGTGAGC CTGGGCGACCAGGCCTCTATTTCTTGCCGGTCTAGCCAGAGC ATCGTGCACTCCAACGGCAACACATACTTGGAGTGGTATCTA CAGAAGCCCGGCCAGTCCCCTAAGCTGCTGATATACAAGGT GTCTAACCGCTTCTCCGGCGTGCCCGACAGGTTCTCTGGCAG

2018349387 10 Apr 2020

	CGGCTCTGGCACCGACTTCACCCTCAAAATATCTAGGGTGGA GGCCGAGGACCTGGGCGTGTACTACTGCTTCCAGGGCTCCCA CGTTCCATACACATTCGGCGGCGGCACAAAGTTGGAAATTA AGCGCGCTGACGCAGCCCCAACAGTGAGCATCTTTCCTCCAT CCTCTGAACAACTTACCTCTGGAGGAGCCTCTGTGGTGTGTT TCCTGAACAACTTCTACCCAAAGGACATCAATGTGAAGTGG AAGATTGATGGCTCTGAGAGACAGAATGGAGTGCTGAACTC CTGGACAGACCAGGACAGCAAGGACAGCACCTACAGTATGA GTAGCACCCTGACCCTGACCAAGGATGAATATGAGAGACAC AACTCCTACACTTGTGAGGCTACCCACAAGACCAGCACCAG CCCAATTGTCAAATCCTTCAACAGGAATGAGTGTTAA (SEQ ID NO: 21)
B264 heavy chain	CAGGTGCAGCTCCAGCAGTCCGGCGCCGAACTGGCCAGACCTG GCGCCAGCGTGAAGATGAGCTGCAAGGCCTCCGGCTACACATT CACATCTTACACCATGCACTGGGTGAAGCAGAGACCCGGCCAG GGCCTGGAGTGGATTGGCTACATTAACCCAACATCCGACTACAC AAACTACAACCAGAAGTTCAAGGACAAGGCCACACTCACCGCC GACAAGTCTTCTAGCACAGCCTACATGCAGCTGTCTAGCCTGAC AAGCGAGGACTCTGCCGTGTACTTCTGCGCCTCTGAGGGCGGCT TCCTGTACTACTTCGACTACTGGGGCCAGGGCACCACCCTGACC GTGTCCTCTGCCAAAACGACACCCCCATCTGTCTATCCACTGGC CCCTGGATCTGCTGCCCAAACTAACTCCATGGTGACCCTGGGAT GCCTGGTCAAGGGCTATTTCCCTGAGCCAGTGACAGTGACCTGG AACTCTGGATCCCTGTCCAGCGGTGTGCACACCTTCCCAGCTGT CCTGCAGTCTGACCTCTACACTCTGAGCAGCTCAGTGACTGTCC CCTCCAGCACCTGGCCCAGCGAGACCGTCACCTGCAACGTTGCC CACCCGGCCAGCAGCACCAAGGTGGACAAGAAAATTGTGCCCA GGGATTGTGGTTGTAAGCCTTGCATATGTACAGTCCCAGAAGTA TCATCTGTCTTCATCTTCCCCCCAAAGCCCAAGGATGTGCTCAC CATTACTCTGACTCCTAAGGTCACGTGTGTTGTGGTAGACATCA GCAAGGATGATCCCGAGGTCCAGTTCAGCTGGTTTGTAGATGAT GTGGAGGTGCACACAGCTCAGACGCAACCCCGGGAGGAGCAGT TCAACAGCACTTTCCGCTCAGTCAGTGAACTTCCCATCATGCAC CAGGACTGGCTCAATGGCAAGGAGTTCAAATGCAGGGTCAACA GTGCAGCTTTCCCTGCCCCCATCGAGAAAACCATCTCCAAAACC AAAGGCAGACCGAAGGCTCCACAGGTGTACACCATTCCACCTC CCAAGGAGCAGATGGCCAAGGATAAAGTCAGTCTGACCTGCAT GATAACAGACTTCTTCCCTGAAGACATTACTGTGGAGTGGCAGT GGAATGGGCAGCCAGCGGAGAACTACAAGAACACTCAGCCCAT CATGGACACAGATGGCTCTTACTTCGTCTACAGCAAGCTCAATG TGCAGAAGAGCAACTGGGAGGCAGGAAATACTTTCACCTGCTC TGTGTTACATGAGGGCCTGCACAACCACCATACTGAGAAGAGC CTCTCCCACTCTCCTGGTAAATAA (SEQ ID NO: 22)
B266	CAGATCGTGCTCACACAGTCTCCAGCCATCATGAGCGCCTCT

2018349387 10 Apr 2020

light chain	CCTGGCGAGAAGGTGACAATGACCTGCTCTGCCTCTAGCCGC ATTTCTTACATGTACTGGTATCAGCAGAAGCCAGGCACCTCC CCTAAGAGGTGGATATACGACACATCCAAGCTGGCCTCCGG CGTGCCCGCCCGGTTCAGCGGCTCTGGCAGCGGCACAAGCT ACTCCCTGACAATTAGCACGATGGAGGCCGAGGACGCCGCC ACATACTACTGCCACCAGCGCTCGTCCTACCCAACATTCGGC GCCGGCACAAAATTGGAACTGAAGAGAGCTGACGCAGCCCC AACAGTGAGCATCTTTCCTCCATCCTCTGAACAACTTACCTC TGGAGGAGCCTCTGTGGTGTGTTTCCTGAACAACTTCTACCC AAAGGACATCAATGTGAAGTGGAAGATTGATGGCTCTGAGA GACAGAATGGAGTGCTGAACTCCTGGACAGACCAGGACAGC AAGGACAGCACCTACAGTATGAGTAGCACCCTGACCCTGAC CAAGGATGAATATGAGAGACACAACTCCTACACTTGTGAGG CTACCCACAAGACCAGCACCAGCCCAATTGTCAAATCCTTCA ACAGGAATGAGTGTTAA (SEQ ID NO: 23)
B266 heavy chain	GAGGTGCAGTTACAACAGTCCGGCGCCGAGCTAGTGAAGCCAG GCGCCAGCGTGAAGCTGTCTTGCACAGCCAGCGGCTTCAACATT AAGGACACCTTCATGCACTGGGTGAAGCAGAGACCTGAGCAGG GCTTAGAGTGGATTGGCCGGATCGACCCCGCCAACGGCAACAC AAAGTACGACCCAAAGTTCCAGGGCAAGGCCACAATTACCGCC GACACATCTTCCAACACAGCCTACCTCCAGCTGTCGTCTCTCAC CAGCGAGGACACCGCCGTGTACTACTGCGCCCTGCTCCAGTACT CCGCGATGGACTACTGGGGCCAGGGCACATCTGTGACCGTGTCT AGCGCCAAGACCACCCCACCATCCGTGTACCCACTCGCCCCAG GCTGCGGCGACACCACAGGCTCTAGCGTGACACTGGGCTGCCT GGTGAAGGGCTACTTCCCCGAGTCTGTGACAGTGACCTGGAACT CTGGCTCTCTGTCTAGCTCTGTGCACACCTTCCCCGCCCTGCTGC AATCCGGCCTGTACACAATGTCTTCTTCTGTGACAGTGCCTAGC TCTACATGGCCATCTCAGACAGTGACATGCTCTGTGGCCCACCC CGCCTCTAGCACAACCGTGGACAAGAAGCTGGAGCCATCCGGC CCTATTTCTACAATTAACCCTTGCCCTCCTTGCAAAGAATGCCA CAAGTGCCCCGCCCCAAACCTGGAGGGCGGCCCTTCTGTGTTCA TTTTCCCTCCTAACATTAAGGACGTGCTGATGATCAGCCTCACC CCAAAGGTGACATGCGTGGTGGTGGACGTGTCCGAGGACGACC CTGACGTGCAGATTTCTTGGTTCGTGAACAACGTGGAGGTGCAC ACCGCCCAGACCCAGACCCACCGGGAGGACTACAACTCCACCA TTCGGGTGGTGTCTACACTGCCTATTCAGCACCAGGACTGGATG AGCGGCAAAGAGTTCAAGTGCAAGGTGAACAACAAGGACCTGC CATCTCCTATTGAGAGAACAATTTCTAAGATTAAGGGCCTGGTG CGCGCCCCTCAGGTGTACATTCTGCCTCCTCCCGCCGAGCAGCT GAGCCGGAAGGACGTGTCCCTCACATGCCTCGTGGTGGGCTTCA ACCCTGGCGACATTAGCGTGGAGTGGACATCTAACGGCCACAC AGAAGAAAACTACAAGGACACAGCCCCTGTGCTCGACTCCGAC GGCTCTTACTTCATATACTCTAAGCTGAACATGAAAACATCTAA

	GTGGGAAAAGACCGACTCTTTCTCTTGCAACGTGCGGCACGAG GGCCTGAAGAACTACTACCTCAAGAAAACCATTAGCAGAAGTC CAGGCTAA (SEQ ID NO: 24)

6-2. Expression and purification of antibodies B264 and B266

A HEK293 cell line was co-transfected with pcDNA3-SSJ11-L and pcDNA3-SSJ11-H to express a B264 antibody or pcDNA3-SSJ12-L and pcDNA3-SSJ12-H to express a B266 antibody, and cultured for 7 days. The cell line was cultured, and recombinant monoclonal antibodies secreted into the culture medium were collected and purified through protein A chromatography. An eluent containing the recombinant monoclonal antibodies was concentrated by ultrafiltration, and the antibodies were obtained with high purity using a 0.2-μm sterile filter.

The purity and size of the purified antibodies were determined through SDS-PAGE. As a result of SDS-PAGE, as shown in FIG. 6, it was confirmed that the antibodies B264 and B266 are expressed with sizes, for example, 47 kDa for the heavy chain and 25 kDa for the light chain under a reducing condition, and 150 kDa under a non-reducing condition, suggesting that the sizes correspond to estimated sizes.

[Example 7]

Confirmation of pairing of two types of monoclonal antibodies obtained through sandwich ELISA

100 μl of a coating buffer (0.015 M Na_2CO_3, 0.035 M $NaHCO_3$, 0.003 M NaN_3, pH9.6) and 100 ng of a coating antibody (B266) were mixed and dispensed to each well, and an O/N reaction was performed at 4 °C. 200 μl of 1% BSA-containing PBS (PBSA; blocking buffer) per well was dispensed, and subjected to a reaction at room temperature for 60 minutes. Afterward, 20 μl of an antigen (50, 25, 12.5 or 0 ng) was dispensed, 80 μl of a detection antibody (biotin-labeled B264; B264-B) was dispensed, and the resulting mixture was reacted

at 37 °C for 90 minutes. A reaction solution was removed, and washing was performed by dispensing 200 μl of PBS containing 0.05% Tween 20 (PBST; washing buffer) to each well. The above-described process was performed three times.

100 μl of streptavidin-HRP diluted 1:200 was treated in each well and reacted at 37 °C for 30 minutes. After a reaction solution was removed, washing was performed by dispensing 200 μl of PBS containing 0.05% Tween 20 (PBST; washing buffer) to each well. The above-described process was performed three times.

100 μl of a TMB solution was dispensed to each well and reacted under a dark condition at room temperature for 10 minutes, 100 μl of a 2.5M sulfuric acid solution (H_2SO_4; stop buffer) was treated in each well, and the result was confirmed at 450 nm.

As a result, as shown in Table 8, the reaction value increases according to the concentration of an antigen, showing the detection of the antigen by these antibodies. However, since the O.D. value is high when there is no antigen, a performance improvement experiment using an antibody is needed.

[Table 8]

Sandwich ELISA using B266 as coating antibody and B264 as detection antibody

Trx1 (ng/mL)	0	12.5	25	50
$O.D._{450nm}$	0.828	1.226	1.506	2.257

[Example 8]

Alteration of isotype of Fc part for improving antibody performance

Since the expression system of an antibody is transient transfection using a recombinant plasmid, rather than a hybridoma, among these recombinant plasmids, a plasmid having a heavy chain was co-transfected with a plasmid having a different isotype of heavy chain. That is, a plasmid having a gene encoding a different heavy chain, rather than

pcDNA3-SSJ12-H of pcDNA3-SSJ12-L and pcDNA3-SSJ12-H used to express 9G7(AB1), was co-transfected.

An antibody (B266-1) in which the Fc part of B266 is changed to human IgG1 was obtained by the above-described method. The characteristics of the antibody were determined through SDS-PAGE (FIG. 7).

CDR sequences of the finally selected monoclonal antibodies B264 and B266-1 were determined by fusion with an Fc region suitable for back translation and recombinant expression.

IMTG-gap alignment is IMTG database and "determined sequence" alignment, and the closest germline sequence and hypermutation were identified by a database search. The IMTG-gap alignment results for the light chain and heavy chain of each of the antibodies B266-1 and B264 are shown in FIGS. 8A to 8D, amino acid sequences of light chains CDR1 to CDR3 and heavy chains CDR1 to CDR3 are shown in Table 9, and amino acid sequences of a light chain variable region and a heavy chain variable region are shown in Table 10. In addition, the amino acid sequences and gene sequences of the light chains and heavy chains of B266-1 are shown in Table 11.

[Table 9]

	Amino acid sequence
Light chain CDR1 of B264	QSIVHSNGNTY (SEQ ID NO: 1)
Light chain CDR2 of B264	KVS (SEQ ID NO: 2)
Light chain CDR3 of B264	CFQGSHVPYT (SEQ ID NO: 3)
Heavy chain CDR1 of B264	GYTFTSYT (SEQ ID NO: 4)
Heavy chain CDR2 of B264	INPTSDYTN (SEQ ID NO: 5)
Heavy chain CDR3 of B264	FCASEGGFLYYFDY (SEQ ID NO: 6)
Light chain CDR1 of B266-1	SRISY (SEQ ID NO: 7)
Light chain CDR2 of B266-1	DTS (SEQ ID NO: 8)
Light chain CDR3 of B266-1	CHQRSSYPTF (SEQ ID NO: 9)
Heavy chain CDR1 of B266-1	GFNIKDTF (SEQ ID NO: 10)
Heavy chain CDR2 of B266-1	IDPANGNT (SEQ ID NO: 11)
Heavy chain CDR3 of B266-1	CALLQYSAMDY (SEQ ID NO: 12)

[Table 10]

	Amino acid sequence
Light chain variable region of B264	DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNT YLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGS GTDFTLKISRVEAEDLGVYYCFQGSHVPYTFGGGT KLEIK (SEQ ID NO: 13)
Heavy chain variable region of B264	QVQLQQSGAELARPGASVKMSCKASGYTFTSYTM HWVKQRPGQGLEWIGYINPTSDYTNYNQKFKDKA TLTADKSSSTAYMQLSSLTSEDSAVYFCASEGGFLY YFDYWGQGTTLTVSS (SEQ ID NO: 14)
Light chain variable region of B266-1	QIVLTQSPAIMSASPGEKVTMTCSASSRISYMYWYQ QKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSL TISTMEAEDAATYYCHQRSSYPTFGAGTKLELK (SEQ ID NO: 15)
Heavy chain variable region of B266-1	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTFMH WVKQRPEQGLEWIGRIDPANGNTKYDPKFQGKATI TADTSSNTAYLQLSSLTSEDTAVYYCALLQYSAMD YWGQGTSVTVSS (SEQ ID NO: 16)

[Table 11]

	Sequence
Amino acid sequence of B266-1 light chain	QIVLTQSPAIMSASPGEKVTMTCSASSRISYMYWYQQKPGT SPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISTMEAEDA ATYYCHQRSSYPTFGAGTKLELKSVAAPSVFIFPPSDEQLK SGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPV TKSFNRGEC (SEQ ID NO: 25)
Amino acid sequence of B266-1 heavy chain	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTFMHWVKQ RPEQGLEWIGRIDPANGNTKYDPKFQGKATITADTSSNTAY LQLSSLTSEDTAVYYCALLQYSAMDYWGQGTSVTVSSAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLF PPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK (SEQ ID NO: 26)
Gene sequence of B266-1 light chain	CAGATCGTGCTCACACAGTCTCCAGCCATCATGAGCGCC TCTCCTGGCGAGAAGGTGACAATGACCTGCTCTGCCTCT AGCCGCATTTCTTACATGTACTGGTATCAGCAGAAGCCA

2018349387 10 Apr 2020

	GGCACCTCCCCTAAGAGGTGGATATACGACACATCCAA GCTGGCCTCCGGCGTGCCCGCCCGGTTCAGCGGCTCTGG CAGCGGCACAAGCTACTCCCTGACAATTAGCACGATGG AGGCCGAGGACGCCGCCACATACTACTGCCACCAGCGC TCGTCCTACCCAACATTCGGCGCCGGCACAAAATTGGAA CTGAAGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCA TCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTG TGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTA CAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTC CCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCA CCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCA GACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCAC CCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAA CAGGGGAGAGTGTTAG (SEQ ID NO: 27)
Gene sequence of B266-1 heavy chain	GAGGTGCAGTTACAACAGTCCGGCGCCGAGCTAGTGAAG CCAGGCGCCAGCGTGAAGCTGTCTTGCACAGCCAGCGGC TTCAACATTAAGGACACCTTCATGCACTGGGTGAAGCAG AGACCTGAGCAGGGCTTAGAGTGGATTGGCCGGATCGAC CCCGCCAACGGCAACACAAAGTACGACCCAAAGTTCCAG GGCAAGGCCACAATTACCGCCGACACATCTTCCAACACA GCCTACCTCCAGCTGTCGTCTCTCACCAGCGAGGACACCG CCGTGTACTACTGCGCCCTGCTCCAGTACTCCGCGATGGA CTACTGGGGCCAGGGCACATCTGTGACCGTGTCTAGACC AAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGA GCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCA AGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACT CAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTG TCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGT GACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACAT CTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGA CAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACAC ATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACC GTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTC ATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTG GACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGG TACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAG CCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTC AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGC AAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCA GCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAG CCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGG GAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTG GTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGG GAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCAC

	GCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTAC AGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGG GAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCAC AACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT AAATGA (SEQ ID NO: 28)

[Example 9]

Confirmation of pairing of monoclonal antibodies B266-1 and B264 obtained through sandwich ELISA

100 μl of a coating buffer and 100 ng of a coating antibody (B266-1) were mixed and dispensed to each well, and an O/N reaction was performed at 4 °C. Washing was performed by dispensing 200 μl of a washing buffer. The above-described process was performed two times.

200 μl of PBSA was dispensed to each well and reacted at room temperature for 120 minutes, and then 20 μl of an antigen (25 or 0 ng) was dispensed, 80 μl of a detection antibody (B264-B) was dispensed, and a reaction was performed at 37 °C for 90 minutes. A reaction solution was removed, and then washing was performed by dispensing 200 μl of a washing buffer to each well. The above-described process was performed three times.

100 μl of streptavidin-HRP diluted 1:200 was treated in each well, a reaction was performed at 37 °C for 30 minutes, a reaction solution was removed, and then washing was performed by dispensing 200 μl of washing buffer to each well. The above-described process was performed three times.

100 μl of a TMB solution was dispensed to each well, a reaction was performed under a dark condition at room temperature for 10 minutes, 100 μl of a stop buffer was treated in each well, and the result was confirmed at 450 nm.

As a result, as shown in Table 12, it was confirmed that the antibodies are suitably reacted with antigens, and a blank value was decreased as compared with the antibodies used

10 Apr 2020 2018349387

in Example 6.

[Table 12]

Sandwich ELISA using B266-1 as coating antibody and B264 as detection antibody

Trx1 (ng/mL)	0		25	
O.D.$_{450nm}$	0.425	0.415	1.571	1.426

[Example 10]

Analysis of affinity of monoclonal antibody to antigen

Two types of monoclonal antibodies specifically acting on the antigen Trx1 were expressed using a transient transfection system using a plasmid, and thus stably produced. To confirm the affinity to an antigen, analysis was performed through ELISA ((a) in FIG. 9).

100 μl of a coating buffer and 100 ng of Trx1 were mixed and dispensed to each well, and then reacted at 4 °C for 16 hours or more. After the reaction solution was removed, 200 μl of PBSA was dispensed to each well and reacted at 37 °C for 120 minutes. After the reaction solution was removed, the produced antibody B266-1 or B264 was diluted 1/5 from 0.1 μM, and dispensed to each well at 100 μl, and then reacted at 37 °C for 120 minutes. After the reaction solution was removed, washing was performed by dispensing 200 μl of a washing buffer to each well. The above-described process was performed two times.

100 μl of human IgG-HRP (diluted to 1:4000) as the antibody B266-1 was reacted with 100 μl of mouse IgG-HRP (diluted to 1:4000) as the antibody B264 at 37 °C for 60 minutes. After the reaction solution was removed, washing was performed by dispensing 200 μl of a washing buffer to each well. The above-described process was performed three times.

100 μl of a TMB solution was dispensed to each well, a reaction was performed under a dark condition at room temperature for 10 minutes, 100 μl of a stop buffer was treated in each well, and the result was confirmed at 450 nm. The resulting values were analyzed using Prism

10 Apr 2020 2018349387

(Graphpad) ((b) in FIG. 9).

As a result of analyzing the affinity of the coating antibody B266-1 and the detection antibody B264, it was confirmed that a blank value is high due to the reactivity of B266-1, but B266-1 and B264 are increased in binding degree according to an increased concentration of an antigen. This shows that B266-1 and B264 are bound with an antigen. When an equilibrium dissociation constant (K_D) value is calculated through analysis using the Prism program, the K_D of B266-1 was 1.1×10^{-11}, and the K_D of B264 was 1.3×10^{-10}. When the K_D value is between 10^{-10} and 10^{-12}, it was evaluated that the antibody has a picomole (pM) level of sensitivity to an antigen, showing that B266-1 and B264 have a high level of sensitivity to an antigen.

[Example 11]

Sandwich ELISA of serum of breast cancer patient

Sandwich ELISA using a coating antibody (B266-1) was prepared in a process as follows.

A 1 μg/mL coating antibody solution was prepared by adding 100 mL of a coating buffer and 0.1 mL of 1 mg/mL B266-1. 100 μl of the prepared coating antibody solution was dispensed to each well of a 96-well plate, and reacted at 4 °C for 12 hours. The antibody solution was removed, and washing was performed by dispensing 200 μl of 0.05% PBST to each well. The washing was performed three times. 200 μl of PBSA was treated in each well, and a reaction (blocking process) was performed at 4 °C for 4 hours. The PBSA was removed, and then the 96-well plate was dried in a thermo-hygrostat (20 °C, 30% R.H.) for 3 hours.

Afterward, the detection antibody (B264) was biotinylated with a process as follows.

Dimethyl sulfoxide (DMSO) is mixed with 20 mg/mL biotin-7-NHS, thereby

2018349387 10 Apr 2020

preparing 2 mg/mL biotin-7-NHS. 15 μl (30 μg) of 2 mg/mL biotin-7-NHS was added to the 1 mg/mL B264 antibody, and reacted at 15 to 25 °C for 2 hours. A reaction solution was added to AMICON ultra-15 (Millipore), filled with a PBS solution to the final volume, and centrifuged at 3,600 x g until it remained at 0.5 mL. The process was performed three times. The antibody solution (biotinylated B264; B264-B) remaining in the AMICON filter was transferred to a 1.5 mL tube, and filled with PBSA to the final concentration of 0.3 mg/mL.

Subsequently, human Trx1 antigen detection from the serum of a breast cancer patient was performed as follows.

A standard antigen solution was dispensed to the first column of a 96-well plate coated with a coating antibody. 20 μl of the serum obtained from a breast cancer was dispensed, and then 80 μl (0.3 mg/mL) of a B264-B solution was dispensed. Afterward, after a reaction at 37 °C for 60 minutes, an antigen-antibody reaction solution was removed, and then washing was performed by dispensing 200 μl of PBST to each well. The washing process was performed three times. 100 μl of a 1:400-dilution of streptavidin-HRP (R&D Systems) was dispensed, and a reaction was performed at 37 °C for 30 minutes. After the reaction, a reaction solution was removed, and washing was performed by dispensing 200 μl of PBST to each well. The washing process was performed three times. 100 μl of a TMB solution (Sure Blue) was treated, and a reaction was performed at room temperature for 15 minutes under a dark condition. 100 μl of a 2N H_2SO_4 solution was dispensed, and an absorbance was measured at 450 nm using a microplate reader.

Finally, ROC analysis was performed as follows.

Sensitivity and specificity were calculated by analyzing a result of ELISA using monoclonal antibodies B266-1 and B264 against Trx1. When a cut-off value was 10.8 ng/mL, the sensitivity was 93.0%, and the sensitivity was 97.4% (FIG. 10).

[Example 12]

Comparative analysis with another ELISA kit for breast cancer diagnosis

In this example, to evaluate the performance of recombinant monoclonal antibodies B266-1 and B264, another ELISA kit for detecting another biomarker CA15-3 for breast cancer diagnosis was comparatively analyzed (Table 13).

As a result, as shown in Table 13, when a monoclonal antibody specifically binding to Trx1 is used, sensitivity and specificity were exceptionally higher than those of CA15-3.

[Table 13]

Comparison of kit of the present invention with AxSYM CA15-3 kit

	Trx1	CA15-3 (AxSYM)
Sensitivity (%)	93	54
Specificity (%)	97.4	94
Test sample	Serum	Serum and plasma

[Example 13]

Expression of *Chrysochloris asiatica* Trx1 protein

13-1. Comparison of sequences of human Trx1 (hTrx1) and *Chrysochloris asiatica* Trx1 (CaTrx1)

As a result of the comparison of amino acid sequences between hTrx1 and *Chrysochloris asiatica* Trx1, which is structurally similar but has low amino acid sequence similarity to hTrx1, it was confirmed that they have a homology of 82% (FIG. 10).

A gene was synthesized using a known base sequence of CaTrx1 (NCBI Accession Number XM_006863001.1), and to store the gene in *E. coli*, the gene was cloned into a pUCIDT-AMT plasmid. The gene-cloning plasmid was treated with restriction enzymes Sfi I and Xho I, followed by electrophoresis. As a result, as shown in FIG. 12, in the restriction

enzyme-treated plasmid (lane 2), a 357-bp DNA fragment cleaved from the plasmid was identified, indicating that the CaTrx1 gene was synthesized (arrow of FIG. 12).

13-2. Expression of CaTrx1 protein

Following the transfection of an animal cell with the CaTrx1 plasmid prepared in Example 13-1, CaTrx1 secreted from the cell line was purified, and the protein was confirmed by 15% SDS-PAGE, and the result is shown in FIG. 13. In FIG. 13, in lanes 1 and 2, amounts of a total protein in a CaTrx1 transformant cell culture solution were 5 μg and 10 μg, respectively, in lane 3, an amount of a control protein (BSA; bovine serum albumin) was 3 μg, confirming that the productivity of the purified CaTrx1 protein was 28.75 mg/L.

[Example 14]

Confirmation of affinity of two types of antibodies for hTrx1 and CaTrx1

In this example, the CaTrx1 binding affinity of two types of antibodies B266-1 (Trx1-hIgG1) and B264 (Trx1-mIgG1) was examined.

To confirm the binding affinity of B266-1 (Trx1-hIgG1) and B264 (Trx1-mIgG1) for hTrx1 and CaTrx1, a 96-well ELISA plate was coated with each of 200 ng of hTrx1 and 10 μg of CaTrx1, 200 μL of a blocking buffer (4% Skim milk/1x PBS) was dispensed into each well, followed by a reaction for 1 hour at 37 °C. After the removal of a reaction solution, 100 uL each of B266-1 (Trx1-hIgG1) and B264 (Trx1-mIgG1) was dispensed into each well coated with each antigen, and allowed to react at 37 °C for 2 hours. A reaction solution was removed, followed by washing five times with 200 μL of 1x PBST. 100 μL each of anti-human Fc-HRP and mouse-HRP, diluted 1:4,000, was dispensed into each of the B266-1 (Trx1-hIgG1)-treated wells and each of the B264 (Trx1-mIgG1)-treated wells, respectively, followed by a reaction at 37 °C for 2 hours. A reaction solution was removed, and washed five times with 200 μL of 1x PBST. 100 μL of a color reagent was dispensed into each well, and after a 10-minute reaction, 50 μL of 2.5M H_2SO_4 was dispensed into each well. After color

2018349387 10 Apr 2020

development, the extent of the color development was assessed using an ELISA reader.

As a result of confirmation of the hTrx1 binding affinity of B266-1 (Trx1-hIgG1) and B264 (Trx1-mIgG1), as shown in Table 14 below, for 200 ng of the antigen, it was confirmed that KD=2.1 x 10^{-10} M for B266-1, and the affinity of was detected at KD=1.7 x 10^{-10} M for B264. In addition, referring to A in FIG. 14, it was seen that, compared to B266-1, the reaction value (OD 490) by B264 binding is as low as approximately 50%.

As a result of confirmation of the binding affinity of antibodies B266-1 and B264 for 10 μg of CaTrx1, as shown in B in FIG. 14 and Table 14, it was seen that none of the two types of antibodies bind to CaTrx1.

[Table 14]

	hTRX1		CaTRX1	
	K_D (M)	R^2	K_D (M)	R^2
B266-1	2.1 x 10^{-10}	0.99	Not binding	Not binding
B264	1.7 x 10^{-10}	0.99	Not binding	Not binding

[Example 15]

Manufacture of mutant antigen for hTrx1

15-1. Positioning of mutations through amino acid sequencing between hTrx1 and CaTrx1

A known amino acid sequence of hTrx1 (NCBI Accession Number NP_003320.2) was compared with that of CaTrx1 (NCBI Accession Number XP_006863063.1). As shown in FIG. 15A, although the amino acid sequence homology between hTrx1 and CaTrx1 was 82%, the binding affinity of the antibodies for an antigen was significantly different, and thus there were 8 different parts in which hTrx1 and CaTrx1 have different amino acid sequences (FIG. 15B).

2018349387 10 Apr 2020

15-2. Fusion PCR and cloning for expressing mutant proteins

A) Fragment PCR

In the 8 parts in which hTrx1 and CaTrx1 have different amino acid sequences, identified in Example 15-1, a hTrx1 sequence was substituted with a CaTrx1 sequence, and then a DNA fragment of a cassette for manufacturing a mutant was amplified (FIG. 15D).

Specifically, to manufacture a gene for expressing each mutant protein, two DNA fragments for fusion PCR have to be amplified. Therefore, two types of primers (F2 and R1; FIG. 15C and Table 15) containing a part requiring mutation of a base sequence were manufactured, and DNA fragments were amplified using two pairs of primers F1 and R1 and F2 and R2. To amplify the DNA fragments, template DNA (100-200 ng) and 1 μL each of forward and reverse primers (10 pmol each) were added to 25 μL of 2 x EF-Taq PCR Smart mix (0.5X Band Doctor) (Solgent, SEF02-M50h), and the final volume was adjusted with sterile purified water, followed by stirring well and amplification using a PCR device (Thermal cycler, T100).

[Table 15]

Purpose	Primer name	Sequence (5'->3')	Role of primer in FIG. 15C	SEQ ID NO:
Fragment amplification	Vector-F	GGCGTGTACGGTGGGAGGT	F1	SEQ ID NO: 46
	Vector-R	AGCAGCGTATCCACATAGCG	R2	SEQ ID NO: 47
TRX1-M1 mutation	TRX M1-F	CATCACGTCAAAGAGATCGAAGGCAAAGAAGATTTTCAAGAAGCCCTGGACGCCGCT	F2	SEQ ID NO: 48
	TRX M1-R	GGCTTCTTGAAAATCTTCTTTGCCTTCGATCTCTTTGACGTGATGATGATGATGATGAT	R1	SEQ ID NO: 49
TRX1-M2 mutation	TRX M2-F	AAAACCGCATTTCATGCTGCCCTGAGCAGTGCTGGTGACAAACTGGTCGTGG	F2	SEQ ID NO: 50
	TRX M2-R	TTTGTCACCAGCACTGCTCAGGGCAGCATGAAATGCGGTTTTG	R1	SEQ ID NO: 51

2018349387 10 Apr 2020

		ATTCGATCTG		
TRX1-M3 mutation	TRX-M3-OV-F	ATTAAACCGTTTTATCATAGCCTGTCTGAAAAATACAGTAACGTTATCTTTCTGGAAG	F2	SEQ ID NO: 52
	TRX-M3-OV-R	AGACAGGCTATGATAAAACGGTTTAATCATTTTACACGGGCCGCACCAGG	R1	SEQ ID NO: 53
TRX1-M4 mutation	TRX-M4-OV-F	CTGTCTGAAAAATTTGGCAACATGGTGTTCCTGGAAGTGGATGTTGATGACTGCCAGGACGTCGC	F2	SEQ ID NO: 54
	TRX-M4-OV-R	ATCCACTTCCAGGAACACCATGTTGCCAAATTTTTCAGACAGGCTATGGAAAAACGGTTTAATCATTTTACAC	R1	SEQ ID NO: 55
TRX1-M5 mutation	TRX-M5-OV-F	GTGAAATGTATGATAACGTTCCAGTTTTTCAAAAAAGGTCAAAAAGTCGGTGAAT	F2	SEQ ID NO: 56
	TRX-M5-OV-R	AAACTGGAACGTTATCATACATTTCACTTCGCATTCGCTCGCGACGTCC	R1	SEQ ID NO: 57
TRX1-M6 mutation	TRX-M6-OV-F	ACGTTCCAGTTTTATAAAAAAAGGGAAAAAGTCGGTGAATTTAGCGGTGCCAACAAAGAAAAACT	F2	SEQ ID NO: 58
	TRX-M6-OV-R	TTCACCGACTTTTTCCCTTTTTTTATAAAACTGGAACGTCGGCATACATTTCACTTCGCATTCG	R1	SEQ ID NO: 59
TRX1-M7 mutation	TRX-M7-Xho-R	GAATTCTCGAGCTATCACACCAGTTCGTTAATCGTGGCTTCCAGTTTTTCTTTGTTAACACCGCTAAATTCACCGACTTTTTGA	F2	SEQ ID NO: 60
TRX1-M8 mutation	TRX-M8-Xho-R	GAATTCTCGAGCTATCAACACAGTTCGTTAATGATGGCTTCCAGTTTTTCTTTGTTGGC	R1	SEQ ID NO: 61
Colony PCR	N293F-colo-F	GGCGTGTACGGTGGGAGGT	-	SEQ ID NO: 62
	N293F-colo-R	AGCAGCGTATCCACATAGCG	-	SEQ ID NO: 63

PCR was carried out under conditions of 1 cycle of pre-denaturation at 95 °C for 2 min, 30 cycles of 3-step amplification at 95 °C for 20 sec; at 62 °C for 40 sec; and at 72 °C for 1 min, and 1 cycle of post-extension at 72 °C for 5 min, and then the reaction was terminated.

10 Apr 2020 2018349387

The amplified DNA fragment was confirmed using a 1% agarose gel (FIG. 15D). Purification of a gene was carried out using a QIAquick Gel Extraction Kit (QIAGEN, 28704) according to the manufacturer's protocol.

B) Fusion PCR for fusing two types of DNA fragments and purification of PCR product

To fuse the amplified DNA fragments, PCR was carried out using two DNA fragments and primers F1 and R2 (FIG. 15C). A PCR mixture for fusion PCR was prepared by adding 100 to 150 ng each of the two types of DNA fragments and 1 μL each of forward and reverse primers (10 pmol each) to 25 μL 2 x EF-Taq PCR Smart mix(0.5X Band Doctor) (Solgent, SEF02-M50h), and the final volume was adjusted with sterile purified water, followed by stirring well and amplification with a PCR device. PCR was carried out under conditions of 1 cycle of pre-denaturation at 95 °C for 2 min, 30 cycles of 3-step amplification at 95 °C for 20 sec; at 62 °C for 40 sec; and at 72 °C for 1 min, and 1 cycle of post-extension at 72 °C for 5 min, and then the reaction was terminated. After the termination of the reaction, a PCR product was confirmed using a 1% agarose gel (FIG. 15E).

After the termination of the fusion PCR, the produced PCR product was purified using ethanol precipitation. 3 M sodium acetate (pH 5.2) and 100% ethanol were respectively added to the amplified PCR product at 1/10-fold and 2-fold of the total volume of the PCR product, and well stirred, reacted in a -70 °C ultra-low temperature freezer for 10 minutes. Afterward, the resulting mixture was centrifuged at 13,000 rpm for 10 minutes, a supernatant was removed, 1 mL of 70% ethanol was added, and then the resulting mixture was stirred, followed by centrifugation at 13,000 rpm for 10 minutes. A supernatant was removed and residual ethanol was removed by a reaction in a 70 °C heat block for 3 minutes, and a DNA pellet was dissolved well in 50 μL of distilled water.

2018349387 10 Apr 2020

C) Cloning of PCR product

To clone the purified PCR product into a N293F plasmid, a restriction enzyme was treated. Specifically, 50 μL of the PCR product and the N293F plasmid was treated with each of 7 μL of Kpn I and 8 μL of a 10x buffer, and a total volume was adjusted to 80 μL. After stirring well, the resulting mixture was reacted in a 37 °C water bath for 3 hours. After the termination of the reaction, the resulting mixture was purified by ethanol precipitation. Afterward, the purified mixture was treated with 7 μL of Xho I and 8 μL of a 10x buffer, and the total volume was adjusted to 80 μL. After stirring well, the resulting product was reacted in a 37 °C water bath for 3 hours. To purify the reaction-terminated DNA, an experiment was carried out using a QIAquick Gel Extraction Kit (QIAGEN, 28704) according to the manufacturer's protocol.

To clone the purified DNA fragment into N293F, 20 ng of N293F which was treated with a DNA fragment (100 ng; 1Kb or less, 300 ng; 3 kb or less) and the restriction enzymes, was treated with1 μL of a T4 DNA ligase (Thermo Scientific, EL0011) and 1 μL of a 10x buffer were added, and the total volume was adjusted to 10 μL with distilled water. The resulting mixture was reacted for 16 hours at 22 °C. After termination of the reaction, DH5 competent cells were extracted to be transformed into *E. coli*, and dissolved on ice. 2 μL of a ligation product was well mixed with DH5α competent cells, and then reacted on ice for 30 minutes. Subsequently, the reaction product was reacted in a 42 °C water bath for 90 seconds, and further reacted on ice for 3 minutes. 500 μL of an SOC medium (20 g of Bacto Tryptone, 5 g of Bacto Yeast Extract, and 0.5 g of NaCl per liter) were added to the reaction product, and incubated in a 37 °C shaking incubator for 30 minutes. After incubation, 100 μL of the reaction product was sprayed and spread on a 100 μg/mL ampicillin-added LB medium (10 g of Bacto Tryptone, 5 g of Bacto Yeast Extract, and 10 g of NaCl per liter), and incubated in a 37 °C incubator for 12 to 16 hours.

2018349387 10 Apr 2020

D) Colony PCR and sequencing to confirm transformation

To confirm the presence or absence of a cloning plasmid, colony PCR was performed. A PCR mixture for fusion PCR was prepared by adding 0.5 mL each of forward and reverse primers (10 pmol each) to 12.5 μL 2 x EF-Taq PCR Smart mix(0.5X Band Doctor) (Solgent, SEF02-M50h), and the final volume was adjusted with sterile distilled water, followed by stirring well and amplification by PCR. PCR was performed under conditions of 1 cycle of pre-denaturation at 95 °C for 2 min, 25 cycles of 3-step amplification at 95 °C for 20 sec; at 62 °C for 40 sec; and at 72 °C for 1 min, and 1 cycle of post-extension at 72 °C for 5 min, and then the reaction was terminated.

After the termination of the reaction, the amplified product was confirmed using a 1% agarose gel (FIG. 15F). The amplified product was purified, and Neoprobe Corp was commissioned to carry out sequencing. Sequencing data is shown in Table 16 below. Sequences underlined in bold type indicate sequences that have been mutated.

[Table 16]

Name	Base sequence data	SEQ ID NO:
TRX-N-His-M1	GTCAAA**GAGATCGAAGGCAAAGAAGAT**TTT CAAGAAGCCCTGGACGCCGCTGGTGACAAAC TGGTCGTGGTGGACTTTAGTGCTACCTGGTG CGGCCCGTGTAAAATGATTAAACCGTTTTTC CATAGCCTGTCTGAAAAATACAGTAACGTTA TCTTTCTGGAAGTGGATGTTGATGACTGCCA GGACGTCGCGAGCGAATGCGAAGTGAAATG TATGCCGACGTTCCAGTTTTTCAAAAAAGGT CAAAAAGTCGGTGAATTTAGCGGTGCCAACA AAGAAAAACTGGAAGCCACGATTAACGAAC TGGTG	SEQ ID NO: 38
TRX-N-His-M2	GTCAAACAGATCGAATCAAAAACCGCATTT**C** **ATGCTGCCCTGAGCAGT**GCTGGTGACAAAC TGGTCGTGGTGGACTTTAGTGCTACCTGGTG CGGCCCGTGTAAAATGATTAAACCGTTTTTC CATAGCCTGTCTGAAAAATACAGTAACGTTA TCTTTCTGGAAGTGGATGTTGATGACTGCCA	SEQ ID NO: 39

2018349387 10 Apr 2020

	GGACGTCGCGAGCGAATGCGAAGTGAAATG TATGCCGACGTTCCAGTTTTTCAAAAAAGGT CAAAAAGTCGGTGAATTTAGCGGTGCCAACA AAGAAAAACTGGAAGCCACGATTAACGAAC TGGTG	
TRX-N-His-M3	GTCAAACAGATCGAATCAAAAACCGCATTTC AAGAAGCCCTGGACGCCGCTGGTGACAAACT GGTCGTGGTGGACTTTAGTGCTACCTGGTGC GGCCCGTGTAAAATGATTAAACCG**TTTTAT**C ATAGCCTGTCTGAAAAATACAGTAACGTTAT CTTTCTGGAAGTGGATGTTGATGACTGCCAG GACGTCGCGAGCGAATGCGAAGTGAAATGT ATGCCGACGTTCCAGTTTTTCAAAAAAGGTC AAAAAGTCGGTGAATTTAGCGGTGCCAACAA AGAAAAACTGGAAGCCACGATTAACGAACT GGTG	SEQ ID NO: 40
TRX-N-His-M4	GTCAAACAGATCGAATCAAAAACCGCATTTC AAGAAGCCCTGGACGCCGCTGGTGACAAACT GGTCGTGGTGGACTTTAGTGCTACCTGGTGC GGCCCGTGTAAAATGATTAAACCGTTTTTCC ATAGCCTGTCTGAAAAA**TTTGGCAACATGG** **TG**TTCCTGGAAGTGGATGTTGATGACTGCCA GGACGTCGCGAGCGAATGCGAAGTGAAATG TATGCCGACGTTCCAGTTTTTCAAAAAAGGT CAAAAAGTCGGTGAATTTAGCGGTGCCAACA AAGAAAAACTGGAAGCCACGATTAACGAAC TGGTG	SEQ ID NO: 41
TRX-N-His-M5	GTCAAACAGATCGAATCAAAAACCGCATTTC AAGAAGCCCTGGACGCCGCTGGTGACAAACT GGTCGTGGTGGACTTTAGTGCTACCTGGTGC GGCCCGTGTAAAATGATTAAACCGTTTTTCC ATAGCCTGTCTGAAAAATACAGTAACGTTAT CTTTCTGGAAGTGGATGTTGATGACTGCCAG GACGTCGCGAGCGAATGCGAAGTGAAATGT ATG**ATA**ACGTTCCAGTTTTTCAAAAAAGGTC AAAAAGTCGGTGAATTTAGCGGTGCCAACAA AGAAAAACTGGAAGCCACGATTAACGAACT GGTG	SEQ ID NO: 42
TRX-N-His-M6	GTCAAACAGATCGAATCAAAAACCGCATTTC AAGAAGCCCTGGACGCCGCTGGTGACAAACT GGTCGTGGTGGACTTTAGTGCTACCTGGTGC GGCCCGTGTAAAATGATTAAACCGTTTTTCC ATAGCCTGTCTGAAAAATACAGTAACGTTAT CTTTCTGGAAGTGGATGTTGATGACTGCCAG GACGTCGCGAGCGAATGCGAAGTGAAATGT	SEQ ID NO: 43

2018349387 10 Apr 2020

	ATGCCGACGTTCCAGTTT**TATAAAAAAAGGG** **AA**AAAGTCGGTGAATTTAGCGGTGCCAACAA AGAAAAACTGGAAGCCACGATTAACGAACT GGTG	
TRX-N-His-M7	GTCAAACAGATCGAATCAAAAACCGCATTTC AAGAAGCCCTGGACGCCGCTGGTGACAAACT GGTCGTGGTGGACTTTAGTGCTACCTGGTGC GGCCCGTGTAAAATGATTAAACCGTTTTTCC ATAGCCTGTCTGAAAAATACAGTAACGTTAT CTTTCTGGAAGTGGATGTTGATGACTGCCAG GACGTCGCGAGCGAATGCGAAGTGAAATGT ATGCCGACGTTCCAGTTTTTCAAAAAAGGTC AAAAAGTCGGTGAATTTAGCGGT**GTT**AACAA AGAAAAACTGGAAGCCACGATTAACGAACT GGTG	SEQ ID NO: 44
TRX-N-His-M8	GTCAAACAGATCGAATCAAAAACCGCATTTC AAGAAGCCCTGGACGCCGCTGGTGACAAACT GGTCGTGGTGGACTTTAGTGCTACCTGGTGC GGCCCGTGTAAAATGATTAAACCGTTTTTCC ATAGCCTGTCTGAAAAATACAGTAACGTTAT CTTTCTGGAAGTGGATGTTGATGACTGCCAG GACGTCGCGAGCGAATGCGAAGTGAAATGT ATGCCGACGTTCCAGTTTTTCAAAAAAGGTC AAAAAGTCGGTGAATTTAGCGGTGCCAACAA AGAAAAACTGGAAGCC**ATCATTAACGAACT** **GTGT**	SEQ ID NO: 45

E) Plasmid preparation (Midi-preparation)

Colonies containing plasmids that have been sequenced were inoculated into 100 mL of a 2 x YT medium (17 g of tryptone, 10 g of a yeast extract, and 5 g of NaCl per liter) containing 100 μg/mL of ampicillin, and incubated at 37 °C and 210 rpm for 16 hours. The incubated bacteria were obtained by centrifugation at 4,500 rpm for 8 minutes. To obtain a purified plasmid, NucleoBond® Xtra Midi (Macherey-Nagel, Cat. 740410.100) was used, and an experiment was carried out according to the manufacturer’s protocol.

F) Animal cell culture

19.4 g of Freestyle™ 293 expression medium AGT™ powder (AG100009, Thermo

2018349387 10 Apr 2020

Scientific) was dissolved in 1 L of deionized water and sterilized. 35 mL of the Freestyle™ 293 expression medium AGT™ media, which was heated in a 37 °C water bath for 30 minutes, was put into a 125 mL Erlenmeyer flask (CC-431143, Corning). After thawing a frozen cell line 293F (510029, Invitrogen) in a 37 °C water bath for approximately 1 to 2 minutes, the thawed cell line was mixed with 5 mL of Freestyle™ 293 expression medium AGT™ media, and dispensed into a 125 mL Erlenmeyer flask containing 35 mL of the medium, followed by incubation in an 8% CO_2 shaking incubator at 37 °C and 85 rpm. After 2 to 3 days of incubation, 10 μL of the cell line was mixed with 10 μL of trypan blue, and 10 μL of the resulting mixture was added to a Luna cell counting chip (L12002, Biosystems), and cell viability and a cell count were confirmed using a Luna™ automated cell counter (L10001, Biosystems). After 4 to 7×10^5 cells/mL of the cells were suspended in a 40 mL medium, the resulting suspension was centrifuged at 100 x g for 5 minutes to remove a supernatant. After removal of the supernatant, the cell pellet was mixed with 10 mL of a medium to resuspend the pellet, and then 30 mL of the medium was inoculated into a 125 mL Erlenmeyer flask. The cells were incubated in an 8% CO_2 shaking incubator at 37 °C and 85 rpm, and the above-described process was performed two or more times.

G) Transfection into animal cells

A 40 mL aliquot of 5.5×10^5 cells/mL of cells were put into a tube, and centrifuged at 100 x g for 5 minutes. After removal of a culture solution, a pellet was suspended using 10 mL of Freestyle™ 293 expression medium AGT™ media, and inoculated into a 125 mL Erlenmeyer flask. The cells were incubated in an 8% CO_2 shaking incubator at 37 °C and 85 rpm. The cell count and viability were confirmed to be 1×10^6 cells/mL and 90% or more, respectively, using a Luna™ automated cell counter. Based on 40 mL of the culture solution,

each of 25 μg DNA for transfection and 100 μg PEI (23966, Polysciences) was stirred by vortexing, followed by centrifugation at 10,000 rpm for 1 second. DNA and PEI mixed in 800 μL of Freestyle™ 293 expression medium AGT™ were stirred, and allowed to react at room temperature for 20 minutes. The reacted DNA-PEI mixture was reacted in the 125 mL flask in which the cell line was incubated. After 24 hours, supplements were added to 5 g/L. Subsequently, the cells were further incubated for 5 days, and the culture solution was collected.

H) Experiment for confirming expression in culture medium

After 5-day culture, 500 μL of the collected culture solution was dispensed into tubes. One of the tubes was placed in a centrifuge tube rack for 20 minutes, a supernatant (sample that had not been centrifuged) was used, and the other tubes were centrifuged at 10,000 rpm for 2 minutes to remove the cells, and only a supernatant (sample that had been centrifuged) was used. 10 μL of a 5x reduction sample buffer was mixed with 40 μL of the supernatant, followed by boiling at 100 °C for 5 minutes. The prepared sample was confirmed by 15% SDS-PAGE using Mini-PROTEAN® Tetra Cell (BR165-8029, Bio-Rad) (FIG. 16).

I) Purification using affinity chromatography (Ni-NTA)

A transformed cell line was incubated for 6 days, and centrifuged at 4,800 rpm for 30 minutes to remove a supernatant. A PolyPrep column (731-1553, Bio-Rad) was washed using a 10 mM imidazole washing buffer (pH 7.4), and packed with Ni-Sepharose™ 6 Fast Flow beads (17-5318-02, GE Healthcare). Afterward, the column was washed with a 10 mM imidazole washing buffer (pH 7.4) twice. When approximately 2 to 3 mL of a 10 mM imidazole washing buffer (pH 7.4) remained in the column, the column was washed again with 20 mL of a 10 mM imidazole washing buffer (pH 7.4). A medium was added to the washed column. The beads were washed with a 10 mM imidazole washing buffer (pH 7.4), and elusion was performed with a 500 mM imidazole elution buffer (pH 7.4). 10 μL of the sample was mixed with 200 μL of a Coomassie Plus™ protein detection reagent (1856210, Thermo

Scientific) and eluted until the sample did not turn blue. A purification solution for the eluted protein was concentrated using an Amicon® ultracentrifuge (UFC901096, Millipore), and the buffer was exchanged by repeating reconcentration with a PBS solution at least twice. A protein concentration was measured using a Nano-drop, and diluted to be 0.3 to 0.5 mg/mL. 3 μg of each protein was confirmed by SDS-PAGE (FIG. 17).

In addition, the concentrations and productivity of the 8 types of hTrx1 mutant proteins were assessed, and the results are shown in Table 17 below. Referring to Table 17, it can be seen that the 8 types of the hTrx1 mutant proteins are expressed at concentrations ranging from 3.15 to 5.31 mg/mL.

[Table 17]

ID	hTrx1 mutant protein	Concentration (mg/mL)	Protein (mg)	Productivity (mg/L)
S1790	TRX-N-His-M1	4.76	4.71	117.75
S1791	TRX-N-His-M2	4.12	4.28	107.0
S1792	TRX-N-His-M3	3.81	3.73	93.25
S1793	TRX-N-His-M4	3.99	3.63	90.75
S1794	TRX-N-His-M5	3.15	3.30	82.50
S1795	TRX-N-His-M6	3.98	4.33	108.25
S1796	TRX-N-His-M7	5.31	5.15	128.75
S1797	TRX-N-His-M8	3.07	3.07	76.75

[Example 16]

ELISA for confirming binding affinity

In this example, the binding affinity of each of the B266-1 and B264 antibodies for the 8 types of hTrx1 mutant proteins prepared in Example 15 was confirmed.

The 8 types of hTrx1 mutant proteins prepared in Example 3 were dissolved in a coating buffer (DPBS; LB001-02, Welgene) at a concentration of 2 μg/mL, thereby preparing antigen solutions, each antigen solution was dispensed into a 96-well plate at 100 μL per well, and the plate was covered with a sealing tape, followed by a reaction at 4 °C for 16 hours.

After removal of the antigen solution, 200 μL of a blocking buffer (1 x PBS w/ 4% skim milk) was dispensed into each well, and the plate was covered with a sealing tape, followed by a reaction in a 37 °C incubator for 1 hour. After the completion of the reaction, the blocking buffer was removed, 100 μL of the antibody solution diluted to a certain concentration was dispensed into each well, and the plate was covered with a sealing tape, followed by a reaction in a 37 °C incubator for 2 hours. The antibody solution was removed, a process of treating and discarding 200 μL of a washing buffer (1 x PBST) solution per well was repeated a total of 5 times. HRP-binding antibodies (anti-human Fc-HRP against B266, anti-mouse Fc-HRP against B264) were diluted 1:4000 in an antibody dilution solution (1 x PBS w/ 1% Skim milk), 100 μL of the resulting dilution was dispensed into each well, and the plate was covered with a sealing tape, followed by a reaction in a 37 °C incubator for 2 hours. The antibody solution was removed, and a process of treating and discarding 200 μL of a washing buffer (1 x PBST) solution was repeated a total of five times. 10 μL of H_2O_2 was added to a color reagent [one OPD tablet, 10 mL PC buffer (5.1 g of $C_6H_8O_7 \cdot H_2O$ and 7.3 g of Na_2HPO_4 per liter], and then 100 μL of the resulting mixture was dispensed into each well, followed by a reaction in a dark place for 10 minutes. 50 μL per well of a stop buffer (2.5 M H_2SO_4) was treated, and OD at 490 nm was measured.

As a result, as shown in FIG. 18A, it was confirmed that the B266-1 (hTrx1-hIgG1) antibody was decreased in binding strength with a protein having a mutation at an M4 site (YSNVIFGNMV), and the B264 (hTrx1-mIgG1) antibody was decreased in binding strength with a protein having mutations at M1, M2 and M4 sites (M1: QIESKTAEIEGKED, M2: QEALDAHAALSS, and M3: YSNVIFGNMV).

Tables 18 and 19 below show original amino acid sequences and base sequences of

2018349387 10 Apr 2020

the M1, M2 and M4 sites having mutations in hTrx1.

[Table 18]

hTrx1 site	Amino acid sequence	SEQ ID NO:
M1	QIEGSTA	SEQ ID NO: 32
M2	QEALDA	SEQ ID NO: 33
M4	YSNVI	SEQ ID NO: 34

[Table 19]

hTrx1 site	Base sequence	SEQ ID NO:
M1	CAGATCGAATCAAAAACCGCA	SEQ ID NO: 35
M2	CAAGAAGCCCTGGACGCC	SEQ ID NO: 36
M4	TACAGTAACGTTATC	SEQ ID NO: 37

From the above result, it was confirmed that the B266-1 antibody and the B264 antibody are likely to share the M4 part (YSNVI) of an antigen-binding site.

[Example 17]

Antibody profiling using peptide microarrays

In this example, an accurate amino acid sequence was identified through Trx1 antigen epitope mapping analysis using antibodies B266-1 and B264. Specifically, PepStar^{TM} peptide microarray technology (JPT Peptide Technologies (Germany)) was used, and as shown in FIG. 19, an epitope was detected using an overlapping peptide scan.

17-1. Sequences

Antibody profiling experiments were performed on a peptide library consisting of 108 peptides. The complete list of the peptides is shown in Tables 20 to 22 below. Here, SEQ ID NOs: 64 to 81 corresponding to Peptide_001 to Peptide_018 are not native forms, and include recombinant insert regions. For a known amino acid sequence of the hTrx1 protein, GenBank Accession No. AAF87085.1 was referenced.

[Table 20]

Peptides immobilized on microarrays

SEQ ID NO:	Amino acid sequence	Name
64	VATAADVHSQHHHHH	Peptide_001
65	ATAADVHSQHHHHHH	Peptide_002
66	TAADVHSQHHHHHHH	Peptide_003
67	AADVHSQHHHHHHHH	Peptide_004
68	ADVHSQHHHHHHHHV	Peptide_005
69	DVHSQHHHHHHHHVK	Peptide_006
70	VHSQHHHHHHHHVKQ	Peptide_007
71	HSQHHHHHHHHVKQI	Peptide_008
72	SQHHHHHHHHVKQIE	Peptide_009
73	QHHHHHHHHVKQIES	Peptide_010
74	HHHHHHHHVKQIESK	Peptide_011
75	HHHHHHHVKQIESKT	Peptide_012
76	HHHHHHVKQIESKTA	Peptide_013
77	HHHHHVKQIESKTAF	Peptide_014
78	HHHHVKQIESKTAFQ	Peptide_015
79	HHHVKQIESKTAFQE	Peptide_016
80	HHVKQIESKTAFQEA	Peptide_017
81	HVKQIESKTAFQEAL	Peptide_018
82	VKQIESKTAFQEALD	Peptide_019
83	KQIESKTAFQEALDA	Peptide_020
84	QIESKTAFQEALDAA	Peptide_021
85	IESKTAFQEALDAAG	Peptide_022
86	ESKTAFQEALDAAGD	Peptide_023
87	SKTAFQEALDAAGDK	Peptide_024
88	KTAFQEALDAAGDKL	Peptide_025
89	TAFQEALDAAGDKLV	Peptide_026
90	AFQEALDAAGDKLVV	Peptide_027
91	FQEALDAAGDKLVVV	Peptide_028
92	QEALDAAGDKLVVVD	Peptide_029
93	EALDAAGDKLVVVDF	Peptide_030
94	ALDAAGDKLVVVDFS	Peptide_031
95	LDAAGDKLVVVDFSA	Peptide_032
96	DAAGDKLVVVDFSAT	Peptide_033
97	AAGDKLVVVDFSATW	Peptide_034
98	AGDKLVVVDFSATWC	Peptide_035
99	GDKLVVVDFSATWCG	Peptide_036
100	DKLVVVDFSATWCGP	Peptide_037
101	KLVVVDFSATWCGPC	Peptide_038

[Table 21]

Peptides immobilized on microarrays

SEQ ID NO:	Amino acid sequence	Name
102	LVVVDFSATWCGPCK	Peptide_039
103	VVVDFSATWCGPCKM	Peptide_040
104	VVDFSATWCGPCKMI	Peptide_041
105	VDFSATWCGPCKMIK	Peptide_042
106	DFSATWCGPCKMIKP	Peptide_043
107	FSATWCGPCKMIKPF	Peptide_044
108	SATWCGPCKMIKPFF	Peptide_045
109	ATWCGPCKMIKPFFH	Peptide_046
110	TWCGPCKMIKPFFHS	Peptide_047
111	WCGPCKMIKPFFHSL	Peptide_048
112	CGPCKMIKPFFHSLS	Peptide_049
113	GPCKMIKPFFHSLSE	Peptide_050
114	PCKMIKPFFHSLSEK	Peptide_051
115	CKMIKPFFHSLSEKY	Peptide_052
116	KMIKPFFHSLSEKYS	Peptide_053
117	MIKPFFHSLSEKYSN	Peptide_054
118	IKPFFHSLSEKYSNV	Peptide_055
119	KPFFHSLSEKYSNVI	Peptide_056
120	PFFHSLSEKYSNVIF	Peptide_057
121	FFHSLSEKYSNVIFL	Peptide_058
122	FHSLSEKYSNVIFLE	Peptide_059
123	HSLSEKYSNVIFLEV	Peptide_060
124	SLSEKYSNVIFLEVD	Peptide_061
125	LSEKYSNVIFLEVDV	Peptide_062
126	SEKYSNVIFLEVDVD	Peptide_063
127	EKYSNVIFLEVDVDD	Peptide_064
128	KYSNVIFLEVDVDDC	Peptide_065
129	YSNVIFLEVDVDDCQ	Peptide_066
130	SNVIFLEVDVDDCQD	Peptide_067
131	NVIFLEVDVDDCQDV	Peptide_068
132	VIFLEVDVDDCQDVA	Peptide_069
133	IFLEVDVDDCQDVAS	Peptide_070
134	FLEVDVDDCQDVASE	Peptide_071
135	LEVDVDDCQDVASEC	Peptide_072
136	EVDVDDCQDVASECE	Peptide_073
137	VDVDDCQDVASECEV	Peptide_074
138	DVDDCQDVASECEVK	Peptide_075
139	VDDCQDVASECEVKC	Peptide_076

[Table 22]

Peptides immobilized on microarrays

SEQ ID NO:	Amino acid sequence	Name
140	DDCQDVASECEVKCM	Peptide_077
141	DCQDVASECEVKCMP	Peptide_078
142	CQDVASECEVKCMPT	Peptide_079
143	QDVASECEVKCMPTF	Peptide_080
144	DVASECEVKCMPTFQ	Peptide_081
145	VASECEVKCMPTFQF	Peptide_082
146	ASECEVKCMPTFQFF	Peptide_083
147	SECEVKCMPTFQFFK	Peptide_084
148	ECEVKCMPTFQFFKK	Peptide_085
149	CEVKCMPTFQFFKKG	Peptide_086
150	EVKCMPTFQFFKKGQ	Peptide_087
151	VKCMPTFQFFKKGQK	Peptide_088
152	KCMPTFQFFKKGQKV	Peptide_089
153	CMPTFQFFKKGQKVG	Peptide_090
154	MPTFQFFKKGQKVGE	Peptide_091
155	PTFQFFKKGQKVGEF	Peptide_092
156	TFQFFKKGQKVGEFS	Peptide_093
157	FQFFKKGQKVGEFSG	Peptide_094
158	QFFKKGQKVGEFSGA	Peptide_095
159	FFKKGQKVGEFSGAN	Peptide_096
160	FKKGQKVGEFSGANK	Peptide_097
161	KKGQKVGEFSGANKE	Peptide_098
162	KGQKVGEFSGANKEK	Peptide_099
163	GQKVGEFSGANKEKL	Peptide_100
164	QKVGEFSGANKEKLE	Peptide_101
165	KVGEFSGANKEKLEA	Peptide_102
166	VGEFSGANKEKLEAT	Peptide_103
167	GEFSGANKEKLEATI	Peptide_104
168	EFSGANKEKLEATIN	Peptide_105
169	FSGANKEKLEATINE	Peptide_106
170	SGANKEKLEATINEL	Peptide_107
171	GANKEKLEATINELV	Peptide_108

Full-length mouse IgG was co-immobilized on a microarray slide as an assay control, and an additional sequence was included in the peptide library by JPT as an inner process

2018349387 10 Apr 2020

control.

17-2. Assay conditions

Profiling experiments were performed using a total of two antibody samples (B266-1 and B264) diluted in a blocking buffer (Pierce International, Superblock TBS T20, order# 37536). 5, 1, 0.2, 0.04, 0.008 and 0.0016 μg/mL serial dilutions were incubated on a single multi-well microarray slide at 30 °C for 1 hour. The slide includes 21 individual mini-arrays (one mini-array per sample dilution).

After sample incubation, 1 μg/ml of a fluorescence-labeled secondary anti-mouse-IgG antibody (anti-mouse IgG(H+L) (Thermo 84545)) was added to a corresponding well, followed by a reaction for 1 hour. DyLight 650 was used as a label. False-positive binding to a peptide was evaluated by performing one additional control incubation in which only a secondary antibody was applied on the same microarray slide. Before performing each step, the microarrays were washed with a washing buffer.

After washing and drying, the slide was scanned using a 635-nm high-resolution laser scanner (Axon GenePix Scanner 4300 SL50) to obtain fluorescence intensity profiles, and the obtained image was quantified using spot-recognition software, GenePix, to calculate the average pixel value for each peptide. For each spot, the average signal intensity was extracted (light units between 0 and 65535).

17-3. Image of processed arrays

An exemplary fluorescence readout image of a mini-array cultured with one of the antibody samples is shown in FIG. 20. Low background levels were observed in all samples. Black indicates no signal, red shadow indicates an increase in detected signal intensity, white indicates detector saturation, and each individual subarray is outlined in green.

17-4. Heatmap evaluation

To visualize the obtained results and compare binding regions across individual

2018349387 10 Apr 2020

cultures, as shown in FIGS. 21A to 21D, heatmap diagrams were calculated. In FIGS. 21A to 21D, the fluorescence intensity is expressed in a color-coded manner, white indicates no binding, and red indicates strong binding. For all evaluations, the MMC2-value of the average pixel fluorescence for each peptide was calculated.

MMC2 is the same as the average value of all three cases on a microarray except when the coefficient of variation (CV), which is the standard deviation divided by the average value, is larger than 0.5. In this case, the average of the two closest values (MC2) is assigned to MMC2. The thick black line in the heatmap indicates the culture of a control only using a secondary anti-mouse IgG antibody. The culture of individual antibody samples is indicated by a thin blue line.

In the case of the antibody B266-1, as shown in Table 23, the highest signal, approximately 8-fold the average background level, was detected for Peptide_004 and Peptide_005 (SEQ ID NOs: 67 and 68). However, since Peptide_004 and Peptide_005 are not native forms, these peptides were excluded from an epitope candidate group.

[Table 23]

B266-1(Ab1)									
Description	ID	NAME	Control IgG	5ug	1ug	0.2ug	0.04ug	0.008ug	0.0016ug
Negative control	AA	blank-control	1	1	1	1	1	1	1
Positive Control	Human_IgG	Control-Spot	46.60	35.79	52.82	49.65	49.71	47.85	35.43
	Mouse_IgG	Control-Spot	54.60	46.96	65.38	71.40	79.65	74.60	84.79
It is not native form but recombinant insert region.	AADVHSQHHHHHHHH	Peptide_004	0.87	5.78	2.71	1.41	1.14	1.00	0.98
	ADVHSQHHHHHHHHV	Peptide_005	1.07	7.63	3.58	1.78	1.60	1.28	1.60
	ATWCGPCKMIKPFFH	Peptide_046	1.56	6.41	3.18	2.00	1.96	1.64	1.79
	TWCGPCKMIKPFFHS	Peptide_047	1.11	5.58	2.25	1.58	1.50	1.11	1.18
	WCGPCKMIKPFFHSL	Peptide_048	4.63	6.10	6.00	5.99	6.57	7.25	7.61
	CGPCKMIKPFFHSLS	Peptide_049	1.25	2.89	1.96	1.45	1.51	1.31	1.37
	GPCKMIKPFFHSLSE	Peptide_050	0.42	2.19	1.09	0.66	0.68	0.52	0.62
	PCKMIKPFFHSLSEK	Peptide_051	0.47	1.24	0.81	0.61	0.62	0.60	0.83
	CKMIKPFFHSLSEKY	Peptide_052	1.18	3.84	2.38	1.38	1.23	1.12	1.37
	KMIKPFFHSLSEKYS	Peptide_053	1.16	2.45	2.13	1.66	1.35	1.44	1.42
	MIKPFFHSLSEKYSN	Peptide_054	0.64	2.36	1.15	0.84	0.71	0.71	0.73
	IKPFFHSLSEKYSNV	Peptide_055	0.83	2.08	1.38	1.04	1.41	0.85	1.05
	KPFFHSLSEKYSNVI	Peptide_056	1.09	2.89	1.84	1.24	1.11	1.07	1.18
	PFFHSLSEKYSNVIF	Peptide_057	1.83	2.39	2.07	1.94	1.87	2.09	1.93
	PTFQFFKKGQKVGEF	Peptide_092	2.38	3.50	2.62	1.86	1.62	1.33	1.75

The antibody B264 showed a concentration-dependent signal profile, and considerably strong interactions with some peptides. The most significant binding was obtained with peptides listed in Table 24 below, particularly at two highest culture sample concentrations.

As shown in Table 24, the highest signal, approximately 7-fold the average background level, was measured for Peptide_012 and Peptide_018 (SEQ ID NOs: 75 and 81). However, since the Peptide_012 and Peptide_018 are not native forms, they were excluded from an epitope candidate group.

Subsequently, the peptides of SEQ ID NOs: 82 to 88, corresponding to Peptide_019 to Peptide_025 for which the strongest signal was measured were expected to be antibody B264-binding sites, and “VKQIESKTAFQEALDAAGDKL” (SEQ ID NO: 179) was finally determined as an epitope of the antibody B264.

Afterward, the peptides of SEQ ID NO: 109 to SEQ ID NO: 120, corresponding to

2018349387 10 Apr 2020

2018349387 10 Apr 2020

Peptide_046 to Peptide_057 for which the strongest signal was measured were expected to be antibody B264-binding sites, which has the same epitope as a B266-1-binding site.

[Table 24]

B264(Ab2)									
Description	ID	NAME	Control IgG	5ug	1ug	0.2ug	0.04ug	0.008ug	0.0016ug
Negative control	AA	blank-control	1	1	1	1	1	1	1
Positive Control	Human_IgG	Control-Spot	46.60	6.70	20.77	36.30	48.06	52.63	45.73
	Mouse_IgG	Control-Spot	54.60	7.16	24.51	46.01	69.54	76.34	74.50
It is not native form but recombinant insert region.	HHHHHHHVKQIESKT	Peptide_012	0.74	4.49	3.65	1.72	1.15	0.88	0.81
	HHHHHHVKQIESKTA	Peptide_013	0.88	4.87	4.06	1.85	1.40	0.96	0.75
	HHHHHVKQIESKTAF	Peptide_014	0.83	6.90	6.71	3.16	1.69	1.14	0.69
	HHHHVKQIESKTAFQ	Peptide_015	0.54	5.96	5.11	2.60	1.64	0.79	0.58
	HVKQIESKTAFQEAL	Peptide_018	0.74	6.15	5.62	3.49	1.97	0.85	0.68
	VKQIESKTAFQEALD	Peptide_019	0.96	1.98	1.67	1.48	1.20	1.02	0.85
	KQIESKTAFQEALDA	Peptide_020	0.82	2.41	2.30	1.84	1.33	0.80	0.71
	QIESKTAFQEALDAA	Peptide_021	0.80	2.69	2.48	2.08	1.35	0.54	0.73
	IESKTAFQEALDAAG	Peptide_022	0.76	5.54	5.88	4.20	2.89	1.00	0.72
	ESKTAFQEALDAAGD	Peptide_023	1.02	1.26	1.19	1.12	1.15	0.91	0.73
	SKTAFQEALDAAGDK	Peptide_024	0.87	6.00	6.60	4.00	2.38	1.00	0.72
	KTAFQEALDAAGDKL	Peptide_025	1.00	6.40	7.24	4.90	2.39	1.03	0.88
	FSATWCGPCKMIKPF	Peptide_044	1.73	3.33	2.93	2.30	2.12	1.87	1.60
	SATWCGPCKMIKPFF	Peptide_045	4.14	4.90	5.11	4.68	4.69	5.89	4.08
	ATWCGPCKMIKPFFH	Peptide_046	1.56	6.20	5.62	3.44	2.87	2.11	1.69
	TWCGPCKMIKPFFHS	Peptide_047	1.11	4.89	4.07	2.62	1.97	1.52	1.15
	WCGPCKMIKPFFHSL	Peptide_048	4.63	2.15	3.91	4.61	6.34	7.68	7.46
	CGPCKMIKPFFHSLS	Peptide_049	1.25	1.11	1.20	1.34	1.46	1.43	1.18
	GPCKMIKPFFHSLSE	Peptide_050	0.42	0.54	0.47	0.46	0.64	0.65	0.51
	PCKMIKPFFHSLSEK	Peptide_051	0.47	4.28	3.91	2.32	1.41	0.70	0.58
	CKMIKPFFHSLSEKY	Peptide_052	1.18	5.14	4.43	2.56	2.02	1.23	1.15
	KMIKPFFHSLSEKYS	Peptide_053	1.16	6.49	8.52	4.75	2.64	1.76	1.41
	MIKPFFHSLSEKYSN	Peptide_054	0.64	1.46	1.43	0.80	0.99	0.63	0.56
	IKPFFHSLSEKYSNV	Peptide_055	0.83	3.57	3.26	2.21	1.51	0.99	0.81
	KPFFHSLSEKYSNVI	Peptide_056	1.09	2.86	2.58	1.72	1.36	1.11	0.90
	PFFHSLSEKYSNVIF	Peptide_057	1.83	2.44	2.19	2.08	2.15	2.27	1.73
	SECEVKCMPTFQFFK	Peptide_084	0.90	3.79	3.26	2.36	1.83	1.33	0.97
	ECEVKCMPTFQFFKK	Peptide_085	0.54	3.87	3.56	2.23	1.48	0.90	0.86
	CEVKCMPTFQFFKKG	Peptide_086	0.79	1.90	1.56	1.16	1.14	1.02	0.82
	PTFQFFKKGQKVGEF	Peptide_092	2.28	6.78	9.76	6.81	5.18	3.07	1.86
	TFQFFKKGQKVGEFS	Peptide_093	1.21	6.18	5.33	3.72	2.46	1.53	1.12
	FQFFKKGQKVGEFSG	Peptide_094	0.63	4.13	3.26	2.11	1.49	1.00	0.62
	QFFKKGQKVGEFSGA	Peptide_095	1.44	3.44	3.62	2.13	1.66	1.15	1.07
	FFKKGQKVGEFSGAN	Peptide_096	1.18	1.90	2.04	1.37	1.44	0.94	0.82
	FKKGQKVGEFSGANK	Peptide_097	1.34	2.26	2.18	1.68	1.31	1.08	0.91

No significant binding was detected in culture of a secondary antibody control. Strong signals up to the saturation level were obtained at a spot of the control containing full-length mouse IgG during all cultures, indicating excellent analysis performance.

The epitope regions obtained through the above-described procedures are shown in Table 25 below, and as a result of confirming tertiary (3D) structures by 3D filing by downloading the NMR sequence of hTrx1 certified through a protein database (PDB), as shown in FIGS. 22A to 22F, when native forms, their sequences are present at the outside thereof, confirming that the peptides can serve as epitopes.

[Table 25]

Tertiary (3D) structure	Amino acid sequence	Gene sequence	Comparison with Example 13	Description
FIGS. 22A, 22D	ATWCGPCKMIK PFFHSLSEK**YSN VIF** (SEQ ID NO: 172)	gctacctggtgcggcccgtgtaaaatgat taaaccgtttttccatagcctgtctgaaaaa tacagtaacgttatcttt (SEQ ID NO: 177)	Including M4 region	Epitopes of antibodies B264 and B266-1
FIG. 22B	PTFQ**FFKKG**QK VGEF(SEQ ID NO: 173)	ccgacgttccagtttttcaaaaaaggtcaa aaagtcggtgaattt (SEQ ID NO: 178)	Including M6 region	Epitope of antibody B266-1
FIG. 22C	VK**QIESKTAFQE ALDA**AGDKL (SEQ ID NO: 174)	gtcaaacagatcgaatcaaaaaccgcatt tcaagaagccctggacgccgctggtgac aaactg (SEQ ID NO: 179)	Integration of M1 and M2 regions	Epitope of antibody B264
FIG. 22E	SECEVKCMPTFQ **FFKKG**(SEQ ID NO: 175)	agcgaatgcgaagtgaaatgtatgccga cgttccagtttttcaaaaaaggt (SEQ ID NO: 180)	Including M6 region	Epitope of antibody B264
FIG. 22F	PTFQ**FFKKG**QK VGEFSGANK(SEQ ID NO: 176)	ccgacgttccagtttttcaaaaaaggtcaa aaagtcggtgaatttagcggtgccaacaa a (SEQ ID NO: 181)	Including M6 region	Epitope of antibody B264

[Industrial Applicability]

The monoclonal antibody of the present invention can very specifically bind to Trx1 due to excellent binding affinity therefor, and can be effectively used in screening of breast cancer patients due to very high sensitivity and specificity. Further, the accuracy and

2018349387 10 Apr 2020

reliability of breast cancer diagnosis can significantly increase because exceptionally high sensitivity and specificity are exhibited by detecting the monoclonal antibody of the present invention, which specifically binds to Trx1, rather than detecting CA15-3, another conventional breast cancer diagnostic biomarker. An epitope region of a human Trx1 antigen to which the antibody of the present invention binds can be effectively used in development of an improved antibody to enhance the binding affinity of an anti-Trx1 antibody.

2018349387 30 Apr 2022

【Claims】

【Claim 1】

A monoclonal antibody specifically binding to thioredoxin-1 (Trx1) or an antigen-binding fragment thereof, comprising:

a light chain variable region including light chain CDR1 consisting of an amino acid sequence of SEQ ID NO: 1, light chain CDR2 consisting of an amino acid sequence of SEQ ID NO: 2 and light chain CDR3 consisting of an amino acid sequence of SEQ ID NO: 3, and a heavy chain variable region including heavy chain CDR1 consisting of an amino acid sequence of SEQ ID NO: 4, heavy chain CDR2 consisting of an amino acid sequence of SEQ ID NO: 5 and heavy chain CDR3 consisting of an amino acid sequence of SEQ ID NO: 6.

【Claim 2】

A monoclonal antibody specifically binding to thioredoxin-1 (Trx1) or an antigen-binding fragment thereof, comprising:

a light chain variable region including light chain CDR1 consisting of an amino acid sequence of SEQ ID NO: 7, light chain CDR2 consisting of an amino acid sequence of SEQ ID NO: 8 and light chain CDR3 consisting of an amino acid sequence of SEQ ID NO: 9, and a heavy chain variable region including heavy chain CDR1 consisting of an amino acid sequence of SEQ ID NO: 10, heavy chain CDR2 consisting of an amino acid sequence of SEQ ID NO: 11 and heavy chain CDR3 consisting of an amino acid sequence of SEQ ID NO: 12.

【Claim 3】

The monoclonal antibody or antigen-binding fragment thereof of claim 1, wherein the antibody comprises a light chain variable region consisting of an amino acid sequence of SEQ ID NO: 13 and a heavy chain variable region consisting of an amino acid sequence of SEQ ID NO: 14.

【Claim 4】

The monoclonal antibody or antigen-binding fragment thereof of claim 2, wherein the antibody comprises a light chain variable region consisting of an amino acid sequence of SEQ ID NO: 15 and a heavy chain variable region consisting of an amino acid sequence of SEQ ID NO: 16.

【Claim 5】

The monoclonal antibody or antigen-binding fragment thereof of claim 2, wherein the antibody comprises a light chain consisting of an amino acid sequence of SEQ ID NO: 25 and a heavy chain consisting of an amino acid sequence of SEQ ID NO: 26.

【Claim 6】

The monoclonal antibody or antigen-binding fragment thereof of any one of claims 1 to 4, wherein the antibody comprises an IgG1 heavy chain and a kappa (κ) light chain.

【Claim 7】

The monoclonal antibody or antigen-binding fragment thereof of any one of claims 1 to 5, wherein the antigen-binding fragment is Fab, F(ab'), F (ab')$_2$, Fv or a single chain antibody molecule.

【Claim 8】

The monoclonal antibody or antigen-binding fragment thereof of any one of claims 1 to 5, wherein the antibody is a chimeric antibody, a humanized antibody or a human antibody.

【Claim 9】

A nucleic acid molecule encoding a light chain and a heavy chain of the monoclonal antibody or antigen-binding fragment thereof of claim 1.

2018349387 30 Apr 2022

【Claim 10】

A nucleic acid molecule encoding a light chain and a heavy chain of the monoclonal antibody or antigen-binding fragment thereof of claim 2.

【Claim 11】

The nucleic acid molecule of claim 10, wherein the nucleic acid molecule encoding the light chain of the monoclonal antibody or antigen-binding fragment of claim 2 consists of a nucleotide sequence of SEQ ID NO: 27; and the nucleic acid molecule encoding the heavy chain of the monoclonal antibody or antigen-binding fragment of claim 2 consists of a nucleotide sequence of SEQ ID NO: 28.

【Claim 12】

A recombinant vector comprising the nucleic acid molecule of claim 9.

【Claim 13】

A recombinant vector comprising the nucleic acid molecule of claim 10 or 11.

【Claim 14】

A host cell comprising the recombinant vector of claim 12.

【Claim 15】

A host cell comprising the recombinant vector of claim 13.

【Claim 16】

An isolated polypeptide consisting of:

an epitope of a human thioredoxin-1 (Trx1) antigen specifically binding to the monoclonal antibody or an antigen-binding fragment thereof of claim 1, consisting of any one amino acid sequence selected from the group consisting of SEQ ID NOs: 32, 33 and 174 to

2018349387 30 Apr 2022

176;

an epitope of a human thioredoxin-1 (Trx1) antigen specifically binding to the monoclonal antibody or an antigen-binding fragment thereof of claim 2, consisting of an amino acid sequence of SEQ ID NO: 173; or

an epitope of a human thioredoxin-1 (Trx1) antigen specifically binding to the monoclonal antibody or an antigen-binding fragment thereof of claim 1 or 2, consisting of any one amino acid sequence selected from the group consisting of SEQ ID NOs: 34 and 172.

【Claim 17】

A recombinant vector comprising the nucleic acid molecule encoding the isolated polypeptide of claim 16.

【Claim 18】

A host cell comprising the recombinant vector of claim 17.

【Claim 19】

A method of preparing a monoclonal antibody specifically binding to thioredoxin-1 (Trx1) or antigen-binding fragment thereof, comprising culturing the host cell of claim 14.

【Claim 20】

A kit for diagnosing breast cancer, comprising the monoclonal antibody or antigen-binding fragment thereof of any one of claims 1 to 5.

【Claim 21】

The kit of claim 20, which is an Enzyme-Linked Immunosorbent Assay (ELISA) kit.

【Claim 22】

The kit of claim 21, wherein the ELISA is one or more selected from the group

consisting of direct ELISA, indirect ELISA, direct sandwich ELISA and indirect sandwich ELISA.

【Claim 23】

A method of providing information necessary for breast cancer diagnosis, comprising:

(a) bringing the monoclonal antibody or antigen-binding fragment thereof of any one of claims 1 to 5 into contact with a biological sample isolated from a subject suspected of having breast cancer;

(b) measuring an expression level of the thioredoxin-1 (Trx1) protein binding to the monoclonal antibody or antigen-binding fragment thereof in the biological sample through the formation of an antigen-antibody complex; and

(c) comparing the expression level of the Trx1 protein, measured in Step (b) with that of a control and, if the protein expression level is higher than that of the control, determining the subject to be a breast cancer patient.

【Claim 24】

The method of claim 23, wherein the expression level of the Trx1 protein is measured by any one method selected from the group consisting of Western blotting, ELISA, sandwich ELISA, a radioimmunoassay, radioimmunodiffusion, Ouchterlony immunodiffusion, an immunoprecipitation assay, a complement fixation assay, an immunochromatographic assay, FACS and a protein chip assay.

【Claim 25】

The method of claim 23, wherein the isolated biological sample is any one or more selected from the group consisting of whole blood, serum, plasma, breast tissue and breast cells.

【Claim 26】

A method of providing information necessary for breast cancer diagnosis, comprising:

(a) coating a solid support with the monoclonal antibody or antigen-binding fragment

2018349387 30 Apr 2022

thereof of any one of claims 2, 4, or 5;

(b) applying a biological sample isolated from a subject suspected of having breast cancer to the coated solid support;

(c) removing an unbound sample;

(d) applying the monoclonal antibody or antigen-binding fragment thereof of claim 1 or 3 to the solid support;

(e) removing an unbound monoclonal antibody or antigen-binding fragment thereof;

(f) measuring an expression level of the thioredoxin-1 (Trx1) protein; and

(g) comparing the expression level of the Trx1 protein, measured in Step (f), with that of a control, and, if the protein expression level is higher than that of the control, determining the subject to be a breast cancer patient.

【Claim 27】

The method of claim 26, wherein the expression level of the Trx1 protein is measured by any one method selected from the group consisting of Western blotting, ELISA, sandwich ELISA, a radioimmunoassay, radioimmunodiffusion, Ouchterlony immunodiffusion, an immunoprecipitation assay, a complement fixation assay, an immunochromatographic assay, FACS and a protein chip assay.

【Claim 28】

The method of claim 26, wherein the isolated biological sample is any one or more selected from the group consisting of whole blood, serum, plasma, breast tissue and breast cells.

【Claim 29】

A method of preparing a monoclonal antibody specifically binding to thioredoxin-1 (Trx1) or antigen-binding fragment thereof, comprising culturing the host cell of claim 15.

(a)



(b)

Clone	IgG1	IgG2a	IgG2b	IgG3	IgA	IgM	κ	λ	H-chain	L-chain
2B4	0.411	0.074	0.076	0.084	0.074	0.101	1.043	0.087	IgG1	κ
8F3	0.064	0.607	0.057	0.056	0.054	0.056	1.137	0.061	IgG2a	κ
9G7	0.061	0.059	1.226	0.084	0.072	0.101	1.303	0.081	IgG2b	κ

FIG. 1

(a)

SEQUENCE: >Unnamed-1

```
         ---------+---------+---------+---------+---------+---------+---------+---------+
   1     QIVLTQSPAIMSASPGEKVTMTCSASSRLSYMYWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISTMEAE
  81     DAATYYCHQRSSYPTFGAGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNS
 161     WTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC
```

COMPOSITION:



(b)

SEQUENCE: >Unnamed-1

```
         ---------+---------+---------+---------+---------+---------+---------+---------+
   1     EVQLQQSGAELVKPGASVKLSCTASGFNIKDTFMHWVKQRPEQGLEWIGRIDPANGNTKYDPKFQGKATITADTSSNTAY
  81     LQLSSLTSEDTAVYYCALLQYSAMDYWGQGTSVTVSSAKTTPPSVYPLAPGCGDTTGSSVTLGCLVKGYFPESVTVTWNS
 161     GSLSSSVHTFPALLQSGLYTMSSSVTVPSSTWPSQTVTCSVAHPASSTTVDKKLEPSGPISTINPCPPCKECHKCPAPNL
 241     EGGPSVFIFPPNIKDVLMISLTPKVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTIRVVSTLPIQHQDWM
 321     SGKEFKCKVNNKDLPSPIERTISKIKGLVRAPQVYILPPPAEQLSRKDVSLTCLVVGFNPGDISVEWTSNGHTEENYKDT
 401     APVLDSDGSYFIYSKLNMKTSKWEKTDSFSCNVRHEGLKNYYLKKTISRSPG
```

COMPOSITION:



FIG. 2

(a)

SEQUENCE:

```
>Unnamed-1
---------+---------+---------+---------+---------+---------+---------+---------+
  1  DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLLYKVSNRFSGVPDRFSGSGSGTDFTLKI
 81  SRVEAEDLGVYYCFQGSHVPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSER
161  QNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC
```

COMPOSITION:



Number of residues = 219 Molecular weight = 24157.65

(b)

SEQUENCE:

```
>Unnamed-1
---------+---------+---------+---------+---------+---------+---------+---------+
  1  QVQLQQSGAELARPGASVKMSCKASGYTFTSYTMHWVKQRPGQGLEWIGYINPTSDYTNYNQKFKDKATLTADKSSSTAY
 81  MQLSSLTSEDSAVYFCASEGGPLYYFDYWGQGTTLTVSSAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTW
161  NSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVPEVSSVFIFP
241  PKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVN
321  SAAFPAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSY
401  FVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPG
```

COMPOSITION:



Number of residues = 442 Molecular weight = 48807.7

FIG. 3



FIG. 4



FIG. 5



FIG. 6



FIG. 7

Alignment with the closest gene and allele from the IMGT V domain directory: (All species)

```
                      FR1-IMGT                  CDR1-IMGT       FR2-IMGT          CDR2-IMGT
                       (1-26)                    (27-38)         (39-55)           (56-65)
                   A                 B              BC          C          C'        C'C"
                (1-15)            (16-26)        (27-38)     (39-46)    (47-55)    (56-65)
              --------------->  ------------->                -------->  -------->
              1        10  15  16      23 26  27         38  3941   46 47       55 56       65
              |........|....|  |......|..|    |..........|  |.|....|  |.......|  |........|
S             DVLMTQTPLSLPVSL  GDQASISCRSS    QSIVHS.NGNTY  LEWYLQKP  GQSPKLLIY  KV.......S

IGKV1-117*01  DVLMTQTPLSLPVSL  GDQASISCRSS    QSIVHS.NGNTY  LEWYLQKP  GQSPKLLIY  KV.......S
Mus musculus

                           FR3-IMGT                                 CDR3-IMGT        FR4-IMGT
                           (66-104)                                 (105-117)        (118-128)
       C"          D             E                F                    FG               G
    (66-74)     (75-84)       (85-96)         (97-104)             (105-117)        (118-128)
    -------->  --------->  ---------------->  --------->                           ------------>
    66      74 75       84 85  89       96 97      104  105 11112 117   118        128
    |.......|  |........|  |...|.......|   |.......|    |.....||....|   |..........|
    NRFSGVP.D  RFSGSG..SG  TDFTLKISRVEA    EDLGVYYC     FQGSH....VPYT   FGGGTKLEIK.

    NRFSGVP.D  RFSGSG..SG  TDFTLKISRVEA    EDLGVYYC     FQGSHVP

                                                                  YT  FGGGTKLEIK
```

FIG. 8A

Alignment with the closest gene and allele from the IMGT V domain directory: (All species)

```
              FR1-IMGT                 CDR1-IMGT       FR2-IMGT          CDR2-IMGT
               (1-26)                   (27-38)        (39-55)            (56-65)
            A             B               BC           C         C'         C'C"
          (1-15)       (16-26)          (27-38)     (39-46)   (47-55)     (56-65)
         ----------->  --------->                  --------> -------->
         1        10   15 16    23 26 27         38 3941  46 47     55 56       65
         |........|....| |......|..| |..........| |.|....| |.......| |........|
S        QVQLQQSGA.ELARP GASVKMSCKAS GYTF....TSYT MHWVKQRP GQGLEWIGY INPT..SDYT

IGHV1-4*01    QVQLQQSGA.ELARP GASVKMSCKAS GYTF....TSYT MHWVKQRP GQGLEWIGY INPS..SGYT
Mus musculus                                                                   T   D

                        FR3-IMGT                              CDR3-IMGT     FR4-IMGT
                        (66-104)                              (105-117)     (118-128)
         C"          D            E              F               FG             G
      (66-74)     (75-84)      (85-96)       (97-104)        (105-117)      (118-128)
      -------->  --------->  ------------>  -------->                    -------------->
      66     74 75       84 85  89      96 97    104 105 11112 117 118        128
      |.......| |........| |...|......| |......| |.....||....| |..........|
      NYNQKFK.D KATLTADKSS STAYMQLSSLTS EDSAVYFC ASEGGF.LYYFDY WGQGTTLTVSS

      KYNQKFK.D KATLTADKSS STAYMQLSSLTS EDSAVYYC AR
      N                                        F  S

                                                     YFDY WGQGTTLTVSS     IGHJ2*01
                                                                          Mus musculus
```

FIG. 8B

● Alignment with the closest gene and allele from the IMGT V domain directory: (All species)

```
                 FR1-IMGT                 CDR1-IMGT     FR2-IMGT        CDR2-IMGT
                  (1-26)                   (27-38)      (39-55)          (56-65)
              A              B               BC          C       C'        C'C"
           (1-15)         (16-26)          (27-38)    (39-46)  (47-55)   (56-65)
          --------------> -----------> ---------- ---------> ---------->
          1        10  15 16     23 26 27         38 3941  46 47      55 56       65
          |........|....| |......|..| |..........| |.|....| |.......| |........|
S         QIVLTQSPAIMSASP GEKVTMTCSAS SRI.......SY MYWYQQKP GTSPKRWIY DT.......S

IGKV4-70*01 QIVLTQSPAIMSASP GEKVTMTCSAS SSI.......SY MHWYQQKP GTSPKRWIY DT.......S
Mus musculus                            R            Y

                       FR3-IMGT                          CDR3-IMGT     FR4-IMGT
                       (66-104)                          (105-117)     (118-128)
           C"         D             E            F          FG             G
          (66-74)  (75-84)       (85-96)      (97-104)   (105-117)     (118-128)
          -------> ---------> ------------> --------->               ----------->
          66     74 75      84 85  89     96 97    104 105 11112 117 118       128
          |.......| |........| |...|......| |......| |.....||....| |.........|
          KLASGVP.A RFSGSG..SG TSYSLTISTMEA EDAATYYC HQRS.....SYPT FGAGTKLELK.

          KLASGVP.A RFSGSG..SG TSYSLTISSMEA EDAATYYC HQRSSYP
                                      T

                                                           LT FGAGTKLELK     IGKJ5*01
                                                           P                 Mus musculus
```

FIG. 8C



FIG. 8D

(a)

Ab (nM)	B266-1	B264
100.000	3.6493	3.6823
20.000	3.6489	3.5407
4.000	3.6870	3.4951
0.800	3.7470	2.9941
0.160	3.4954	1.9640
0.032	3.3288	0.7787
0.006	2.4329	0.1928
Blank	1.8768	0.0542



FIG. 9

(b)

	Nonlin fit	A	B
		B266-1	B264
		Y	Y
1	One site -- Total		
2	Best-fit values		
3	Bmax	1.848	3.485
4	Kd	0.01116	0.1330
5	NS	-0.0006139	0.001395
6	Background	1.855	0.06177
7	Std. Error		
8	Bmax	0.09473	0.04572
9	Kd	0.002304	0.008048
10	NS	0.001038	0.0006252
11	Background	0.08482	0.03346
12	95% Confidence Intervals		
13	Bmax	1.585 to 2.111	3.358 to 3.612
14	Kd	0.004759 to 0.01755	0.1107 to 0.1554
15	NS	-0.003495 to 0.002267	-0.0003403 to 0.003131
16	Background	1.619 to 2.090	-0.03111 to 0.1546
17	Goodness of Fit		
18	Degrees of Freedom	4	4
19	R square	0.9911	0.9995
20	Absolute Sum of Squares	0.03013	0.008499
21	Sy.x	0.08680	0.04610
22			
23	Number of points		
24	Analyzed	8	8



FIG. 10

PREDICTED: thioredoxin-like [Chrysochloris asiatica] 케이프 황금두더지

Sequence ID: XP_006863063.1 Length: 105 Number of Matches: 1

Query : human TRX1
Sbject : *Chrysochloris asiatica* TRX1

Range 1: 2 to 104 GenPept Graphics

▼ Next Match ▲ Previous Match

Score	Expect	Method	Identities	Positives	Gaps
176 bits(446)	1e-55	Compositional matrix adjust	84/103(82%)	92/103(89%)	0/103(0%)

```
Query  1    VKQIESKTAFQEALDAAGDKLVVVDFSATWCGPCKMIKPFFHSLSEKYSNVIFLEVDVDD  60
            VK+IE K   F  AL +AGDKLVVVDFSATWCGPCKMIKPF+HSLSEK+ N++FLEVDVDD
Sbjct  2    VKEIEGKEDFHAALSSAGDKLVVVDFSATWCGPCKMIKPFYHSLSEKFGNMVFLEVDVDD  61

Query  61   CQDVASECEVKCMPTFQFFKKGQKVGEFSGANKEKLEATINEL  103
            CQDVASECEVKCM TFQF+KK +KVGEFSG NKEKLEA INEL
Sbjct  62   CQDVASECEVKCMITFQFYKKREKVGEFSGVNKEKLEAIINEL  104
```

FIG. 11



FIG. 12



FIG. 13

A





B



FIG. 14



FIG. 15A

M1 M2 M3 M4 M5 M6 M7 M8

Human VKQIESKTAFQEALDAAGDKLVVVDFSATWCGPCKMIKPFFHSLSEKYSNVIFLEVDVDDCQDVASECEVKCMPTFQFFKKGQKVGEFSGANKEKLEATINELV

Asiatica VKEIEGKEDFHAALSSAGDKLVVVDFSATWCGPCKMIKPFYHSLSEKFGNMVFLEVDVDDCQDVASECEVKCMITFQFYKKREKVGEFSGVNKEKLEAIINELC

VKQIESKTAFQEALDAAGDKLVVVDFSATWCGPCKMIKPFFHSLSEKYSNVIFLEVDVDDCQDVASECEVKCMPTFQFFKKGQKVGEFSGANKEKLEATINELV

M1 -------- VKEIEGKEDFQEALDAAGDKLVVVDFSATWCGPCKMIKPFFHSLSEKYSNVIFLEVDVDDCQDVASECEVKCMPTFQFFKKGQKVGEFSGANKEKLEATINELV

M2 -------- VKQIESKTAFHAALSSAGDKLVVVDFSATWCGPCKMIKPFFHSLSEKYSNVIFLEVDVDDCQDVASECEVKCMPTFQFFKKGQKVGEFSGANKEKLEATINELV

M3 -------- VKQIESKTAFQEALDAAGDKLVVVDFSATWCGPCKMIKPFYHSLSEKYSNVIFLEVDVDDCQDVASECEVKCMPTFQFFKKGQKVGEFSGANKEKLEATINELV

M4 -------- VKQIESKTAFQEALDAAGDKLVVVDFSATWCGPCKMIKPFFHSLSEKFGNMVFLEVDVDDCQDVASECEVKCMPTFQFFKKGQKVGEFSGANKEKLEATINELV

M5 -------- VKQIESKTAFQEALDAAGDKLVVVDFSATWCGPCKMIKPFFHSLSEKYSNVIFLEVDVDDCQDVASECEVKCMITFQFFKKGQKVGEFSGANKEKLEATINELV

M6 -------- VKQIESKTAFQEALDAAGDKLVVVDFSATWCGPCKMIKPFFHSLSEKYSNVIFLEVDVDDCQDVASECEVKCMPTFQFYKKREKVGEFSGANKEKLEATINELV

M7 -------- VKQIESKTAFQEALDAAGDKLVVVDFSATWCGPCKMIKPFFHSLSEKYSNVIFLEVDVDDCQDVASECEVKCMPTFQFFKKGQKVGEFSGVNKEKLEATINELV

M8 -------- VKQIESKTAFQEALDAAGDKLVVVDFSATWCGPCKMIKPFFHSLSEKYSNVIFLEVDVDDCQDVASECEVKCMPTFQFFKKGQKVGEFSGANKEKLEAIINELC

FIG. 15B



FIG. 15C



Lane	Fragment	Lane	Fragment
1	TRX1-M1-F1	9	TRX1-M5-F1
2	TRX1-M1-F2	10	TRX1-M5-F2
3	TRX1-M2-F1	11	TRX1-M6-F1
4	TRX1-M2-F2	12	TRX1-M6-F2
5	TRX1-M3-F1	13	TRX1-M7-F1
6	TRX1-M3-F2	14	TRX1-M7-F2
7	TRX1-M4-F1	15	TRX1-M8-F1
8	TRX1-M4-F2	16	TRX1-M8-F2

FIG. 15D



Lane	Cassette
1	TRX1-M1
2	TRX1-M2
3	TRX1-M3
4	TRX1-M4
5	TRX1-M5
6	TRX1-M6
7	TRX1-M7
8	TRX1-M8

FIG. 15E



Lane	Plasmid
1	N293F-TRX1-M1
2	N293F-TRX1-M2
3	N293F-TRX1-M3
4	N293F-TRX1-M4
5	N293F-TRX1-M5
6	N293F-TRX1-M6
7	N293F-TRX1-M7
8	N293F-TRX1-M8

FIG. 15F



Lane	Clone code	Protein
1	S1790	TRX-N-His-M1
2	S1791	TRX-N-His-M2
3	S1792	TRX-N-His-M3
4	S1793	TRX-N-His-M4
C1		BSA-0.5ug
C2		BSA-2ug

Lane	Clone code	Protein
5	S1794	TRX-N-His-M5
6	S1795	TRX-N-His-M6
7	S1796	TRX-N-His-M7
8	S1797	TRX-N-His-M8
C1		BSA-0.5ug
C2		BSA-2ug

FIG. 16



Lane	Clone code	Protein	Lane	Clone code	Protein
1	S1790	TRX-N-His-M1	5	S1794	TRX-N-His-M5
2	S1791	TRX-N-His-M2	6	S1795	TRX-N-His-M6
3	S1792	TRX-N-His-M3	7	S1796	TRX-N-His-M7
4	S1793	TRX-N-His-M4	8	S1797	TRX-N-His-M8
C		BSA-0.5ug	C		BSA-0.5ug

FIG. 17



FIG. 18A



FIG. 18B

	TRX N-His W(wild) & M(mutants) & C (asiatica TRX N-his)									
Antibody	**W**	**M1**	**M2**	**M3**	**M4**	**M5**	**M6**	**M7**	**M8**	**C**
Ab1-hIgG1	2.5023	2.3086	2.3268	2.2046	0.4352	2.4078	2.1154	2.2253	2.2148	0.045
Ab2-mIgG1	1.1369	0.0424	0.094	0.824	0.1813	0.4921	0.6594	0.7608	0.999	0.048

FIG. 18C



FIG. 19



FIG. 20



FIG. 21A



FIG. 21B



FIG. 21C



FIG. 21D



FIG. 22A



FIG. 22B



FIG. 22C



FIG. 22D



FIG. 22E



FIG. 22F

SEQUENCE LISTING

<110> E&S Healthcare Co., Ltd.

<120> Thioredoxin-1 Epitope and Monoclonal Antibody Specifically
       Binding thereto

<130> 1064685

<150> KR 10-2017-0132536
<151> 2017-10-12

<160> 181

<170> PatentIn version 3.2

<210> 1
<211> 11
<212> PRT
<213> Artificial

<220>
<223> B264 light chain CDR1

<400> 1

Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr
1   5   10

<210> 2
<211> 3
<212> PRT
<213> Artificial

<220>
<223> B264 light chain CDR2

<400> 2

Lys Val Ser
1

<210> 3
<211> 10
<212> PRT
<213> Artificial

<220>
<223> B264 light chain CDR3

<400> 3

Cys Phe Gln Gly Ser His Val Pro Tyr Thr
1   5   10

<210> 4
<211> 8
<212> PRT
<213> Artificial

<220>
<223> B264 heavy chain CDR1

<400> 4

Gly Tyr Thr Phe Thr Ser Tyr Thr
1   5

<210> 5
<211> 9
<212> PRT
<213> Artificial

<220>
<223> B264 heavy chain CDR2

<400> 5

Ile Asn Pro Thr Ser Asp Tyr Thr Asn
1   5

<210> 6
<211> 14
<212> PRT
<213> Artificial

<220>
<223> B264 heavy chain CDR3

<400> 6

Phe Cys Ala Ser Glu Gly Gly Phe Leu Tyr Tyr Phe Asp Tyr
1   5   10

<210> 7
<211> 5
<212> PRT
<213> Artificial

<220>
<223> B266-1 light chain CDR1

<400> 7

Ser Arg Ile Ser Tyr
1   5

<210> 8
<211> 3
<212> PRT
<213> Artificial

<220>
<223> B266-1 light chain CDR2

<400> 8

Asp Thr Ser
1

<210> 9
<211> 10
<212> PRT
<213> Artificial

<220>
<223> B266-1 light chain CDR3

<400> 9

Cys His Gln Arg Ser Ser Tyr Pro Thr Phe
1   5   10

<210> 10
<211> 8
<212> PRT
<213> Artificial

<220>
<223> B266-1 heavy chain CDR1

<400> 10

Gly Phe Asn Ile Lys Asp Thr Phe
1   5

<210> 11
<211> 8
<212> PRT
<213> Artificial

<220>
<223> B266-1 heavy chain CDR2

<400> 11

Ile Asp Pro Ala Asn Gly Asn Thr
1   5

<210> 12
<211> 11
<212> PRT
<213> Artificial

<220>
<223> B266-1 heavy chain CDR3

<400> 12

Cys Ala Leu Leu Gln Tyr Ser Ala Met Asp Tyr
1   5   10

<210> 13
<211> 112
<212> PRT
<213> Artificial

<220>
<223> B264 light chain variable region

<400> 13

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1   5   10   15

Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser
            20   25   30

Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser
        35   40   45

Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
    50   55   60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65   70   75   80

Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly
                85   90   95

Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100   105   110

<210> 14
<211> 119
<212> PRT
<213> Artificial

<220>
<223> B264 heavy chain variable region

<400> 14

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala
1   5   10   15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
            20   25   30

Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
        35   40   45

Gly Tyr Ile Asn Pro Thr Ser Asp Tyr Thr Asn Tyr Asn Gln Lys Phe
    50   55   60

Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65   70   75   80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
                85   90   95

Ala Ser Glu Gly Gly Phe Leu Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly
            100   105   110

Thr Thr Leu Thr Val Ser Ser
        115

<210> 15
<211> 105
<212> PRT
<213> Artificial

<220>
<223> B266-1 light chain variable region

<400> 15

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
1   5   10   15

Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Arg Ile Ser Tyr Met
            20   25   30

Tyr Trp Tyr Gln Gln Lys Pro Gly Thr Ser Pro Lys Arg Trp Ile Tyr
        35   40   45

Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser
    50   55   60

Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Thr Met Glu Ala Glu
65   70   75   80

Asp Ala Ala Thr Tyr Tyr Cys His Gln Arg Ser Ser Tyr Pro Thr Phe
                85   90   95

Gly Ala Gly Thr Lys Leu Glu Leu Lys
            100   105

<210> 16
<211> 117
<212> PRT
<213> Artificial

<220>
<223> B266-1 heavy chain variable region

<400> 16

```
Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
1               5                   10                  15


Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr
            20                  25                  30


Phe Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile
        35                  40                  45


Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro Lys Phe
    50                  55                  60


Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr
65                  70                  75                  80


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95


Ala Leu Leu Gln Tyr Ser Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser
            100                 105                 110


Val Thr Val Ser Ser
        115


<210>  17
<211>  219
<212>  PRT
<213>  Artificial

<220>
<223>  B264 light chain

<400>  17

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1               5                   10                  15


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser
            20                  25                  30


Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser
        35                  40                  45
```

```
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
    50                  55                  60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65                  70                  75                  80

Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly
                85                  90                  95

Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100                 105                 110

Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu
        115                 120                 125

Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe
    130                 135                 140

Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg
145                 150                 155                 160

Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser
                165                 170                 175

Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu
            180                 185                 190

Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser
        195                 200                 205

Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
    210                 215
```

```
<210>  18
<211>  443
<212>  PRT
<213>  Artificial

<220>
```

<223> B264 heavy chain

<400> 18

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala
1   5   10   15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
            20   25   30

Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
        35   40   45

Gly Tyr Ile Asn Pro Thr Ser Asp Tyr Thr Asn Tyr Asn Gln Lys Phe
    50   55   60

Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65   70   75   80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
                85   90   95

Ala Ser Glu Gly Gly Phe Leu Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly
            100   105   110

Thr Thr Leu Thr Val Ser Ser Ala Ser Thr Thr Pro Pro Ser Val Tyr
        115   120   125

Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr Leu
    130   135   140

Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr Trp
145   150   155   160

Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu
                165   170   175

Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser Ser
            180   185   190

```
Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala Ser
        195                 200                 205

Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly Cys Lys
    210                 215                 220

Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser Val Phe Ile Phe Pro
225                 230                 235                 240

Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu Thr Pro Lys Val Thr
                245                 250                 255

Cys Val Val Val Asp Ile Ser Lys Asp Asp Pro Glu Val Gln Phe Ser
            260                 265                 270

Trp Phe Val Asp Asp Val Glu Val His Thr Ala Gln Thr Gln Pro Arg
        275                 280                 285

Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val Ser Glu Leu Pro Ile
    290                 295                 300

Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys Cys Arg Val Asn
305                 310                 315                 320

Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys
                325                 330                 335

Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro Pro Pro Lys Glu
            340                 345                 350

Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met Ile Thr Asp Phe
        355                 360                 365

Phe Pro Glu Asp Ile Thr Val Glu Trp Gln Trp Asn Gly Gln Pro Ala
    370                 375                 380

Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asp Thr Asp Gly Ser Tyr
385                 390                 395                 400
```

```
Phe Val Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn Trp Glu Ala Gly
                405                 410                 415


Asn Thr Phe Thr Cys Ser Val Leu His Glu Gly Leu His Asn His His
            420                 425                 430


Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys
        435                 440


<210>  19
<211>  212
<212>  PRT
<213>  Artificial

<220>
<223>  B266 light chain

<400>  19

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
1               5                   10                  15


Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Arg Ile Ser Tyr Met
            20                  25                  30


Tyr Trp Tyr Gln Gln Lys Pro Gly Thr Ser Pro Lys Arg Trp Ile Tyr
        35                  40                  45


Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser
    50                  55                  60


Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Thr Met Glu Ala Glu
65                  70                  75                  80


Asp Ala Ala Thr Tyr Tyr Cys His Gln Arg Ser Ser Tyr Pro Thr Phe
                85                  90                  95


Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala Pro Thr
            100                 105                 110


Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala
        115                 120                 125
```

```
Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val
    130                 135                 140

Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser
145                 150                 155                 160

Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr
                165                 170                 175

Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys
            180                 185                 190

Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn
        195                 200                 205

Arg Asn Glu Cys
    210


<210>  20
<211>  452
<212>  PRT
<213>  Artificial

<220>
<223>  B266 heavy chain

<400>  20

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
1               5                   10                  15

Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr
            20                  25                  30

Phe Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile
        35                  40                  45

Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro Lys Phe
    50                  55                  60
```

```
Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr
65                  70                  75                  80


Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95


Ala Leu Leu Gln Tyr Ser Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser
            100                 105                 110


Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu
        115                 120                 125


Ala Pro Gly Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys
    130                 135                 140


Leu Val Lys Gly Tyr Phe Pro Glu Ser Val Thr Val Thr Trp Asn Ser
145                 150                 155                 160


Gly Ser Leu Ser Ser Ser Val His Thr Phe Pro Ala Leu Leu Gln Ser
                165                 170                 175


Gly Leu Tyr Thr Met Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp
            180                 185                 190


Pro Ser Gln Thr Val Thr Cys Ser Val Ala His Pro Ala Ser Ser Thr
        195                 200                 205


Thr Val Asp Lys Lys Leu Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn
    210                 215                 220


Pro Cys Pro Pro Cys Lys Glu Cys His Lys Cys Pro Ala Pro Asn Leu
225                 230                 235                 240


Glu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Asn Ile Lys Asp Val
                245                 250                 255


Leu Met Ile Ser Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Val
            260                 265                 270
```

```
Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val
        275                 280                 285


Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser
    290                 295                 300


Thr Ile Arg Val Val Ser Thr Leu Pro Ile Gln His Gln Asp Trp Met
305                 310                 315                 320


Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ser
                325                 330                 335


Pro Ile Glu Arg Thr Ile Ser Lys Ile Lys Gly Leu Val Arg Ala Pro
            340                 345                 350


Gln Val Tyr Ile Leu Pro Pro Pro Ala Glu Gln Leu Ser Arg Lys Asp
        355                 360                 365


Val Ser Leu Thr Cys Leu Val Val Gly Phe Asn Pro Gly Asp Ile Ser
    370                 375                 380


Val Glu Trp Thr Ser Asn Gly His Thr Glu Glu Asn Tyr Lys Asp Thr
385                 390                 395                 400


Ala Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Ile Tyr Ser Lys Leu
                405                 410                 415


Asn Met Lys Thr Ser Lys Trp Glu Lys Thr Asp Ser Phe Ser Cys Asn
            420                 425                 430


Val Arg His Glu Gly Leu Lys Asn Tyr Tyr Leu Lys Lys Thr Ile Ser
        435                 440                 445


Arg Ser Pro Gly
    450


<210>  21
<211>  660
<212>  DNA
<213>  Artificial
```

<220>
<223> B264 light chain

<400> 21
gacgtgctga tgacacagac accactcagc ctccctgtga gcctgggcga ccaggcctct   60

atttcttgcc ggtctagcca gagcatcgtg cactccaacg gcaacacata cttggagtgg   120

tatctacaga agcccggcca gtcccctaag ctgctgatat acaaggtgtc taaccgcttc   180

tccggcgtgc ccgacaggtt ctctggcagc ggctctggca ccgacttcac cctcaaaata   240

tctagggtgg aggccgagga cctgggcgtg tactactgct tccagggctc ccacgttcca   300

tacacattcg gcggcggcac aaagttggaa attaagcgcg ctgacgcagc cccaacagtg   360

agcatctttc ctccatcctc tgaacaactt acctctggag gagcctctgt ggtgtgtttc   420

ctgaacaact tctacccaaa ggacatcaat gtgaagtgga agattgatgg ctctgagaga   480

cagaatggag tgctgaactc ctggacagac caggacagca aggacagcac ctacagtatg   540

agtagcaccc tgaccctgac caaggatgaa tatgagagac acaactccta cacttgtgag   600

gctacccaca agaccagcac cagcccaatt gtcaaatcct tcaacaggaa tgagtgttaa   660

<210> 22
<211> 1332
<212> DNA
<213> Artificial

<220>
<223> B264 heavy chain

<400> 22
caggtgcagc tccagcagtc cggcgccgaa ctggccagac ctggcgccag cgtgaagatg   60

agctgcaagg cctccggcta cacattcaca tcttacacca tgcactgggt gaagcagaga   120

cccggccagg gcctggagtg gattggctac attaacccaa catccgacta cacaaactac   180

aaccagaagt tcaaggacaa ggccacactc accgccgaca agtcttctag cacagcctac   240

atgcagctgt ctagcctgac aagcgaggac tctgccgtgt acttctgcgc ctctgagggc   300

ggcttcctgt actacttcga ctactggggc cagggcacca ccctgaccgt gtcctctgcc   360

aaaacgacac ccccatctgt ctatccactg gcccctggat ctgctgccca aactaactcc   420

atggtgaccc tgggatgcct ggtcaagggc tatttccctg agccagtgac agtgacctgg   480

aactctggat ccctgtccag cggtgtgcac accttcccag ctgtcctgca gtctgacctc 540

tacactctga gcagctcagt gactgtcccc tccagcacct ggcccagcga gaccgtcacc 600

tgcaacgttg cccacccggc cagcagcacc aaggtggaca agaaaattgt gcccagggat 660

tgtggttgta agccttgcat atgtacagtc ccagaagtat catctgtctt catcttcccc 720

ccaaagccca aggatgtgct caccattact ctgactccta aggtcacgtg tgttgtggta 780

gacatcagca aggatgatcc cgaggtccag ttcagctggt ttgtagatga tgtggaggtg 840

cacacagctc agacgcaacc ccgggaggag cagttcaaca gcactttccg ctcagtcagt 900

gaacttccca tcatgcacca ggactggctc aatggcaagg agttcaaatg cagggtcaac 960

agtgcagctt tccctgcccc catcgagaaa accatctcca aaaccaaagg cagaccgaag 1020

gctccacagg tgtacaccat tccacctccc aaggagcaga tggccaagga taaagtcagt 1080

ctgacctgca tgataacaga cttcttccct gaagacatta ctgtggagtg gcagtggaat 1140

gggcagccag cggagaacta caagaacact cagcccatca tggacacaga tggctcttac 1200

ttcgtctaca gcaagctcaa tgtgcagaag agcaactggg aggcaggaaa tactttcacc 1260

tgctctgtgt tacatgaggg cctgcacaac caccatactg agaagagcct ctcccactct 1320

cctggtaaat aa 1332

<210> 23
<211> 639
<212> DNA
<213> Artificial

<220>
<223> B266 light chain

<400> 23
cagatcgtgc tcacacagtc tccagccatc atgagcgcct ctcctggcga gaaggtgaca 60

atgacctgct ctgcctctag ccgcatttct tacatgtact ggtatcagca gaagccaggc 120

acctccccta agaggtggat atacgacaca tccaagctgg cctccggcgt gcccgcccgg 180

ttcagcggct ctggcagcgg cacaagctac tccctgacaa ttagcacgat ggaggccgag 240

gacgccgcca catactactg ccaccagcgc tcgtcctacc caacattcgg cgccggcaca 300

aaattggaac tgaagagagc tgacgcagcc ccaacagtga gcatctttcc tccatcctct 360

gaacaactta cctctggagg agcctctgtg gtgtgtttcc tgaacaactt ctacccaaag 420

gacatcaatg tgaagtggaa gattgatggc tctgagagac agaatggagt gctgaactcc 480

tggacagacc aggacagcaa ggacagcacc tacagtatga gtagcaccct gaccctgacc 540

aaggatgaat atgagagaca caactcctac acttgtgagg ctacccacaa gaccagcacc 600

agcccaattg tcaaatcctt caacaggaat gagtgttaa 639

<210> 24
<211> 1359
<212> DNA
<213> Artificial

<220>
<223> B266 heavy chain

<400> 24
gaggtgcagt tacaacagtc cggcgccgag ctagtgaagc caggcgccag cgtgaagctg 60

tcttgcacag ccagcggctt caacattaag gacaccttca tgcactgggt gaagcagaga 120

cctgagcagg gcttagagtg gattggccgg atcgaccccg ccaacggcaa cacaaagtac 180

gacccaaagt tccagggcaa ggccacaatt accgccgaca catcttccaa cacagcctac 240

ctccagctgt cgtctctcac cagcgaggac accgccgtgt actactgcgc cctgctccag 300

tactccgcga tggactactg gggccagggc acatctgtga ccgtgtctag cgccaagacc 360

accccaccat ccgtgtaccc actcgcccca ggctgcggcg acaccacagg ctctagcgtg 420

acactgggct gcctggtgaa gggctacttc cccgagtctg tgacagtgac ctggaactct 480

ggctctctgt ctagctctgt gcacaccttc cccgccctgc tgcaatccgg cctgtacaca 540

atgtcttctt ctgtgacagt gcctagctct acatggccat ctcagacagt gacatgctct 600

gtggcccacc ccgcctctag cacaaccgtg gacaagaagc tggagccatc cggccctatt 660

tctacaatta acccttgccc tccttgcaaa gaatgccaca agtgccccgc cccaaacctg 720

gagggcggcc cttctgtgtt cattttccct cctaacatta aggacgtgct gatgatcagc 780

ctcaccccaa aggtgacatg cgtggtggtg gacgtgtccg aggacgaccc tgacgtgcag 840

atttcttggt tcgtgaacaa cgtggaggtg cacaccgccc agacccagac ccaccgggag 900

gactacaact ccaccattcg ggtggtgtct acactgccta ttcagcacca ggactggatg 960

agcggcaaag agttcaagtg caaggtgaac aacaaggacc tgccatctcc tattgagaga 1020

acaatttcta agattaaggg cctggtgcgc gcccctcagg tgtacattct gcctcctccc 1080

gccgagcagc tgagccggaa ggacgtgtcc ctcacatgcc tcgtggtggg cttcaaccct 1140

ggcgacatta gcgtggagtg gacatctaac ggccacacag aagaaaacta caaggacaca 1200

gcccctgtgc tcgactccga cggctcttac ttcatatact ctaagctgaa catgaaaaca 1260

tctaagtggg aaaagaccga ctctttctct tgcaacgtgc ggcacgaggg cctgaagaac 1320

tactacctca agaaaaccat tagcagaagt ccaggctaa 1359

<210> 25
<211> 211
<212> PRT
<213> Artificial

<220>
<223> B266-1 light chain

<400> 25

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
1   5   10   15

Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Arg Ile Ser Tyr Met
            20   25   30

Tyr Trp Tyr Gln Gln Lys Pro Gly Thr Ser Pro Lys Arg Trp Ile Tyr
        35   40   45

Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser
    50   55   60

Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Thr Met Glu Ala Glu
65   70   75   80

Asp Ala Ala Thr Tyr Tyr Cys His Gln Arg Ser Ser Tyr Pro Thr Phe
                85   90   95

Gly Ala Gly Thr Lys Leu Glu Leu Lys Ser Val Ala Ala Pro Ser Val
            100   105   110

Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser
        115   120   125

Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln
    130   135   140

Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val
145   150   155   160

Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu
                165   170   175

Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu
            180   185   190

Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg
        195   200   205

Gly Glu Cys
    210

<210> 26
<211> 447
<212> PRT
<213> Artificial

<220>
<223> B266-1 heavy chain

<400> 26

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
1   5   10   15

Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr
            20   25   30

Phe Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile
        35   40   45

```
Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro Lys Phe
    50                  55                  60

Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr
65                  70                  75                  80

Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95

Ala Leu Leu Gln Tyr Ser Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser
            100                 105                 110

Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
        115                 120                 125

Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
    130                 135                 140

Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145                 150                 155                 160

Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
                165                 170                 175

Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
            180                 185                 190

Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
        195                 200                 205

Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His
    210                 215                 220

Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val
225                 230                 235                 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
                245                 250                 255
```

```
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
            260                 265                 270

Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
        275                 280                 285

Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
    290                 295                 300

Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305                 310                 315                 320

Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
                325                 330                 335

Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
            340                 345                 350

Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
        355                 360                 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
    370                 375                 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385                 390                 395                 400

Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
                405                 410                 415

Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
            420                 425                 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
        435                 440                 445


<210>  27
<211>  633
<212>  DNA
<213>  Artificial
```

<220>
<223> B266-1 light chain

<400> 27
cagatcgtgc tcacacagtc tccagccatc atgagcgcct ctcctggcga gaaggtgaca   60

atgacctgct ctgcctctag ccgcatttct tacatgtact ggtatcagca gaagccaggc   120

acctccccta agaggtggat atacgacaca tccaagctgg cctccggcgt gcccgcccgg   180

ttcagcggct ctggcagcgg cacaagctac tccctgacaa ttagcacgat ggaggccgag   240

gacgccgcca catactactg ccaccagcgc tcgtcctacc caacattcgg cgccggcaca   300

aaattggaac tgaaggtggc tgcaccatct gtcttcatct tcccgccatc tgatgagcag   360

ttgaaatctg gaactgcctc tgttgtgtgc ctgctgaata acttctatcc cagagaggcc   420

aaagtacagt ggaaggtgga taacgccctc caatcgggta actcccagga gagtgtcaca   480

gagcaggaca gcaaggacag cacctacagc ctcagcagca ccctgacgct gagcaaagca   540

gactacgaga aacacaaagt ctacgcctgc gaagtcaccc atcagggcct gagctcgccc   600

gtcacaaaga gcttcaacag gggagagtgt tag   633

<210> 28
<211> 1337
<212> DNA
<213> Artificial

<220>
<223> B266-1 heavy chain

<400> 28
gaggtgcagt tacaacagtc cggcgccgag ctagtgaagc caggcgccag cgtgaagctg   60

tcttgcacag ccagcggctt caacattaag gacaccttca tgcactgggt gaagcagaga   120

cctgagcagg gcttagagtg gattggccgg atcgaccccg ccaacggcaa cacaaagtac   180

gacccaaagt tccagggcaa ggccacaatt accgccgaca catcttccaa cacagcctac   240

ctccagctgt cgtctctcac cagcgaggac accgccgtgt actactgcgc cctgctccag   300

tactccgcga tggactactg gggccagggc acatctgtga ccgtgtctag accaagggcc   360

catcggtctt ccccctggca ccctcctcca agagcacctc tgggggcaca gcggccctgg   420

gctgcctggt caaggactac ttccccgaac cggtgacggt gtcgtggaac tcaggcgccc   480

tgaccagcgg cgtgcacacc ttcccggctg tcctacagtc ctcaggactc tactccctca 540

gcagcgtggt gaccgtgccc tccagcagct tgggcaccca gacctacatc tgcaacgtga 600

atcacaagcc cagcaacacc aaggtggaca agaaagttga gcccaaatct tgtgacaaaa 660

ctcacacatg cccaccgtgc ccagcacctg aactcctggg gggaccgtca gtcttcctct 720

tcccccaaa acccaaggac accctcatga tctcccggac ccctgaggtc acatgcgtgg 780

tggtggacgt gagccacgaa gaccctgagg tcaagttcaa ctggtacgtg gacggcgtgg 840

aggtgcataa tgccaagaca aagccgcggg aggagcagta caacagcacg taccgtgtgg 900

tcagcgtcct caccgtcctg caccaggact ggctgaatgg caaggagtac aagtgcaagg 960

tctccaacaa agccctccca gcccccatcg agaaaaccat ctccaaagcc aaagggcagc 1020

cccgagaacc acaggtgtac accctgcccc catcccggga ggagatgacc aagaaccagg 1080

tcagcctgac ctgcctggtc aaaggcttct atcccagcga catcgccgtg gagtgggaga 1140

gcaatgggca gccggagaac aactacaaga ccacgcctcc cgtgctggac tccgacggct 1200

ccttcttcct ctacagcaag ctcaccgtgg acaagagcag gtggcagcag gggaacgtct 1260

tctcatgctc cgtgatgcat gaggctctgc acaaccacta cacgcagaag agcctctccc 1320

tgtctccggg taaatga 1337

<210> 29
<211> 315
<212> DNA
<213> Artificial

<220>
<223> Trx1 gene

<400> 29
atggtcaaac agatcgaatc aaaaaccgca tttcaagaag ccctggacgc cgctggtgac 60

aaactggtcg tggtggactt tagtgctacc tggtgcggcc cgtgtaaaat gattaaaccg 120

tttttccata gcctgtctga aaaatacagt aacgttatct ttctggaagt ggatgttgat 180

gactgccagg acgtcgcgag cgaatgcgaa gtgaaatgta tgccgacgtt ccagtttttc 240

aaaaaaggtc aaaaagtcgg tgaatttagc ggtgccaaca aagaaaaact ggaagccacg 300

attaacgaac tggtg 315

<210> 30
<211> 22
<212> DNA
<213> Artificial

<220>
<223> hTrx1-For primer

<400> 30
taatggtcaa acagatcgaa tc   22

<210> 31
<211> 31
<212> DNA
<213> Artificial

<220>
<223> hTrx1-Rev primer

<400> 31
caccagttcg ttaatcgtgg taatgaaagc t   31

<210> 32
<211> 7
<212> PRT
<213> Artificial

<220>
<223> hTrx1 M1

<400> 32

Gln Ile Glu Gly Ser Thr Ala
1   5

<210> 33
<211> 6
<212> PRT
<213> Artificial

<220>
<223> hTrx1 M2

<400> 33

Gln Glu Ala Leu Asp Ala
1   5

<210> 34
<211> 5
<212> PRT
<213> Artificial

<220>
<223> hTrx1 M4

<400> 34

Tyr Ser Asn Val Ile
1 5

<210> 35
<211> 21
<212> DNA
<213> Artificial

<220>
<223> hTrx1 M1

<400> 35
cagatcgaat caaaaaccgc a 21

<210> 36
<211> 18
<212> DNA
<213> Artificial

<220>
<223> hTrx1 M2

<400> 36
caagaagccc tggacgcc 18

<210> 37
<211> 15
<212> DNA
<213> Artificial

<220>
<223> hTrx1 M4

<400> 37
tacagtaacg ttatc 15

<210> 38
<211> 312
<212> DNA
<213> Artificial

<220>
<223> TRX-N-His-M1

<400> 38
gtcaaagaga tcgaaggcaa agaagatttt caagaagccc tggacgccgc tggtgacaaa   60

ctggtcgtgg tggactttag tgctacctgg tgcggcccgt gtaaaatgat taaaccgttt   120

ttccatagcc tgtctgaaaa atacagtaac gttatctttc tggaagtgga tgttgatgac   180

tgccaggacg tcgcgagcga atgcgaagtg aaatgtatgc cgacgttcca gtttttcaaa   240

aaaggtcaaa aagtcggtga atttagcggt gccaacaaag aaaaactgga agccacgatt   300

aacgaactgg tg   312

<210> 39
<211> 312
<212> DNA
<213> Artificial

<220>
<223> TRX-N-His-M2

<400> 39
gtcaaacaga tcgaatcaaa aaccgcattt catgctgccc tgagcagtgc tggtgacaaa   60

ctggtcgtgg tggactttag tgctacctgg tgcggcccgt gtaaaatgat taaaccgttt   120

ttccatagcc tgtctgaaaa atacagtaac gttatctttc tggaagtgga tgttgatgac   180

tgccaggacg tcgcgagcga atgcgaagtg aaatgtatgc cgacgttcca gtttttcaaa   240

aaaggtcaaa aagtcggtga atttagcggt gccaacaaag aaaaactgga agccacgatt   300

aacgaactgg tg   312

<210> 40
<211> 312
<212> DNA
<213> Artificial

<220>
<223> TRX-N-His-M3

<400> 40
gtcaaacaga tcgaatcaaa aaccgcattt caagaagccc tggacgccgc tggtgacaaa   60

ctggtcgtgg tggactttag tgctacctgg tgcggcccgt gtaaaatgat taaaccgttt   120

tatcatagcc tgtctgaaaa atacagtaac gttatctttc tggaagtgga tgttgatgac   180

tgccaggacg tcgcgagcga atgcgaagtg aaatgtatgc cgacgttcca gtttttcaaa   240

aaaggtcaaa aagtcggtga atttagcggt gccaacaaag aaaaactgga agccacgatt   300

aacgaactgg tg   312

<210> 41
<211> 312
<212> DNA
<213> Artificial

<220>
<223> TRX-N-His-M4

<400> 41
gtcaaacaga tcgaatcaaa aaccgcattt caagaagccc tggacgccgc tggtgacaaa   60

ctggtcgtgg tggactttag tgctacctgg tgcggcccgt gtaaaatgat taaaccgttt   120

ttccatagcc tgtctgaaaa atttggcaac atggtgttcc tggaagtgga tgttgatgac   180

tgccaggacg tcgcgagcga atgcgaagtg aaatgtatgc cgacgttcca gtttttcaaa   240

aaaggtcaaa aagtcggtga atttagcggt gccaacaaag aaaaactgga agccacgatt   300

aacgaactgg tg   312

<210> 42
<211> 312
<212> DNA
<213> Artificial

<220>
<223> TRX-N-His-M5

<400> 42
gtcaaacaga tcgaatcaaa aaccgcattt caagaagccc tggacgccgc tggtgacaaa   60

ctggtcgtgg tggactttag tgctacctgg tgcggcccgt gtaaaatgat taaaccgttt   120

ttccatagcc tgtctgaaaa atacagtaac gttatctttc tggaagtgga tgttgatgac   180

tgccaggacg tcgcgagcga atgcgaagtg aaatgtatga taacgttcca gtttttcaaa   240

aaaggtcaaa aagtcggtga atttagcggt gccaacaaag aaaaactgga agccacgatt 300

aacgaactgg tg 312

<210> 43
<211> 312
<212> DNA
<213> Artificial

<220>
<223> TRX-N-His-M6

<400> 43
gtcaaacaga tcgaatcaaa aaccgcattt caagaagccc tggacgccgc tggtgacaaa 60

ctggtcgtgg tggactttag tgctacctgg tgcggcccgt gtaaaatgat taaaccgttt 120

ttccatagcc tgtctgaaaa atacagtaac gttatctttc tggaagtgga tgttgatgac 180

tgccaggacg tcgcgagcga atgcgaagtg aaatgtatgc cgacgttcca gttttataaa 240

aaaagggaaa aagtcggtga atttagcggt gccaacaaag aaaaactgga agccacgatt 300

aacgaactgg tg 312

<210> 44
<211> 312
<212> DNA
<213> Artificial

<220>
<223> TRX-N-His-M7

<400> 44
gtcaaacaga tcgaatcaaa aaccgcattt caagaagccc tggacgccgc tggtgacaaa 60

ctggtcgtgg tggactttag tgctacctgg tgcggcccgt gtaaaatgat taaaccgttt 120

ttccatagcc tgtctgaaaa atacagtaac gttatctttc tggaagtgga tgttgatgac 180

tgccaggacg tcgcgagcga atgcgaagtg aaatgtatgc cgacgttcca gtttttcaaa 240

aaaggtcaaa aagtcggtga atttagcggt gttaacaaag aaaaactgga agccacgatt 300

aacgaactgg tg 312

<210> 45
<211> 312

<212> DNA
<213> Artificial

<220>
<223> TRX-N-His-M8

<400> 45
gtcaaacaga tcgaatcaaa aaccgcattt caagaagccc tggacgccgc tggtgacaaa   60

ctggtcgtgg tggactttag tgctacctgg tgcggcccgt gtaaaatgat taaaccgttt   120

ttccatagcc tgtctgaaaa atacagtaac gttatctttc tggaagtgga tgttgatgac   180

tgccaggacg tcgcgagcga atgcgaagtg aaatgtatgc cgacgttcca gtttttcaaa   240

aaaggtcaaa aagtcggtga atttagcggt gccaacaaag aaaaactgga agccatcatt   300

aacgaactgt gt   312

<210> 46
<211> 19
<212> DNA
<213> Artificial

<220>
<223> Vector-F primer

<400> 46
ggcgtgtacg gtgggaggt   19

<210> 47
<211> 20
<212> DNA
<213> Artificial

<220>
<223> Vector-R primer

<400> 47
agcagcgtat ccacatagcg   20

<210> 48
<211> 57
<212> DNA
<213> Artificial

<220>
<223> TRX M1-F primer

<400> 48
catcacgtca aagagatcga aggcaaagaa gattttcaag aagccctgga cgccgct   57

<210> 49
<211> 58
<212> DNA
<213> Artificial

<220>
<223> TRX M1-R primer

<400> 49
ggcttcttga aaatcttctt tgccttcgat ctctttgacg tgatgatgat gatgatga   58

<210> 50
<211> 52
<212> DNA
<213> Artificial

<220>
<223> TRX M2-F primer

<400> 50
aaaaccgcat ttcatgctgc cctgagcagt gctggtgaca aactggtcgt gg   52

<210> 51
<211> 54
<212> DNA
<213> Artificial

<220>
<223> TRX M2-R primer

<400> 51
tttgtcacca gcactgctca gggcagcatg aaatgcggtt tttgattcga tctg   54

<210> 52
<211> 58
<212> DNA
<213> Artificial

<220>
<223> TRX-M3-OV-F primer

<400> 52
attaaaccgt tttatcatag cctgtctgaa aaatacagta acgttatctt tctggaag   58

<210> 53
<211> 50
<212> DNA
<213> Artificial

<220>
<223> TRX-M3-OV-R primer

<400> 53
agacaggcta tgataaaacg gtttaatcat tttacacggg ccgcaccagg   50

<210> 54
<211> 65
<212> DNA
<213> Artificial

<220>
<223> TRX-M4-OV-F primer

<400> 54
ctgtctgaaa aatttggcaa catggtgttc ctggaagtgg atgttgatga ctgccaggac   60

gtcgc   65

<210> 55
<211> 73
<212> DNA
<213> Artificial

<220>
<223> TRX-M4-OV-R primer

<400> 55
atccacttcc aggaacacca tgttgccaaa tttttcagac aggctatgga aaaacggttt   60

aatcatttta cac   73

<210> 56
<211> 55
<212> DNA
<213> Artificial

<220>
<223> TRX-M5-OV-F primer

<400> 56
gtgaaatgta tgataacgtt ccagtttttc aaaaaaggtc aaaaagtcgg tgaat   55

<210> 57
<211> 49
<212> DNA
<213> Artificial

<220>
<223> TRX-M5-OV-R primer

<400> 57
aaactggaac gttatcatac atttcacttc gcattcgctc gcgacgtcc   49

<210> 58
<211> 65
<212> DNA
<213> Artificial

<220>
<223> TRX-M6-OV-F primer

<400> 58
acgttccagt tttataaaaa aagggaaaaa gtcggtgaat ttagcggtgc caacaaagaa   60

aaact   65

<210> 59
<211> 64
<212> DNA
<213> Artificial

<220>
<223> TRX-M6-OV-R primer

<400> 59
ttcaccgact ttttcccttt ttttataaaa ctggaacgtc ggcatacatt tcacttcgca   60

ttcg   64

<210> 60
<211> 84
<212> DNA
<213> Artificial

<220>
<223> TRX-M7-Xho-R primer

<400> 60
gaattctcga gctatcacac cagttcgtta atcgtggctt ccagtttttc tttgttaaca   60

ccgctaaatt caccgacttt ttga   84

<210> 61
<211> 59
<212> DNA
<213> Artificial

<220>
<223> TRX-M8-Xho-R primer

<400> 61
gaattctcga gctatcaaca cagttcgtta atgatggctt ccagtttttc tttgttggc   59

<210> 62
<211> 19
<212> DNA
<213> Artificial

<220>
<223> N293F-colo-F primer

<400> 62
ggcgtgtacg gtgggaggt   19

<210> 63
<211> 20
<212> DNA
<213> Artificial

<220>
<223> N293F-colo-R primer

<400> 63
agcagcgtat ccacatagcg   20

<210> 64
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_001

<400> 64

Val Ala Thr Ala Ala Asp Val His Ser Gln His His His His His
1   5   10   15

<210> 65
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_002

<400> 65

Ala Thr Ala Ala Asp Val His Ser Gln His His His His His His
1   5   10   15

<210> 66
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_003

<400> 66

Thr Ala Ala Asp Val His Ser Gln His His His His His His His
1   5   10   15

<210> 67
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_004

<400> 67

Ala Ala Asp Val His Ser Gln His His His His His His His His
1   5   10   15

<210> 68
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_005

<400> 68

Ala Asp Val His Ser Gln His His His His His His His His Val
1   5   10   15

<210> 69
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_006

<400> 69

Asp Val His Ser Gln His His His His His His His His Val Lys
1   5   10   15

<210> 70
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_007

<400> 70

Val His Ser Gln His His His His His His His His Val Lys Gln
1   5   10   15

<210> 71
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_008

<400> 71

His Ser Gln His His His His His His His His Val Lys Gln Ile
1   5   10   15

<210> 72
<211> 15
<212> PRT
<213> Artificial

<220>

<223> Peptide_009

<400> 72

Ser Gln His His His His His His His His Val Lys Gln Ile Glu
1   5   10   15

<210> 73
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_010

<400> 73

Gln His His His His His His His His Val Lys Gln Ile Glu Ser
1   5   10   15

<210> 74
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_011

<400> 74

His His His His His His His His Val Lys Gln Ile Glu Ser Lys
1   5   10   15

<210> 75
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_012

<400> 75

His His His His His His His Val Lys Gln Ile Glu Ser Lys Thr
1   5   10   15

<210> 76
<211> 15

<212> PRT
<213> Artificial

<220>
<223> Peptide_013

<400> 76

His His His His His His Val Lys Gln Ile Glu Ser Lys Thr Ala
1   5   10   15

<210> 77
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_014

<400> 77

His His His His His Val Lys Gln Ile Glu Ser Lys Thr Ala Phe
1   5   10   15

<210> 78
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_015

<400> 78

His His His His Val Lys Gln Ile Glu Ser Lys Thr Ala Phe Gln
1   5   10   15

<210> 79
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_016

<400> 79

His His His Val Lys Gln Ile Glu Ser Lys Thr Ala Phe Gln Glu
1   5   10   15

<210> 80
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_017

<400> 80

His His Val Lys Gln Ile Glu Ser Lys Thr Ala Phe Gln Glu Ala
1   5   10   15

<210> 81
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_018

<400> 81

His Val Lys Gln Ile Glu Ser Lys Thr Ala Phe Gln Glu Ala Leu
1   5   10   15

<210> 82
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_019

<400> 82

Val Lys Gln Ile Glu Ser Lys Thr Ala Phe Gln Glu Ala Leu Asp
1   5   10   15

<210> 83
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_020

<400> 83

Lys Gln Ile Glu Ser Lys Thr Ala Phe Gln Glu Ala Leu Asp Ala
1   5   10   15

<210> 84
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_021

<400> 84

Gln Ile Glu Ser Lys Thr Ala Phe Gln Glu Ala Leu Asp Ala Ala
1   5   10   15

<210> 85
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_022

<400> 85

Ile Glu Ser Lys Thr Ala Phe Gln Glu Ala Leu Asp Ala Ala Gly
1   5   10   15

<210> 86
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_023

<400> 86

Glu Ser Lys Thr Ala Phe Gln Glu Ala Leu Asp Ala Ala Gly Asp
1   5   10   15

<210> 87
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_024

<400> 87

Ser Lys Thr Ala Phe Gln Glu Ala Leu Asp Ala Ala Gly Asp Lys
1   5   10   15

<210> 88
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_025

<400> 88

Lys Thr Ala Phe Gln Glu Ala Leu Asp Ala Ala Gly Asp Lys Leu
1   5   10   15

<210> 89
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_026

<400> 89

Thr Ala Phe Gln Glu Ala Leu Asp Ala Ala Gly Asp Lys Leu Val
1   5   10   15

<210> 90
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_027

<400> 90

Ala Phe Gln Glu Ala Leu Asp Ala Ala Gly Asp Lys Leu Val Val
1   5   10   15

<210> 91
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_028

<400> 91

Phe Gln Glu Ala Leu Asp Ala Ala Gly Asp Lys Leu Val Val Val
1   5   10   15

<210> 92
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_029

<400> 92

Gln Glu Ala Leu Asp Ala Ala Gly Asp Lys Leu Val Val Val Asp
1   5   10   15

<210> 93
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_030

<400> 93

Glu Ala Leu Asp Ala Ala Gly Asp Lys Leu Val Val Val Asp Phe
1   5   10   15

<210> 94
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_031

<400> 94

Ala Leu Asp Ala Ala Gly Asp Lys Leu Val Val Val Asp Phe Ser
1   5   10   15

<210> 95
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_032

<400> 95

Leu Asp Ala Ala Gly Asp Lys Leu Val Val Val Asp Phe Ser Ala
1   5   10   15

<210> 96
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_033

<400> 96

Asp Ala Ala Gly Asp Lys Leu Val Val Val Asp Phe Ser Ala Thr
1   5   10   15

<210> 97
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_034

<400> 97

Ala Ala Gly Asp Lys Leu Val Val Val Asp Phe Ser Ala Thr Trp
1   5   10   15

<210> 98
<211> 15
<212> PRT
<213> Artificial

<220>

<223> Peptide_035

<400> 98

Ala Gly Asp Lys Leu Val Val Val Asp Phe Ser Ala Thr Trp Cys
1   5   10   15

<210> 99
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_036

<400> 99

Gly Asp Lys Leu Val Val Val Asp Phe Ser Ala Thr Trp Cys Gly
1   5   10   15

<210> 100
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_037

<400> 100

Asp Lys Leu Val Val Val Asp Phe Ser Ala Thr Trp Cys Gly Pro
1   5   10   15

<210> 101
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_038

<400> 101

Lys Leu Val Val Val Asp Phe Ser Ala Thr Trp Cys Gly Pro Cys
1   5   10   15

<210> 102
<211> 15

<212> PRT
<213> Artificial

<220>
<223> Peptide_039

<400> 102

Leu Val Val Val Asp Phe Ser Ala Thr Trp Cys Gly Pro Cys Lys
1   5   10   15

<210> 103
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_040

<400> 103

Val Val Val Asp Phe Ser Ala Thr Trp Cys Gly Pro Cys Lys Met
1   5   10   15

<210> 104
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_041

<400> 104

Val Val Asp Phe Ser Ala Thr Trp Cys Gly Pro Cys Lys Met Ile
1   5   10   15

<210> 105
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_042

<400> 105

Val Asp Phe Ser Ala Thr Trp Cys Gly Pro Cys Lys Met Ile Lys
1   5   10   15

<210> 106
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_043

<400> 106

Asp Phe Ser Ala Thr Trp Cys Gly Pro Cys Lys Met Ile Lys Pro
1   5   10   15

<210> 107
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_044

<400> 107

Phe Ser Ala Thr Trp Cys Gly Pro Cys Lys Met Ile Lys Pro Phe
1   5   10   15

<210> 108
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_045

<400> 108

Ser Ala Thr Trp Cys Gly Pro Cys Lys Met Ile Lys Pro Phe Phe
1   5   10   15

<210> 109
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_046

<400> 109

Ala Thr Trp Cys Gly Pro Cys Lys Met Ile Lys Pro Phe Phe His
1   5   10   15

<210> 110
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_047

<400> 110

Thr Trp Cys Gly Pro Cys Lys Met Ile Lys Pro Phe Phe His Ser
1   5   10   15

<210> 111
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_048

<400> 111

Trp Cys Gly Pro Cys Lys Met Ile Lys Pro Phe Phe His Ser Leu
1   5   10   15

<210> 112
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_049

<400> 112

Cys Gly Pro Cys Lys Met Ile Lys Pro Phe Phe His Ser Leu Ser
1   5   10   15

<210> 113
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_050

<400> 113

Gly Pro Cys Lys Met Ile Lys Pro Phe Phe His Ser Leu Ser Glu
1   5   10   15

<210> 114
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_051

<400> 114

Pro Cys Lys Met Ile Lys Pro Phe Phe His Ser Leu Ser Glu Lys
1   5   10   15

<210> 115
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_052

<400> 115

Cys Lys Met Ile Lys Pro Phe Phe His Ser Leu Ser Glu Lys Tyr
1   5   10   15

<210> 116
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_053

<400> 116

Lys Met Ile Lys Pro Phe Phe His Ser Leu Ser Glu Lys Tyr Ser
1   5   10   15

<210> 117
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_054

<400> 117

Met Ile Lys Pro Phe Phe His Ser Leu Ser Glu Lys Tyr Ser Asn
1   5   10   15

<210> 118
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_055

<400> 118

Ile Lys Pro Phe Phe His Ser Leu Ser Glu Lys Tyr Ser Asn Val
1   5   10   15

<210> 119
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_056

<400> 119

Lys Pro Phe Phe His Ser Leu Ser Glu Lys Tyr Ser Asn Val Ile
1   5   10   15

<210> 120
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_057

<400> 120

Pro Phe Phe His Ser Leu Ser Glu Lys Tyr Ser Asn Val Ile Phe
1   5   10   15

<210> 121
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_058

<400> 121

Phe Phe His Ser Leu Ser Glu Lys Tyr Ser Asn Val Ile Phe Leu
1   5   10   15

<210> 122
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_059

<400> 122

Phe His Ser Leu Ser Glu Lys Tyr Ser Asn Val Ile Phe Leu Glu
1   5   10   15

<210> 123
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_060

<400> 123

His Ser Leu Ser Glu Lys Tyr Ser Asn Val Ile Phe Leu Glu Val
1   5   10   15

<210> 124
<211> 15
<212> PRT
<213> Artificial

<220>

<223> Peptide_061

<400> 124

Ser Leu Ser Glu Lys Tyr Ser Asn Val Ile Phe Leu Glu Val Asp
1   5   10   15

<210> 125
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_062

<400> 125

Leu Ser Glu Lys Tyr Ser Asn Val Ile Phe Leu Glu Val Asp Val
1   5   10   15

<210> 126
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_063

<400> 126

Ser Glu Lys Tyr Ser Asn Val Ile Phe Leu Glu Val Asp Val Asp
1   5   10   15

<210> 127
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_064

<400> 127

Glu Lys Tyr Ser Asn Val Ile Phe Leu Glu Val Asp Val Asp Asp
1   5   10   15

<210> 128
<211> 15

<212> PRT
<213> Artificial

<220>
<223> Peptide_065

<400> 128

Lys Tyr Ser Asn Val Ile Phe Leu Glu Val Asp Val Asp Asp Cys
1   5   10   15

<210> 129
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_066

<400> 129

Tyr Ser Asn Val Ile Phe Leu Glu Val Asp Val Asp Asp Cys Gln
1   5   10   15

<210> 130
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_067

<400> 130

Ser Asn Val Ile Phe Leu Glu Val Asp Val Asp Asp Cys Gln Asp
1   5   10   15

<210> 131
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_068

<400> 131

Asn Val Ile Phe Leu Glu Val Asp Val Asp Asp Cys Gln Asp Val
1   5   10   15

<210> 132
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_069

<400> 132

Val Ile Phe Leu Glu Val Asp Val Asp Asp Cys Gln Asp Val Ala
1   5   10   15

<210> 133
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_070

<400> 133

Ile Phe Leu Glu Val Asp Val Asp Asp Cys Gln Asp Val Ala Ser
1   5   10   15

<210> 134
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_071

<400> 134

Phe Leu Glu Val Asp Val Asp Asp Cys Gln Asp Val Ala Ser Glu
1   5   10   15

<210> 135
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_072

<400> 135

Leu Glu Val Asp Val Asp Asp Cys Gln Asp Val Ala Ser Glu Cys
1   5   10   15

<210> 136
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_073

<400> 136

Glu Val Asp Val Asp Asp Cys Gln Asp Val Ala Ser Glu Cys Glu
1   5   10   15

<210> 137
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_074

<400> 137

Val Asp Val Asp Asp Cys Gln Asp Val Ala Ser Glu Cys Glu Val
1   5   10   15

<210> 138
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_075

<400> 138

Asp Val Asp Asp Cys Gln Asp Val Ala Ser Glu Cys Glu Val Lys
1   5   10   15

<210> 139
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_076

<400> 139

Val Asp Asp Cys Gln Asp Val Ala Ser Glu Cys Glu Val Lys Cys
1   5   10   15

<210> 140
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_077

<400> 140

Asp Asp Cys Gln Asp Val Ala Ser Glu Cys Glu Val Lys Cys Met
1   5   10   15

<210> 141
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_078

<400> 141

Asp Cys Gln Asp Val Ala Ser Glu Cys Glu Val Lys Cys Met Pro
1   5   10   15

<210> 142
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_079

<400> 142

Cys Gln Asp Val Ala Ser Glu Cys Glu Val Lys Cys Met Pro Thr
1   5   10   15

<210> 143
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_080

<400> 143

Gln Asp Val Ala Ser Glu Cys Glu Val Lys Cys Met Pro Thr Phe
1   5   10   15

<210> 144
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_081

<400> 144

Asp Val Ala Ser Glu Cys Glu Val Lys Cys Met Pro Thr Phe Gln
1   5   10   15

<210> 145
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_082

<400> 145

Val Ala Ser Glu Cys Glu Val Lys Cys Met Pro Thr Phe Gln Phe
1   5   10   15

<210> 146
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_083

<400> 146

Ala Ser Glu Cys Glu Val Lys Cys Met Pro Thr Phe Gln Phe Phe
1   5   10   15

<210> 147
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_084

<400> 147

Ser Glu Cys Glu Val Lys Cys Met Pro Thr Phe Gln Phe Phe Lys
1   5   10   15

<210> 148
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_085

<400> 148

Glu Cys Glu Val Lys Cys Met Pro Thr Phe Gln Phe Phe Lys Lys
1   5   10   15

<210> 149
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_086

<400> 149

Cys Glu Val Lys Cys Met Pro Thr Phe Gln Phe Phe Lys Lys Gly
1   5   10   15

<210> 150
<211> 15
<212> PRT
<213> Artificial

<220>

<223> Peptide_087

<400> 150

Glu Val Lys Cys Met Pro Thr Phe Gln Phe Phe Lys Lys Gly Gln
1   5   10   15

<210> 151
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_088

<400> 151

Val Lys Cys Met Pro Thr Phe Gln Phe Phe Lys Lys Gly Gln Lys
1   5   10   15

<210> 152
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_089

<400> 152

Lys Cys Met Pro Thr Phe Gln Phe Phe Lys Lys Gly Gln Lys Val
1   5   10   15

<210> 153
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_090

<400> 153

Cys Met Pro Thr Phe Gln Phe Phe Lys Lys Gly Gln Lys Val Gly
1   5   10   15

<210> 154
<211> 15

<212> PRT
<213> Artificial

<220>
<223> Peptide_091

<400> 154

Met Pro Thr Phe Gln Phe Phe Lys Lys Gly Gln Lys Val Gly Glu
1   5   10   15

<210> 155
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_092

<400> 155

Pro Thr Phe Gln Phe Phe Lys Lys Gly Gln Lys Val Gly Glu Phe
1   5   10   15

<210> 156
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_093

<400> 156

Thr Phe Gln Phe Phe Lys Lys Gly Gln Lys Val Gly Glu Phe Ser
1   5   10   15

<210> 157
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_094

<400> 157

Phe Gln Phe Phe Lys Lys Gly Gln Lys Val Gly Glu Phe Ser Gly
1   5   10   15

<210> 158
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_095

<400> 158

Gln Phe Phe Lys Lys Gly Gln Lys Val Gly Glu Phe Ser Gly Ala
1   5   10   15

<210> 159
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_096

<400> 159

Phe Phe Lys Lys Gly Gln Lys Val Gly Glu Phe Ser Gly Ala Asn
1   5   10   15

<210> 160
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_097

<400> 160

Phe Lys Lys Gly Gln Lys Val Gly Glu Phe Ser Gly Ala Asn Lys
1   5   10   15

<210> 161
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_098

<400> 161

Lys Lys Gly Gln Lys Val Gly Glu Phe Ser Gly Ala Asn Lys Glu
1   5   10   15

<210> 162
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_099

<400> 162

Lys Gly Gln Lys Val Gly Glu Phe Ser Gly Ala Asn Lys Glu Lys
1   5   10   15

<210> 163
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_100

<400> 163

Gly Gln Lys Val Gly Glu Phe Ser Gly Ala Asn Lys Glu Lys Leu
1   5   10   15

<210> 164
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_101

<400> 164

Gln Lys Val Gly Glu Phe Ser Gly Ala Asn Lys Glu Lys Leu Glu
1   5   10   15

<210> 165
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_102

<400> 165

Lys Val Gly Glu Phe Ser Gly Ala Asn Lys Glu Lys Leu Glu Ala
1   5   10   15

<210> 166
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_103

<400> 166

Val Gly Glu Phe Ser Gly Ala Asn Lys Glu Lys Leu Glu Ala Thr
1   5   10   15

<210> 167
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_104

<400> 167

Gly Glu Phe Ser Gly Ala Asn Lys Glu Lys Leu Glu Ala Thr Ile
1   5   10   15

<210> 168
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_105

<400> 168

Glu Phe Ser Gly Ala Asn Lys Glu Lys Leu Glu Ala Thr Ile Asn
1   5   10   15

<210> 169
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_106

<400> 169

Phe Ser Gly Ala Asn Lys Glu Lys Leu Glu Ala Thr Ile Asn Glu
1   5   10   15

<210> 170
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_107

<400> 170

Ser Gly Ala Asn Lys Glu Lys Leu Glu Ala Thr Ile Asn Glu Leu
1   5   10   15

<210> 171
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide_108

<400> 171

Gly Ala Asn Lys Glu Lys Leu Glu Ala Thr Ile Asn Glu Leu Val
1   5   10   15

<210> 172
<211> 26
<212> PRT
<213> Artificial

<220>
<223> B264 and B266-1 epitope

<400> 172

Ala Thr Trp Cys Gly Pro Cys Lys Met Ile Lys Pro Phe Phe His Ser
1   5   10   15

Leu Ser Glu Lys Tyr Ser Asn Val Ile Phe
            20   25

<210> 173
<211> 15
<212> PRT
<213> Artificial

<220>
<223> B266-1 epitope

<400> 173

Pro Thr Phe Gln Phe Phe Lys Lys Gly Gln Lys Val Gly Glu Phe
1   5   10   15

<210> 174
<211> 21
<212> PRT
<213> Artificial

<220>
<223> B264 epitope

<400> 174

Val Lys Gln Ile Glu Ser Lys Thr Ala Phe Gln Glu Ala Leu Asp Ala
1   5   10   15

Ala Gly Asp Lys Leu
            20

<210> 175
<211> 17
<212> PRT
<213> Artificial

<220>
<223> B264 epitope

<400> 175

Ser Glu Cys Glu Val Lys Cys Met Pro Thr Phe Gln Phe Phe Lys Lys
1   5   10   15

Gly

<210> 176
<211> 20
<212> PRT
<213> Artificial

<220>
<223> B264 epitope

<400> 176

Pro Thr Phe Gln Phe Phe Lys Lys Gly Gln Lys Val Gly Glu Phe Ser
1   5   10   15

Gly Ala Asn Lys
            20

<210> 177
<211> 78
<212> DNA
<213> Artificial

<220>
<223> B264 and B266-1 epitope

<400> 177
gctacctggt gcggcccgtg taaaatgatt aaaccgtttt tccatagcct gtctgaaaaa   60

tacagtaacg ttatcttt   78

<210> 178
<211> 45
<212> DNA
<213> Artificial

<220>
<223> B266-1 epitope

<400> 178
ccgacgttcc agtttttcaa aaaaggtcaa aaagtcggtg aattt   45

<210> 179
<211> 63

<212> DNA
<213> Artificial

<220>
<223> B264 epitope

<400> 179
gtcaaacaga tcgaatcaaa aaccgcattt caagaagccc tggacgccgc tggtgacaaa   60

ctg   63

<210> 180
<211> 51
<212> DNA
<213> Artificial

<220>
<223> B264 epitope

<400> 180
agcgaatgcg aagtgaaatg tatgccgacg ttccagtttt tcaaaaaagg t   51

<210> 181
<211> 60
<212> DNA
<213> Artificial

<220>
<223> B264 epitope

<400> 181
ccgacgttcc agtttttcaa aaaaggtcaa aaagtcggtg aatttagcgg tgccaacaaa   60